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Nire bizitzari zentzua ematen dion pertsonari, Xarles.  
Ezagutu nizun momentu horretan maite izan nizulako, gaur 
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“La alegría está en la lucha, en el esfuerzo, en el sufrimiento 
que supone la lucha y no en la victoria” 
 
Mahatma Gandhi 
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HR  Hazard ratio 
ICU  Intensive care unit 
IRCU  Intermediate Respiratory Care Unit  
OR  Odds ratio 
PCT  Procalcitonin 
ProADM Proadrenomedullin 
PSI  Pneumonia severity index 
RR   Respiratory rate 
SCAP  Severe community-acquired pneumonia index 
SEPAR Spanish Pulmonology and Thoracic Surgery Society  
SBP  Systolic blood pressure  
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Community-acquired pneumonia (CAP) is a major problem of public health with high 
morbimortality. The annual incidence ranges between two and eight cases per 
thousand inhabitants. Together with influenza, it was the seventh cause of mortality in 
the United States in 2008. Short-term mortality rates are high in patients admitted for 
CAP. It is even higher in those admitted to intensive care units, and up to 50% if there 
is a need for vasopressors. On the other hand, long-term mortality rates remain high, 
with 8%, 21%, and 36% within 90 days, one year, and five years, respectively.  
 
Several authors have created severity scores in order to predict short-term mortality. 
Fifteen-day mortality after diagnosis has been related to acute episodes. However, the 
relationship between pneumonia and long-term mortality is controversial. Patients 
admitted for pneumonia have exhibited higher long-term mortality rates than those 
admitted for other reasons. In addition, various studies have tried to identify predictive 
factors for long-term mortality. To date, severity scores for predicting one-year 
mortality in these patients have not been created. The main goal of this thesis was to 
assess one-year mortality in patients admitted for CAP. To that end, three studies 
were conducted with three different cohorts, and one-year mortality was the common 
independent variable in all those cases. 
 
Firstly, a cohort of patients aged over 18 years admitted for CAP to the Galdakao-
Usansolo Hospital was assessed from January 2001 to July 2009. One-year mortality 
after diagnosis was assessed using the computer support of the Public Health System 
of the Basque country. In this sense, since it was long-term mortality and, in order to 
alleviate the impact of the factors associated with short-term mortality, patients who 
had died up to 15 days after diagnosis were excluded from the study. 
 
A total of 2,351 patients were included and divided into two cohorts, a derivation 
cohort with 1,208 patients and a validation cohort with 1,143 patients. After one year, 
250 (10.63%) patients had died. Clinically relevant variables that could be related to 
one-year mortality were assessed, and those that were statistically significant in the 
univariate analysis were included in the multivariate analysis.  
 
Age >80 years, heart failure, dementia, respiratory rate ≥30 breaths per minute, and 
blood urea nitrogen (BUN) >30 mg/dL were significantly related to one-year mortality. 
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A predictive model was created with a weighted score (one-year CAPSI) including five 
variables in order to predict one-year mortality. Patients aged over 80 years received 
four points, heart failure two points, dementia six points, respiratory rate  ≥30breaths 
per minute two points, and BUN >30 mg/dL three points. Considering one-year CAPSI 
as a continuous variable, the C-index was 0.76 in the derivation cohort and 0.77 in the 
validation cohort. Thus, for each increase of one unit on the score, patients exhibited a 
hazard ratio of 1.24 for one-year mortality. When the score was categorized into three 
classes, patients of the derivation cohort that had between four and five points 
exhibited a hazard ratio for one-year mortality of 3.19, whereas those with more than 
five points exhibited a hazard ratio of 9.91. The existing scores for short-term mortality 
risk were compared with the new one-year CAPSI model for the prediction of one-year 
mortality. This new model showed better predictive ability than CURB65 and SCAP 
score. 
 
In the second section of the present study, the role of some biomarkers for prediction 
of one-year mortality were assessed. In addition, the values of serial measurement of 
biomarkers for this prediction were assessed. Systemic inflammation in pneumonia 
has been discussed in recent years and the role of biomarkers has been crucial in 
these studies. It seems clear that patients with severe pneumonia exhibit higher levels 
of biomarkers at the time of diagnosis. These biomarkers can be used to identify those 
patients with high probability of developing complications or even dying. However, 
some biomarkers go beyond and are useful to even identify long-term mortality. 
 
231 patients admitted for CAP between June 2008 and July 2009 were included and 
blood tests were obtained to study the biomarkers at the time of diagnosis and after 3-
5 days when possible. The biomarkers assessed were C-reactive protein, 
procalcitonin, and proadrenomedullin (proADM). In the same way as in the previous 
study, those patients who had died within 15 days after diagnosis were excluded from 
the study (one-year mortality rate of 10.39%). High proADM levels at the time of 
diagnosis were significantly related to severity of the disease measured by means of 
the different prediction scores. Risk scores showed a high predictive accuracy for one-
year mortality. However, biomarkers showed poor predictive accuracy for one-year 
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mortality and were not able to improve the prediction ability of risk scores for one-year 
mortality when added to the scores.  
 
In a subanalysis carried out including all deaths up to one year, proADM showed the 
best predictive ability for one-year mortality (C-index 0.71) and, when added to the 
one-year CAPSI, the prediction ability of the score was significantly improved. On the 
other hand, the role of changes in proADM values from admission to 3-5 days was 
assessed. Once it was adjusted by proADM value at baseline, a decrease in proADM 
from the first 24 hours to 3-5 days was associated with a significantly reduced risk of 
death at one year. However, once it was also adjusted by severity of disease and 
proADM baseline value, only when all deaths within one year were analyzed was 
associated with a significantly reduced risk of death at one year, meaning that, based 
on our sample, its predictive ability is mainly for short-term mortality.  
 
Finally, one-year mortality was assessed in an external cohort of patients with 
pneumonia. To that end, I spent three months in a center of international reference for 
pneumonia in the "Division of Infectious Diseases at the University of Louisville School 
of Medicine". There, I assessed retrospectively one-year mortality from a cohort of 
patients admitted for CAP at the “Louisville Veterans Affairs Medical Center” from 
June 2001 to November 2006. Since this cohort of patients consisted of war veterans 
with very particular characteristics, it was not possible to apply the score used in the 
first study and I carried out a specific analysis in this cohort.  
 
455 patients admitted for CAP at the Louisville Veterans Affairs Medical Center were 
included in the analysis and the clinically relevant variables and their relationship with 
one-year mortality was assessed. A genetic algorithm was used to identify the best 
predictive model for one-and five-year mortality. It was found that 121 (27%) patients 
had died within one year, whereas 265 (58%) had died after five years. A model with 
the inclusion of the variables age greater than 75 years, cancer, heart failure, albumin 
below 3.5 mg/dL, <100,000/L or >400,000/L platelets, and dementia exhibited a 
predictive power of 0.77 (AUC) for one-year mortality. However, that same model 
showed little predictive power for five-year mortality. 
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In summary, short-term mortality in hospitalized patients with CAP has been widely 
assessed while less is known about long-term prognosis. The aim of this thesis was to 
assess one-year mortality in hospitalized patients with CAP. An easy-to-use risk score 
(one-year CAPSI) for one-year mortality was created based on the presence of five 
variables with a high predictive accuracy. On the other hand, proADM was useful, 
based on our sample, for the prediction of one-year mortality; though mainly explain 
by short-term mortality. In addition, a decrease in proADM from the first 24 hours to 3-
5 days, adjusted by proADM value at baseline, was associated with a significantly 
reduced risk of death at one year. Finally, a specific score for one-year mortality was 
created for a cohort of patients admitted for CAP at the Louisville Veterans Affairs 
Medical Center. Future research should focus on the impact of inflammation on CAP 
prognosis at long-term follow-up. 
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Komunitatean hartutako pneumonia (KHP) erikortasun eta hilkortasun handiko osasun 
publiko arazo garrantzitsua da. Urteko inzidentzia bi eta zortzi 1000 biztanlekoa da. 
Estatu Batuetan, gripearekin batera, zazpigarren heriotza kausa izan zen 2008an. Epe 
laburreko hilkortasuna KHP daukaten paziente ospitaleratuetan altua da eta are 
gehiago zainketa intentsiboko unitate batean ospitaleratzean, droga basoaktiboen 
beharra dagoenean hilkortasun tasa %50 igotzen delarik. Epe luzeko hilkortasuna ere, 
altua izaten jarraitzen du %8, %21 eta %36a, 90 egun ondoren, urte batera eta bost 
urtetara, hurrenez hurren. 
 
Hainbat autorek larritasun eskalak garatu dituzte epe laburreko hilkortasunerako. 
Zentzu berean, lehengo 15 egunetan ematen diren heriotzak prosezu akutuarekin 
erlazionatu dira. Hala ere, pneumonia eta epe luzeko hilkortasunaren arteko erlazioa 
ez dako batere argi. Badirudi, pneumoniagatik ospitaleratutako pazienteek, hilkortasun 
tasa handiagoa dutela beste arazoengatik ospitaleratutakoak baino. Badira egile 
batzuk, epe luzeko hilkortasun aurresaleak identifikatzen saitu direnak. Hala ere, 
urtebeteko hilkortasuna aurreikusteko eskala espezifikoak ez dira garatu orain arte. 
Tesi honen helburu nagusia KHP daukaten paziente ospitaleratuetan urtebeteko 
hilkortasuna aztertzea izan zen. Horretarako, hiru azterketa desberdin garatu ziren, 
hiruretan urtebeteko hilkortasuna aldagai independientea izanik. 
 
Lehenengo eta behin, 18 urte baino gehiagoko KHP zuten paziente ospitaleratuak 
urtarrileko 2001tik uztaileko 2009ra aztertu ziren. Urtebeteko hilkortasuna zehaztu zen 
ordenagailu bidezko euskal sistemaren bidez. Prozesu akutuak hilkortasunaren gain 
duen eragina ekiditziko, lehenego 15 egunetan eman ziren heriotza guztiak baztertu 
egin ziren. 
 
2.351 paziente sartu ziren eta lagina bitan zatitu zen, 1.208 paziente deribazio 
laginean eta 1.143 paziente balidazio laginean hain zuzen ere. 250 (10.63%) paziente 
urtebeteko epean hil ziren. Klinikoki urtebeteko hilkortasunarekin garrantzia zuten 
aldagaiak aztertu ziren eta estadistikoki signifikatiboak izan zirenak, analisi 
multibariantean sartu ziren. 
 
Adina > 80 urte, bihotz-gutxiegitasuna, dementzia, arnas tasa ≥ 30 arnas minutuko eta 
BUN > 30 mg/dL urtebeteko hilkortasunarekin estadistikoki erlazionatu zen. Bost 
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aldagaietan oinarritutako urtebeteko hilkortasunerako eredu iragarpen bat garatu zen 
(one-year CAPSI). 80 urte baino gehiago zutenek lau puntu jasotzen zituzten, bihotz-
gutxiegitasuna zutenek puntu bi, dementzia zutenek 6, arnas tasa ≥ 30 arnas 
minutuko zuetenek bi puntu eta BUN > 30 mg/dL zutenek berriz, hiru puntu. One-year 
CAPSI, etengabeko aldagaia bezela hartuta, C-indexa 0.76 izan zen deribazio 
laginean eta 0.77 balidazioan. Eskala puntu gehikuntza bakoitzeko, urtebeteko 
hilkortasun arriskua 1.24 (HR) zen. Eskala hiru zatitan banatzerakoan, hiru eta bost 
puntu arteko puntuazioa jasotzen zuten pazienteen urtebeteko hilkortasun arriskua 
3.19 (HR) zen, bost puntu baino gehiago jasotzen zutenenen arriskua berriz, 9.91(HR) 
zen. One-year CAPSI, egungo eskalekin konparatu egin zen eta CURB65 eta SCAP 
eskalak baino iragarpen ahalmen handiagoa erakutsi zuen urtebeteko 
hilkortasunerako. 
 
Bigarren atal honetan, biomarkadore batzuk aztertu ziren urtebeteko iragarpenean. 
Azkenengo boladan, pneumonian ematen den inflamazioa asko neurtu da eta 
biomarkadoreak garrantzi handikoak bilakatzen ari dira arlo honetan. Biomarkadoreen 
erabilera gaixotasunaren larritasuna neurtzeko eta  epe laburreko konplikazioak 
iragartzeko argi dago. Gainera, badira biomarkadoreak epe luzeko pronostikoan ere 
erabilgarriak direnak. 
 
Ekainaren 2008tik uztailaren 2009ra odol laginak lortu ahal izan ziren eta KHP zuten 
231 paziente ospitaleratuak aztertu ziren. Odol laginak diagnostikoaren momentuan 
lortzen ziren eta hirugarren eta bostgarren egunen artean ere ahal izanez gero. 
Aztertutako biomarkadoreak proteina C erreaktiboa, prokaltzitonina eta 
proadrenomedulian (proADM) izan ziren. Lehenengo estudioan bezala, lehenengo 15 
egunetako heriotzak analisitik kanpo geratu ziren (10.39%). 
 
ProADM balio altuak gaixotasunaren larritasunarekin, larritasun eskalen bidez neurtua 
erlazionatu zen. Larritasun eskalak urtebaterako iragarpen balio handia erakutsi 
zuten. Biomarkadoreak, aldiz, iragarpen baxua izan zuten urtebeterako, gauza bera 
gertatzen zelarik behin biomarkadoreak eskalei gehituta. Aldi berean, beste analisi bat 
egin zen diagnostiko momentutik urtebeterarte heriotza guztiak barne hartuta. 
ProADM urtebeterako iragarpen altua izan zuen C-index 0.71rekin eta are gehiago, 
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one-year CAPSIri gehitzean, eskalaren iragarpen balioa handitu egin zen. Beste alde 
batetik, proADMren aldaketak aztertu ziren diagnostiko momentutik hiru-bostgarren 
egunera. Behin ProADM lehendabiziko balioagatik egokituta, proADM murrizketa 
diagnostikoko momentutik hirugarren-bostgarren egunera, urtebeteko hilkortasunaren 
murrizketarekin estadistikoki erlazionatu zen. Hala ere, lehendabiziko balioagatik 
aparte gaixotasunaren larritasunagatik egokitzerakoan, urtebeteko hilkortasunaren 
murrizketa heriotza guztiak barne zituen analisian bakarrik frogatu ahal izan zen. 
Ondorioz, behintzat gure paziente laginean, proADMak urtebeteko iragarpen balioa 
dauka baina batez ere, epe laburreko hilkortasuna dela-eta. 
 
Azkenik, KHP zuten ospitaleratutako pazienteen urtebeteko hilkortasuna kanpoko 
lagin batean aztertu zen. Horretarako, hiru hile egon nintzen pneumonia arloan 
internazionalki ezaguna den zentru batean, Division of Infectious Diseases at the 
University of Louisville School of Medicine. Han nengoela, erretrospektiboki aztertu 
genituen 2001eko ekainatik 2006ko azarorarte KHPgatik ospitaleratutako pazienteak 
Louisvilleko Veterans Affairs Medical Centereko ospitalean. One-year CAPSI lagin 
honetan erabilia izan zenean, huts egin zuen urtebeteko iragarpenean, batez ere, 
laginen arteko desberdintasunengatik. Izan ere, guda zibilean izandako 
pertsonentzako ospitalea da eta horrek, ezaugarri espezifikoak izatea eragiten bait du. 
KHP rekin Kentuckyn, Louisvilleko Veterans Affairs Medical Centerean 
ospitaleratutako 455 paziente aztertu ziren. Algoritmo genetiko bat erabili zen 
urtebeteko eta bost urteko hilkortasunerako eredu iragarpen onenak zehazteko. 121 
(%27) eta 265 (%58) paziente hil ziren urtebetera eta bost urtetara, hurrenez hurren. 
Adina > 75 urte, minbizia, bihotz-gutxiegitasuna, dementzia, albumina <3.5 mg/dL eta 
plaketak <100,000/L o >400,000/L kontuan hartutako ereduak, iragarpen balio handia 
izan zuen, 0.77 (AUC). Hala ere, eredu berak huts egin zuen bost urteko hilkortasuna 
iragartzeko erabilia izan zenean. 
 
Laburbilduz, epe laburreko hilkortasuna luze eta zabal ikertu da, epe luzeko 
hilkortasunari buruz, berriz, gutxiago dakigu. Tesi honen helburu nagusia KHPgatik 
opstaleratutako pazienteetan urtebeteko hilkortasuna aztertzea izan zen. Horretarako, 
errez erabiltzeko eta bost aldagietan oinarritutako potentzia handiko iragarpen eredu 
bat garatu zen. Beste alde batetik, proADM erabilgarria izan zen urtebeteko 
hilkortasuneko iragarpenean, batez ere, epe laburreko hilkortasunagatik azalduta. 
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ProADM murrizketa diagnostikoaren momentutik hirugarren-bostgarren egunera, 
behin proADM hasierako balioagatik egokituta, urtebeteko hilkortasunaren 
murrizketarekin erlazionatu zen. Bukatzeko, urtebeterako iragarpen eredu espezifikoa 
garatu zen Kentucky, Louisvilleko Veterans Affairs Medical Centerean. Etorkizuneko 
ikerketek inflamazioaren eragina pneumoniaren epe luzeko pronostikoarengan aztertu 
behar zuketeen. 
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La neumonía adquirida en la comunidad (NAC) es un importante problema de salud 
pública con una elevada morbi-mortalidad. La incidencia anual oscila entre dos y ocho 
por cada 1000 habitantes. En Estados Unidos, junto con la gripe, fue la séptima causa 
de mortalidad en 2008. La mortalidad a corto plazo de los pacientes ingresados por 
NAC es elevada siendo aún mayor en aquellos pacientes que requieren un ingreso en 
una unidad de cuidados intensivos y de hasta un 50 % en los que necesitan drogas 
vasoactivas. Más allá, la mortalidad a largo plazo persiste siendo elevado a los 90 
días, al cabo de uno y cinco años con tasas del 8%, 21% y 36%, respectivamente. 
 
Diversos autores han elaborado escalas de gravedad para mortalidad a corto plazo. 
En este sentido, la mortalidad a 15 días tras el diagnóstico se ha relacionado con el 
episodio agudo. Sin embargo, la relación entre la neumonía y la mortalidad a largo 
plazo no está del todo esclarecida. Los pacientes ingresados por neumonía padecen 
una mortalidad a largo plazo mayor que aquellos ingresados por otros motivos. 
Algunos autores han tratado de identificar los factores predictores de mortalidad a 
largo plazo. Sin embargo, hasta la fecha, no se han elaborado escalas de predicción 
específicas para la mortalidad a un año en estos pacientes. El principal objetivo de 
esta tesis fue evaluar la mortalidad a un año en pacientes ingresados por NAC. Para 
ello, se llevaron a cabo tres estudios en tres diferentes cohortes siendo la mortalidad 
a un año la variable independiente en todos los casos. 
 
En primer lugar, se evaluó una muestra de pacientes  mayores de 18 años ingresados 
por NAC desde enero de 2001 hasta julio de 2009. Se determinó la mortalidad a un 
año mediante el soporte informático del sistema vasco de salud. Al tratarse de 
mortalidad a largo plazo y tratando de evitar el impacto del episodio de agudo sobre la 
mortalidad, se excluyeron los muertos de los 15 primeros días desde el diagnóstico. 
Se incluyeron un total de 2.351 pacientes dividiéndose la muestra en dos, una 
muestra derivación con 1.208 paciente y otra validación con 1.143. 250 (10.63%) 
pacientes fallecieron al cabo de un año. Se evaluaron las variables clínicamente 
relevantes que pudieran estar asociadas con la mortalidad a un año y aquellas que 
resultaron estadísticamente significativas en el análisis univariante se incluyeron en el 
análisis multivariante. 
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La edad >80 años, la insuficiencia cardíaca, la demencia, la frecuencia respiratoria 
≥30 respiraciones por minuto y el BUN>30 mg/dL se relacionaron de forma 
significativa con la mortalidad a un año. Se elaboró un modelo de predicción para la 
mortalidad a un año mediante una escala ponderada (one-year CAPSI) basada en 
cinco variables. Aquellos pacientes mayores de 80 años obtenían cuatro puntos, la 
insuficiencia cardíaca dos puntos, la demencia seis puntos, la la frecuencia 
respiratoria ≥30 respiraciones por minuto dos puntos y el BUN>30 mg/dL tres puntos. 
Considerando one-year CAPSI en su forma continua, presentó un C-index de 0.76 en 
la muestra derivación y de 0.77 en la muestra validación. Por cada incremento  en un 
punto en la escala, los pacientes presentaban un hazard ratio de 1.24 para la 
mortalidad a un año. Al categorizar la escala en tres clases, aquellos pacientes de la 
muestra derivación que obtenían entre tres y cinco puntos, presentaban un una 
probabilidad 3.19 (HR) veces mayor de muerte al cabo de un año, mientras que en 
aquellos con más de cinco puntos era 9.91(HR) veces mayor. Se comparó one-year 
CAPSI con las escalas existentes en la actualidad en su poder predictivo para la 
mortalidad a un año, siendo one-year CAPSI superior que las escalas CURB65 y 
SCAP. 
 
En la segunda parte de este trabajo, se evaluó el papel de algunos biomarcadores 
para la predicción de mortalidad a un año. Además, se pudo evaluar el valor de los 
biomarcadores obtenidos en el seguimiento para la mortalidad a un año. 
Recientemente, se ha estudiado la inflamación sistémica en la neumonía con un 
papel primordial de los biomarcadores. Parece claro que niveles elevados de ciertos 
biomarcadores se relacionan con una mayor gravedad de la neumonía y de ahí su 
utilidad para la detección de complicaciones o la muerte. Sin embargo, algunos 
biomarcadores van más allá pudiendo incluso predecir la mortalidad a largo plazo. 
 
Se analizaron 231 pacientes con diagnóstico de NAC entre junio de 2008 y julio de 
2009 en los que se pudo obtener muestras sanguíneas para el análisis de 
biomarcadores en el momento del diagnóstico y a los tres cinco días en algunos de 
ellos. Los biomarcadores analizados fueron la proteína C reactiva, la procalcitonina y 
al proadrenomedulina (proADM). De la misma manera que en el primer estudio, se 
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excluyeron los pacientes fallecidos en los 15 primeros días desde el diagnóstico 
(10.39%). 
 
Niveles elevados de proADM se relacionaron de forma significativa con la gravedad 
en el momento del diagnostico medido por las escalas de gravedad. Las escalas de 
gravedad mostraron una elevada capacidad predictiva para la mortalidad a un año. 
Sin embargo, los biomarcadores presentaron un escaso poder predictiva para la 
mortalidad a un año y tras añadir la proADM a las escalas, la capacidad predictiva no 
mejoró. En un subanálisis realizado incluyendo todos los muertes desde el 
diagnóstico hasta el año, la proADM fue el biomarcador que mejor predijo la 
mortalidad a un año con un C-index de 0.71. Asimismo, al añadirlo a one-year CAPSI 
la capacidad predictiva mejoró significativamente. Por otro lado, se evaluó el papel del 
cambio de los niveles de proDAM desde el momento del diagnóstico a los 3-5 días. 
Tras ajustar por el valor de proADM en el momento del diagnóstico, una reducción de 
los niveles de proADM desde el diagnóstico a los 3-5 días se asoció de forma 
significativa con una reducción de la mortalidad a un año. Sin embargo, tras ajustar 
por gravedad de la enfermedad además de por el valor basal de proADM, únicamente 
cuando todos los muertos fueron incluidos se asoció con una disminución de la 
mortalidad a un año. Por lo tanto, basándose en nuestra muestra, la capacidad 
predictiva de mortalidad de la proADM consiste principalmente en la predicción a 
corto plazo. 
 
Por último, se evaluó la mortalidad a un año en una muestra externa de pacientes con 
NAC. Para ello, realicé una estancia de tres meses en un centro de referencia 
internacional en neumonías, Division of Infectious Diseases at the University of 
Louisville School of Medicine. Una vez allí, evalué de forma retrospectiva la 
mortalidad a un año de una muestra de pacientes ingresados por NAC desde junio de 
2001 a noviembre de 2006, en el hospital “Veterans Affairs Medical Center of 
Louisville”, en Louisville, Kentucky. Se trató de replicar one-year CAPSI en dicha 
muestra sin éxito por tratarse de una muestra muy peculiar con pacientes veteranos 
de guerra con características sociodemográficas y clínicas muy específicas. 
 
Se analizaron 455 pacientes  ingresados por NAC en Veterans Affairs Medical Center 
de Louisville, Kentucky, y se evaluaron las variables clínicamente relevantes con la 
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mortalidad a un año. Se utilizó un algoritmo genético para determinar el mejor modelo 
predictivo de mortalidad a uno y cinco años. 121 (27%) pacientes fallecieron a un año 
y 265 (58%) a los cinco años. Un modelo incluyendo la edad mayor de 75 años, el 
cáncer, la insuficiencia cardiaca, demencia, albumina <3.5 mg/dL y plaquetas 
<100,000/L o >400,000/L  presentaron una capacidad predictiva de 0.77 (AUC). Sin 
embargo, el mismo modelo presentó una débil capacidad predictiva para la mortalidad 
a los cinco años. 
 
En resumen, la mortalidad a corto plazo en pacientes ingresados por NAC ha sido 
ampliamente estudiada mientras que el pronóstico a largo plazo no está del todo 
establecido. El objetivo de esta tesis fue evaluar la mortalidad a un año en pacientes 
ingresados por NAC. Para ello, se elaboró una escala de fácil implementación basada 
en cinco variables con un elevado poder predictivo. Por otro lado, a proADM fue de 
utilidad para la predicción de mortalidad a un año aunque principalmente explicado 
por la mortalidad a corto plazo. Asimismo, un descenso de los niveles de proADM 
desde el momento del diagnóstico a los 3-5 días, ajustado pro el valor basal de la 
proADM, se asoció con una reducción de la mortalidad a un año. Finalmente, se 
elaboró una escala específica para la mortalidad a un año en una muestra de 
pacientes ingresados por NAC en Veterans Affairs Medical Center de Louisville, 
Kentucky. Las investigaciones futuras deberían centrar sus esfuerzos en el impacto 
de la inflamación en el pronóstico a largo plazo de la NAC. 
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2.1 Definition 
 
The term “infection” comes from the vernacular language of the Romans: "in-fec" = 
enter, mix; and "tion(em)" = action. Derived from the verb "inficere" (stain, corrupt), its 
pathological value was used for the first time in medieval Latin. The word “pneumonia” 
is a medieval term and comes from the Greek pneumonia or pleumonia. This term 
was not used by the Greek physicians but by Plutarch in the second century AD, and 
subsequently used in English in 1603. 
 
Pneumonia is defined as an infection of the pulmonary parenchyma associated with 
infiltrates on chest radiograph, which did not exist previously, and the presence of two 
or more breathing symptoms, such as fever, cough, expectoration, dyspnea, and 
pleuritic pain (1). Pneumonia can be caused by different microorganisms giving place 
to entities with different physiopathology, clinical picture, and prognosis, which in 
addition require specific treatments. Because of the disparity between the different 
forms, there are multiple classifications which give rise to a more global view and a 
better understanding of the disease (2). 
 
Pneumonia can be classified according to the type of host and can affect 
immunocompetent or immunocompromised patients. On the one hand, the underlying 
etiologic agent is completely different and factors such as the type of 
immunosuppression or its intensity help in the etiologic diagnosis of presumed 
pneumonia. Each entity requires a different management with specific therapeutic 
attitudes and different prognosis. 
 
When the disease affects the general population, it is called community-acquired 
pneumonia (CAP) and differs from that found in patients admitted to hospitals who, in 
the majority of cases, have a worse prognosis. The latter is defined as one that 
develops in patients hospitalized for more than 48 hours and that was not incubating 
at the time of admission. The American guidelines for nosocomial pneumonia 
incorporated the term healthcare-associated-pneumonia (HCAP) (3). Risk factors of 
this type of pneumonia include pathogens which are multidrug-resistant due a prior 
contact with healthcare and that may occur inside or outside hospitals. These risk 
factors include patients admitted in the last 90 days, those admitted to nursing homes 
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or other centers for chronic disease care, those receiving intravenous treatment at 
home, patients on chronic dialysis, and patients in contact with a family member with a 
multidrug-resistant pathogen. However, drug resistant pathogens can arise either in 
CAP or HCAP and it can be predicted by taking into account the cumulative number of 
the risk factors (4). 
 
Another factor to take into account is anatomical involvement, which can be 
characterized by lobar pneumonia, bronchopneumonia, necrotizing pneumonia, lung 
abscess, or interstitial pneumonia. On the other hand, pneumonia can be classified by 
the causal agent. However, in the great majority of cases, the pathogen is not known 
at the time of diagnosis, what makes this classification little feasible in the clinical 
practice. 
 
Finally, CAP has been classically catalogued as typical or atypical pneumonia 
according to the clinical picture and radiological findings. The atypical form usually 
emerges in a subtle manner, with little fever, non-productive cough. and with 
segmental and interstitial patchy infiltrates. The typical CAP is characterized by the 
presence of fever, involvement of the general state, and symptoms attributable to the 
respiratory system, such as cough, expectoration, dyspnea, and pleuritic chest pain. 
 
In the same way, bacteria have been defined as typical and atypical. Among others, 
Streptococcus pneumoniae, Haemophilus influenza, and Moraxella catarrhalis were 
included in the first group. On the other hand, Legionella pneumophila, Mycoplasma 
pneumonia, and Chlamydia pneumoniae were included in the atypical group, even 
though this classification is in disuse. In addition, most of the time, it is not possible to 
identify the etiologic agent. Despite the microbiological definition of CAP, it is usually a 
syndromic diagnosis with the presence of a compatible clinical picture and a 
pulmonary infiltrate observed on the chest radiograph. 
 
Under normal conditions, there is a balance between the host-microorganism 
interaction and, when it is disrupted, the infection occurs with the consequent 
activation of defense mechanisms, whose main function is to reduce the damage and 
restore homeostasis. Recently, new definitions have been published by "The Third 
International Consensus Definitions for Sepsis and Septic Shock", understanding the 
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concept of sepsis as the dysfunction of an organ that threatens life as a result of an 
aberrant or unregulated host response to the infection (5). In clinical practice, organ 
dysfunction can be measured through the Sequential Organ Failure Assessment with 
excess mortality greater than 10% in those patients with scoring over 2 points. When 
sepsis is combined with vasopressor requirement to maintain a mean arterial pressure 
of 65 mmHg or greater and a serum lactate level greater than 2 mmol/L (>18 mg/dL) 
in the absence of hypovolemia, it is called septic shock, and the combination of both 
conditions is associated with in-hospital mortality greater than 40%. 
 
The severity of these patients has been discussed in the last decade. When CAP is 
severe, there is a critical situation characterized by a high short-term mortality rate, 
which, in addition, persists with a high long-term mortality rate (5). The early 
identification of severe patients with high probability of suffering complications, even in 
the long term, is fundamental for the implementation of strategies to improve their 
prognosis. 
 
 
2.2 Epidemiology 
 
The incidence ranges between two and eight cases per 1,000 inhabitants a year, 
although its real estimate is difficult due to the variability of the information obtained 
from studies (7). This incidence increases at the end of life of individuals with 
comorbidities and is slightly higher in men (8).  
 
In the United States, the annual incidence in adult patients admitted for CAP was 248 
cases for 100,000 inhabitants between 2010 and 2012. This incidence increased with 
age, i.e., 630 cases per 100,000 inhabitants (65-79 years) and 1,640 cases per 
100,000 inhabitants (≥80 years) (9). A retrospective study conducted in Spain 
between 2003 and 2007 with hospitalized patients aged 50 years or older, and 
information retrieved from the Minimum Basic Dataset showed an annual incidence of 
627 cases per 100,000 inhabitants (10). 
 
CAP is responsible for 5 to 12% of respiratory infections and represents the first 
infectious cause that explains hospital admission. At the same time, it is an issue of 
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great relevance due to the high direct and indirect costs that it generates (8,10). 
Admission rates varies by country, study period time and study design. A study 
conducted in Biscay, in the reference area of the Galdakao-Usansolo hospital 
covering 300,000 inhabitants, estimated a CAP incidence of 3.1 per 1,000 adults per 
year, whereas 43.5% of patients attending the Emergency Department required 
hospital admission (11). 
 
Recently, Huang et al. (12) published the cost and use of health resources in the 
United States. The study was conducted between 2004 and 2005 and assessed data 
of pneumococcal disease in both hospitalized patients and outpatients. The authors 
observed four million cases of pneumococcal disease with a direct cost of 2.5 billion 
dollars. The greatest severity and, accordingly, the highest cost were observed in 
patients aged over 65 years. However, when the authors assessed the loss of work 
days and productivity (indirect cost) among patients aged 18 to 50 years, the cost was 
equal to that of patients aged over 65 years.  
 
Similarly, a study conducted in Spain showed that the average direct cost for the 
treatment of hospitalized patients was 2,332 Euros, whereas for outpatients the 
average cost was 698 Euros (13). 
 
 
2.3 Long-term prognosis of community-acquired pneumonia 
 
2.3.1 Magnitude of the problem 
 
CAP is considered a major problem of public health due to its high morbimortality (14). 
According to data of the National Statistical Institute, 4,254 men and 3,998 women 
died from pneumonia in 1999 in Spain. The mortality rate in 2002 was 19.5 per 
100,000 inhabitants, ranking as the ninth cause of death in Spain (15). In 2008, 
together with influenza, pneumonia was the seventh cause of mortality in the United 
States with 59,000 deaths in that year (16). 
 
To a large extent, mortality depends on the place where the patients are treated. In 
outpatients, the rate is less than 3%, in patients admitted to a conventional unit, the 
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rate ranges from 5 to 10%, whereas in those patients who require admission to an 
intensive care unit amounts to 25% if they require orotracheal intubation and up to 
50% if they require vasopressors (17). 
 
Patients with pneumonia have a high risk of complications during the episode, such as 
requiring mechanical ventilation and vasopressors, or developing multiorgan failure. 
Most studies published to date have studied the relationship between pneumonia and 
short-term mortality. This way, some authors affirm that death related to the 
pneumonia episode mostly occurs within the first 15 days (18,19). 
 
There are various factors associated with short-term mortality. The most accepted are 
etiology, comorbidities and the form of the disease. In most cases, the etiologic 
diagnosis is unknown. However, there are factors that can influence in a predominant 
manner on the appearance of the microorganism, such as geographic areas, age, 
residing in nursing homes, and comorbidities. This way, in those patients with 
Pseudomonas aeruginosa pneumonia, mortality ranges around 61%, whereas in 
pneumonia caused by enterobacteria mortality will be 35% and in pneumonia 
produced by Legionella or Streptococcus pneumoniae 15% (17). However, the most 
frequent germ in all series and areas is Streptococcus pneumoniae and, in this case, 
severity is influenced by factors such as bacteremia, bacterial load, serotypes, 
antimicrobial resistances, and comorbidities (20). 
 
The incidence and severity of CAP is greater in patients with chronic respiratory 
diseases, since their capacity to respond to external aggressions is decreased (21). 
Similarly, there are various diseases that increase the probability of suffering from 
CAP, and some have been associated with a worse prognosis, such as cancer, 
neurological diseases, and diabetes mellitus (21). 
 
The factors associated with increased short-term mortality due to pneumonia are 
multiple. A meta-analysis conducted by Fine et al. (17) included 33.148 patients and 
identified 11 variables associated with increased mortality, namely: male individuals; 
advanced age; neurological diseases; neoplasms; diabetes mellitus; hypothermia; 
tachypnea; hypotension; leucopenia; bacteremia; and multilobar involvement on chest 
radiograph. The global mortality of these patients was 13.7%, and the variables were: 
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age; comorbidities; and clinical, analytical, and radiological findings. All these factors 
were included in the severity score known as Pneumonia Severity Index (PSI). 
 
Therefore, the short-term prognosis for CAP seems to be well established. However, 
there are data indicating that patients who survive a pneumonia episode have a high 
mortality rate, even in the medium and long term, with figures of 8, 21, and 36% after 
90 days, one year, and five years, respectively (22). Despite the improvement in the 
diagnostic methods and the use of new and more effective broad-spectrum antibiotics, 
the picture does not seem to have changed substantially. 
 
Often, an acute condition in older adults that requires hospitalization implies a 
subsequent clinical worsening. Recently, the need for hospital admission has been 
related to a higher mortality rate after one year in patients admitted for any reason. In 
this sense, Walter et al. (23) published a study in The Journal of the American Medical 
Association in 2001 in which they created an easy procedure to stratify individuals 
aged over 70 years into risk groups according to the risk of death after being admitted 
to hospital by any cause. The authors assessed a cohort of 3,163 patients and 
identified six variables (sex, congestive heart failure, cancer, previous functional state, 
creatinine, and albumin) as predictors of one-year mortality with an area under curve 
(AUC) of 0.75 in the derivation cohort and 0.79 in the validation cohort. Therefore, 
both were over the scores already known and well established for the prediction of 
one-year mortality, as the Charlson Index Score or Acute Physiology and Chronic 
Health Evaluation (APACHE), with AUC of 0.68 and 0.59, respectively. 
 
Levine et al. (24) created and validated a similar prognostic index without the need for 
complementary evidence and using only data obtained from computer support with 
similar results, although with lower AUC values. Some authors have gone beyond 
creating scores to even predict 4-year mortality in outpatients and obtained good 
results. 
 
Kaplan et al. (25) assessed patients admitted for pneumonia and found that in-hospital 
mortality rate was the half in the control group compared with the CAP group. One-
year mortality after hospital discharge and adjusted for comorbidities was 33.6% 
among those patients who had been discharged with a diagnosis of CAP versus 
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24.9% in the control group without CAP (p = 0.001). In the control group, mortality 
increased with age and comorbidities; however, mortality in the CAP group persisted 
and was significantly more elevated. Bourdon et al. (2010) conducted a 7-year follow-
up assessing 6,971 admitted patients retrospectively, of which 624 had diagnosis of 
CAP. Patients admitted for CAP were 40% more likely to die than those admitted for 
other reasons with a hazard ratio of 1.4. 
 
Mortensen et al. (22) conducted a study included in the Patient Outcomes in Renal 
Transplantation (PORT) study and assessed admitted patients and outpatients (n = 
1,555) with a diagnosis of CAP and a 5.9-year follow-up. The authors compared long-
term mortality among those who had survived after 90 days of the episode with a 
control group of similar age. They observed that patients with CAP died more 
frequently and with significant differences. A recent study assessed a German cohort 
and described mortality after a CAP episode within one, five, and seven years with 17, 
43, and 53%, respectively, compared with 4, 19, and 24% in a reference cohort with 
similar age and sex (26). 
 
In the same vein, Yende et al. (27) assessed patients aged 70 to 79 years admitted to 
hospital for various reasons. The authors described that one third of patients admitted 
for CAP died after five years. In addition, they observed one-and five-year mortality, 
which was similar to mortality in those patients admitted for heart failure, 
cerebrovascular disease, or fracture; however, those rates were lower than mortality in 
patients admitted for cancer. The authors found an association between admission for 
CAP and 5-year mortality, independent of previous comorbidities. 
 
A comprehensive Finnish study conducted during 12 years found that the mortality 
rate in survivors to CAP episodes was the double compared to mortality in those 
patients who had not suffered pneumonia, and it was even more elevated if the 
patients had suffered pneumococcal pneumonia (28). 
 
More recently, Eurich et al. (29) compared 6,078 patients with CAP with 29,402 
control patients matched for age, sex and site of treatment with a 10-year follow-up in 
Canada. The authors observed a greater mortality rate in the group with pneumonia, 
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even when they assessed admitted patients and outpatients with CAP separately and 
having excluded patients deceased until the first 90 days. 
 
Therefore, these results make it clear that patients with CAP have increased mortality 
rates, also in the long term. However, the influence that the interaction between acute 
episodes and the various comorbidities and conditions may exert should be assessed 
carefully. Therefore, this disease is considered a major problem of public health and 
should be the subject of further investigations in order to optimize its management 
and, undoubtedly, improve its prognosis. 
 
2.3.2 Causes of mortality 
 
Mortensen et al. (30) reported 208 (9%) deaths after 90 days in a cohort of more than 
2,000 patients with CAP from the PORT study. The most frequent intermediate cases 
were respiratory failure, cardiac conditions, and infectious diseases in decreasing 
order. On the other hand, once the underlying causes of death were assessed, 
neurological conditions, malignancies, and cardiac conditions were the most frequent 
in decreasing order. Moreover, the authors found that age and aspirations were 
predictors of the two types of mortality. 
 
Bruns et al. (26) conducted a prospective observational study assessing patients with 
CAP and identified neoplasia as the most frequent cause of death (27%), followed by 
chronic obstructive pulmonary disease (19%), and cardiovascular disease (16%). 
Indeed, when compared to the general Dutch population, not only patients with CAP 
had higher mortality rates after one, five and seven years, but also had four times 
increased risk to have chronic obstructive pulmonary disease as their cause of death. 
Nevertheless, the fact that patients with chronic obstructive pulmonary disease have a 
higher incidence of CAP may lead to bias. In contrast, cardiovascular events have 
been postulated to contribute to more tan 30% of deaths in patients with CAP in the 
long term (31). 
 
More recently, Adamuz et al. (32) assessed 1,284 patients discharged after a CAP 
episode and 7.2% of them died within a year. The authors found that comorbidity 
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conditions, rehospitalization within 30 days after discharge, and nursing home 
residence were independently associated with one-year mortality after hospital 
discharge. More interestingly, they determined causes of death and observed that 
infectious diseases were the main reason for one-year mortality, followed by acute 
cardiovascular events. Moreover, the mortality rate caused by infectious diseases was 
higher during the first six months and decreased progressively after that moment while 
cardiovascular events were stable throughout the follow-up. 
 
Therefore, several authors suggest that high long-term mortality rate in patients with 
CAP could be due to a persistent inflammatory response after hospital discharge or 
even cardiovascular or neoplastic diseases that were not previously known and 
emerged after the episode. 
 
2.3.3 Predictive factors of mortality 
 
Age 
 
The number of individuals aged over 65 years has increased in recent years and that 
number is expected to rise from 12% in 2000 to 20% in 2030, and even reaching the 
double in 2050 (33). In general, the older adult population suffers from a greater 
number of comorbidities and the functional status is often poor.  
 
Hedlund et al. (34) suggested that the mortality rate increased after three years of a 
CAP episode and was even higher in patients aged over 50 years. However, Bracanti 
et al. (35) published a study with 141 patients admitted for CAP comparing different 
age groups with the group aged between 18 and 44 years. The differences found for 
2-year mortality were not significant. The authors concluded that age was not 
associated with mortality and that the important factor was not the chronological age, 
but the physiological age. 
 
Numerous articles published afterwards differ from Bracanti’s findings and highlight 
age as one of the main predictors of mortality. What still remains to be clarified is the 
cut-off point at which age begins to be a risk factor. Some studies use 50 years, 
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whereas authors such as Sligl et al. (36) have used 70 years as a cut-off point. In a 
Canadian group, in which the authors compared a CAP group with a control group, 
they described a lowest absolute rate difference for mortality among patients aged 
<25 years, whereas patients aged >80 years had the highest absolute rate difference 
(29). However, the hazard ratio was higher in the first group (2.40 vs. 1.42). 
 
Sex and race 
 
Most studies point out that the male sex is associated with higher mortality rates 
(25,22,37). Similarly, some authors found an alarming difference regarding race, with 
increased 2-year mortality rate in black individuals compared with white individuals. In 
addition, this difference remained when the reason for admission was another, such 
as heart failure or cerebrovascular accident, among others (38). 
 
Healthcare-associated-pneumonia (HCAP) 
 
The definition of HCAP includes: patients hospitalized in an acute care hospital for two 
or more days within 90 days of infection; resided in a nursing home or long-term care 
facility; received recent intravenous antibiotic therapy, chemotherapy or wound care 
within the past 30 days of the current infection; attended a hospital or a hemodialysis 
clinic; or had a family member with a drug resistant pathogen. Nursing homes and 
long-term care facilities have been assessed as risk factors for drug-related problems. 
An increasing prevalence of pneumonia caused by drug-related problems have been 
identified. The guidelines provided by the American Thoracic Society (ATS) and the 
Infectious Diseases Society of America (IDSA) in 2005 proposed a HCAP model in 
order to identify the increased risk of drug-related problems in patients from the 
community (3). These patients are known to have a worse prognosis, mostly due to 
poor functional status and treatment restrictions (39). Patients residing in nursing 
homes and long-term care facilities have an increased risk of death due to advanced 
age, high number of comorbidities, and poor functional status. Solh et al. (40) 
assessed 88 nursing home patients with severe pneumonia confirmed by culture and 
showed that both previous use of antibiotics and poor functional status were risk 
factors for drug-related problems. In that study, S. aureus was the predominant 
isolated pathogen (31%), followed by enteric gram-negative bacilli (28%), and S. 
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pneumoniae (25%). Nevertheless, other authors have described similarities in 
pathogen distribution between nursing home-acquired pneumonia and CAP (41). Part 
of the explanation for this heterogeneity may be the differences found when nursing 
homes or skilled nursing facilities are assessed in different countries. 
 
In addition, the definition of HCAP has shown several limitations to identify drug-
related problems in patients with CAP, especially outside the USA. Therefore the 
characteristics and functional status of patients classified as "nursing home residents" 
may be very different from one country to another. 
 
In order to identify the factors associated with mortality and compare the differences 
between CAP and HCAP, Cecere et al. (42) conducted a study with 486 patients 
admitted for the two pathologies. Survival after two years was lower in patients aged 
under 65 years with HCAP than in patients aged over 65 years with CAP. 
 
Disease severity 
 
The majority of the scores created to date were intended to measure short-term 
complications. The CURB65 (confusion, urea, respiratory rate, blood pressure, and 
age >65) and the PSI score have proven to be useful in the prediction of 30-day 
mortality. At the time of making a long-term prognosis, authors such as Sligl and 
Johnstone (36,37) identified that those patients with higher PSI scores had greater 
one-and five-day mortality rates, respectively. This result may be due to the fact that, 
unlike the CURB65, the PSI score includes comorbidities such as heart failure, 
cancer, liver disease, kidney disease, and cerebrovascular disease among its 
variables. However, the CURB65 and the PSI scores have been recently assessed for 
long-term mortality in a 6-year follow-up study conducted with patients with CAP and 
the two scores exhibited excellent predictive accuracy, PSI being the best one though 
(43). It is worth noting that the two scores include blood urea nitrogen (BUN) among 
their variables. BUN has been associated with increased mortality among critically ill 
patients, independently of serum creatinine (44). Currently, BUN has not only been 
incorporated to risk scores for predicting pneumonia, but also to models for predicting 
myocardial infarction (45). 
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Capelastegui et al. (46) created a 90-day mortality prognostic index based on pre-
illness functional status measured by Katz index, comorbid conditions measured by 
Charlson Index Score, and disease severity measured by CURB65 without 
considering age as a variable. Mortensen et al. (22) assessed long-term mortality 
among patients included in the Pneumonia Patient Outcomes Research Team (PORT) 
cohort study after excluding deaths up to 90 days after occurrence of CAP. The 
authors found that age, nursing home residence, and comorbid conditions were more 
strongly associated with long-term mortality rather than acute physiologic or laboratory 
findings. However, PSI risk classes were significantly associated with decreased long-
term survival in this cohort with 5.9-year follow-up. 
 
Recently, easy-to-use scores such as CURB65 and CRB65 have been compared with 
Charlson comorbidity index for one-year mortality prediction after a CAP episode with 
disappointing results (47). All the receiver operating characteristic (ROC) curve 
analyses showed a weak and comparable performance of the three indexes (AUC 
<0.70). However, it is worth noting that these two easy-to-use indexes showed similar 
predictive accuracy than the complex comorbidity index. 
 
Other analyses have been proposed to be associated with long-term mortality after a 
CAP episode. Bracanti et al. (35) published a study conducted with 141 patients 
admitted for CAP and found that hematocrits and comorbidities were predictive factors 
of 2-year mortality. This way, it seems that not only comorbidities have an impact on 
long-term mortality, but also disease severity per se may have a role in long-term 
prognosis. 
 
Comorbidities 
 
Multiple comorbidities, such as cerebrovascular disease, cardiovascular disease, 
neoplasms, HIV, chronic obstructive respiratory disease, and deterioration of the 
functional state, have been associated with increased mortality in patients with CAP 
(25,27,37). Koskela et al. (48) assessed 245 patients with CAP of which 152 survived 
after 30 days and were followed up for five years. These authors found that patients 
suffering from diabetes died less frequently compared to those without diabetes with 
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new postprandial hyperglycemia and those without diabetes with no postprandial 
hyperglycemia (p <0.001). 
 
The previous functional state seems to significantly influence on the mortality of these 
patients. Authors such as Sligl (36) related previous functional state to one-year 
mortality and Waterer (49) related it to 3-year mortality. Moreover, Mortensen et al. 
(22) considered the previous functional state as a risk factor for six-year mortality. 
 
Dementia and cerebrovascular disease have also been considered risk factors by 
numerous studies (28,36). Bordon et al. (50) observed a shorter survival rate in 
patients aged over 65 years with cancer, dementia, and liver disease that had been 
admitted for CAP. The group of Edinburgh carried out an observational study with 
1,348 patients admitted for CAP and observed that patients with poorer long-term 
outcome could be identified by using risk factors to identify risk of aspiration 
pneumonia (51). Similarly, neoplasia has been associated with a high mortality rate. In 
addition, a recent study showed that at least 10% of patients with a CAP episode are 
diagnosed with lung cancer or pulmonary metastases during the years following 
hospital admission. 
 
Cardiovascular diseases seem to have elicited greater interest. A recent review 
suggested a higher incidence of cardiac complications after a CAP episode (52). In 
this sense, Dr Aliberti and Dr Ramírez (31) conducted a review in which they found an 
increased incidence of cardiovascular events, such as myocardial infarction, 
arrhythmias, and heart failure, in patients suffering from pneumonia. Systemic 
inflammation, coronary artery inflammation, platelet activation and thrombosis, 
endothelial dysfunction, and effects of CAP on the heart have been suggested as 
possible mechanisms for increased cardiovascular events following respiratory 
infections (52). 
 
Corrales et al. (53) assessed 5,613 older adults enrolled at the Cardiovascular Health 
Study conducted between 1989 and 1994 in four communities of the United States. 
Patients with previous diagnosis of heart failure were excluded and participants were 
followed up until 2010. Of those older adults assessed, 1,315 developed pneumonia 
during follow-up and 652 were still alive and free of heart failure after 30 days of 
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discharge. The authors described an association between admission for pneumonia 
and increased risk of new-onset heart failure in the intermediate and long-term follow-
up. This association remained significant even after adjusting for traditional risk factors 
including coronary heart disease. An Italian group studied 301 patients admitted for 
CAP with 17-month follow-up and compared patients who suffered cardiac 
complications during hospitalizations with those who did not (54). The authors 
observed a higher incidence of cardiovascular events as well as higher long-term 
mortality rate among patients who suffered in-hospital cardiac complications. 
 
 
2.4 Biomarkers 
 
2.4.1 Introduction 
 
Bacterial products such as lipopolysaccharides or peptidoglycans play a primary role 
in the inflammatory response produced in the lower respiratory tract, because they 
stimulate the alveolar macrophages producing cytokines such as interleukins (IL-1, IL-
6, IL-8) and tumor necrosis factor-alpha (55). These cytokines have been tested in 
order to measure the inflammatory response, but their detection in serum has been 
unhelpful due to their short half-life and their predominantly pulmonary production 
reaching low values in serum (56). 
 
More emphasis has been placed in studies of acute phase reactant proteins that occur 
as a result of these cytokines stimulation. The measurement of these inflammatory 
mediators in serum is easier, because they have a longer half-life. Generally, plasma 
levels of inflammatory mediators seem to correlate with the severity of infectious 
diseases such as pneumonia. 
 
C-reactive protein 
 
It is worth mentioning that these mediators include the C-reactive protein (CRP), which 
is the most used in routine clinical practice. It was first described in 1930 at Oswald 
Avery’s laboratory, when they tried to identify a protein capable of precipitating C-
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polysaccharide of the pneumococcal cell wall in the serum of patients infected with 
Streptococcus pneumoniae. It is an acute phase protein as well as a non-specific 
inflammatory biomarker, but sensitive to systemic inflammation and tissue damage. Its 
main function is the activation of the complement system and other pro-inflammatory 
processes. Its synthesis occurs almost exclusively in hepatocytes mainly regulated by 
cytokines (IL-6 and IL-1). Extrahepatic synthesis in neurons, atheroma plaques, 
monocytes, and lymphocytes has been described. IL-6 is a very sensitive biomarker 
due to its rapid rise in infections; however, its low specificity, short half-life, low 
biostability, and high analytical cost make its clinical application limited (57). 
 
In healthy young individuals, the average serum concentration of CRP is 0.8mg/L, but, 
in the acute phase, it can increase 500 and even up to 1000 times its baseline value, 
whether due to infection or inflammation. CRP synthesis begins immediately after an 
inflammatory stimulus achieving an increase in serum concentrations after 
approximately six hours. However, the maximum value is obtained after 48 hours, due 
to which, at an early infection stage, values can be relatively low. Its half-life is 19 
hours and constant in healthy individuals. 
 
It is a very sensitive marker, but with low specificity. This way, values between 3 and 
10 mg/L may reflect various non-specific inflammation conditions, such as diabetes 
mellitus, obesity, smoking, low physical activity, alcohol consumption, and depression, 
among others (58). 
 
It has been observed that CRP has anti-inflammatory and pro-inflammatory action. 
The first occurs by inducing the expression of the IL-1 receptor antagonist, increasing 
the release of IL-10, and inhibiting the IFN-gamma synthesis. The second occurs by 
activating the complement and increasing the release of IL-1, IL-6 and TNF-alpha, 
among others (58). 
 
The most important factor for CRP concentration is its synthesis, which, in turn, is 
influenced by the degree of pathological stimulus. CRP acts in the defense 
mechanisms of the body and inhibits the harmful effects of an exacerbated 
inflammatory reaction. 
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Procalcitonin 
 
Procalcitonin (PCT) is the propeptide of synthesized calcitonin hormone in thyroid C-
cells and encoded by the CALC-I gene on chromosome 11. It is known as "hormokine" 
due to its production in the typical form of hormone by neuroendocrine cells of thyroid 
C-cells or K cells in the lungs, and in the form of cytokine by several parenchymatous 
cells (59). 
 
In healthy individuals, PCT serum levels are undetectable and they increase 
significantly in different situations. The production of this glycoprotein during 
pathological processes occurs in extrathyroidal tissues, without leading to the increase 
of calcitonin and serum calcium. In fact, it has been found that its level also increases 
in thyroidectomized patients and septic situations. 
 
Its origin in pathological circumstances is uncertain. Its release during infection is 
directly induced by bacterial toxins (endotoxins), or indirectly by humoral factors (IL-
1B, IL-6 and tumor necrosis factors) and cells of the monocyte/macrophage system. 
The induction can be attenuated by cytokines released during viral infections 
(interferon-gamma) (60, 61). 
 
Elevated PCT levels can be detected after two hours of bacterial infectious 
stimulation. Its increase is greater than that of CRP, but not as accelerated as the 
increase accomplished by other cytokines such as, for example, IL-6. PCT is very 
stable, even at room temperature, and it has a half-life of approximately 24 hours (62). 
 
New biomarkers 
 
Recently, data from a study on new biomarkers with cardiovascular profile, such as 
arginine vasopressin (AVP), have been published (63). AVP is a hormone produced in 
the paraventricular nucleus of the hypothalamus and is subsequently stored in the 
pituitary gland. The main function of AVP is the regulation of cardiovascular and 
osmotic homeostasis. In severe diseases, such as sepsis or cardiogenic shock, there 
is an imbalance in the regulation of water and AVP production is augmented by 
osmotic and hemodynamic stimuli. 
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AVP, also known as antidiuretic hormone, is attached to the platelets in more than 
90%, which makes it very difficult to be measured. In addition, its half-life of 24 
minutes and its inability to remain stable in plasma has made it necessary to develop 
a new technique for the measurement of a new fragment of the biomarker. C-terminal 
proAVP fragment, also known as copeptin, is a glycoprotein of 39 amino acids whose 
function is not accurately known. However, given its greater ex vivo stability and 
longer half-life, it could be used as an indirect measure of AVP in selected patients. 
Elevated levels of copeptin have been associated with acute and chronic heart failure. 
In addition, Kruger et al. (63) identified copeptin as an independent factor for mortality 
in patients with CAP. 
 
Brain natriuretic peptide is a polypeptide of 32 amino acids that has been widely used 
for discriminating the cardiac origin of dyspnea. Natriuretic peptides inhibit the renin-
angiotensin system that leads to increased natriuresis, dieresis, and vasodilation. 
Their production mainly occurs during stress of the transmural wall of the heart, due to 
increased volume or cardiac pressure. However, proinflammatory cytokines and the 
sympathetic nervous system have been identified as the stimulators of their secretion 
(64). 
 
Brain natriuretic peptide and N-terminal pro-brain natriuretic peptide are widely 
established in routine clinical practice and included in international guidelines for heart 
failure. However, elevated levels of these biomarkers have been described in septic 
processes. According to Chrits Crain et al. (65), brain natriuretic peptide predicted 
mortality and therapeutic failure in patients with CAP after the exclusion of patients 
with history of heart failures and ischemic and hypertensive heart disease. Therefore, 
the cardiac pathology could not explain the results obtained and, thus, the increase in 
its levels could be related to the severity of pneumonia. 
 
Proadrenomedullin (proADM) is the most stable fragment of adrenomedullin (ADM) 
degradation. ADM is a peptide of 52 amino acids and, similarly as PCT, belongs to the 
CALC gene family being encoded by the CALC-V gene. Its expression has been 
detected in numerous tissues; however, the highest levels have been observed in the 
adrenal medulla, ventricles, kidneys, and lungs. Normal values range from 2 to 3.5 
ng/mL. However, the union of ADM to its receptor immediately after its production and 
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its short half-life (approximately 22 minutes) hinder its direct measurement; therefore, 
the measurement of its more stable fragment is very useful. ProADM is a potent 
vasodilator and has bactericidal properties in addition to its action in the modulation of 
the immune response (66). 
 
Despite the cost of biomarkers, their complementary use has been proposed as a way 
to improve etiologic identification and treatment optimization, as well as to estimate 
clinical severity, evolution, and prognosis in patients (67). 
 
2.4.2 Etiology and adjustment of antibiotic treatment 
 
Usually, despite proper techniques, it is only possible to obtain an etiological diagnosis 
in 50% of cases. The most common pathogen described in the majority of published 
studies has been Streptococcus pnenumoniae (68). The discrimination between 
typical and atypical bacteria that cause pneumonia is an important step for choosing a 
treatment of CAP. However, specific microbiological diagnosis has become 
complicated in the routine clinical practice. The radiological presentation has been 
used to discern between bacteria and viruses, but the results have not been 
conclusive. Since the etiologic agent is usually unknown, empirical antibacterial 
treatment based on the most likely causal pathogens is prescribed. 
 
There is a variation in the antibacterial recommendations provided by guidelines for 
the management of CAP, and the need for specific coverage of atypical 
microorganisms is a key difference. Narrow-spectrum antibiotics are often as effective 
as broad-spectrum antibiotics and cause fewer adverse side effects. However, despite 
significant progress in recent years, the current methods for the identification of causal 
pathogens still have limitations. 
 
As already explained by Prat et al. (69), CRP increases in the acute inflammatory 
response, including viral and bacterial infections, whereas PCT is a sensitive and 
specific marker for the diagnosis of systemic bacterial infection. However, its 
usefulness in localized infections and empyema is limited. For example, Masia et al. 
(70) observed that a biomarker such as PCT may play a role in the prediction of 
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microbial behavior in patients with low PSI scores; but this fact was not observed in 
patients with higher PSI scores. Kruger et al. (71) found significantly higher levels of 
PCT and CRP in patients with classic bacterial etiologies in comparison with those 
with atypical bacteria. 
 
On the other hand, Niederman et al. (72) suggested that the combination of PCT and 
molecular testing with polymerase chain reaction for respiratory virus in patients with 
CAP could identify individuals that may be treated without antibiotics or with antiviral 
drugs, if the results showed a low PCT level and a positive polymerase chain reaction 
test for the virus. 
 
Also, the prognostic value of proADM has been assessed based on the etiology, but 
the results were little satisfactory. Bello et al. (73) conducted a prospective study of 
patients with CAP classifying the etiology into three groups; typical bacteria; atypical 
bacteria (including viruses); and mixed bacteria. The authors found that this biomarker 
had a high predictive value of mortality, independently of the CAP etiology. This way, 
PCT was the best biomarker in discriminating between pneumonia by typical bacteria, 
atypical bacteria, or virus when compared with CRP and proADM. 
 
During recent decades, strategies of early initiation and early switch to oral therapy 
have been thoroughly assessed. However, the optimal duration of antimicrobial 
therapy has not been well established. In this sense, the ProHOSP study assessed a 
control group and an intervention group using different cut-off points for PCT to decide 
whether the administration of antibiotics was required. Precisely, they observed that 
the use of PCT reduced the duration of antibiotic treatment from 12 to five days and 
with no significant differences in the onset of complications between the two groups 
(74). 
 
However, in 2007, the IDSA/ATS provided recommendations for the duration of 
antibiotic treatment based on the stability criteria proposed by Halm et al (75). The 
guidelines suggested a minimum of 5-day treatment, patients’ achievement of an 
afebrile state for 48 to 72 hours, and meeting no more than one CAP-associated 
instability criteria before therapy discontinuation (76). Most guidelines showed a weak 
evidence of current recommendations mainly based on expert opinions (77-79). It 
  LONG‐TERM MORTALITY IN HOSPITALIZED PATIENTS WITH COMMUNITY‐ACQUIRED PNEUMONIA
 
 40
seems that there is an agreement on an individualized approach, though arbitrary 
longer treatments remain prevalent. A recent clinical trial indicated that discontinuing 
antibiotic treatment based on clinical stability criteria after a minimum of five-day 
appropriate treatment did not show less clinical success than traditional treatment 
schedules (80). 
 
2.4.3 Severity and prognosis 
 
In the infectious process of CAP, between 5.7 and 14% of patients who require 
hospital admission will die, and this figure can raise up to a 50% in patients admitted 
to intensive care units (17). Also, medium- and long-term mortality rates remain high, 
with values of 8 and 21% within 90 days and one year, respectively (6). 
 
Furthermore, it seems that patients admitted for a CAP episode have higher mortality 
rates―even in the long term―than those admitted for any other reason, as previously 
explained. The prognostic factors for mortality have been related to the germ-host 
interaction. Despite the growing emergence of germs that are resistant to antibiotics, 
such as Streptococcus pneumoniae, studies have statistically demonstrated that 
mortality is more associated with factors that depend on the patients than with 
resistance of germs. 
 
Severity prognostic scores are static clinical score and lack information on the host 
inflammatory response. The concomitant use of certain biomarkers could provide 
objective criteria to make decisions with respect to these patients. Biomarkers are 
becoming the way to improve the predictive ability of clinical scores. 
 
PCT and CRP are biomarkers that have been most frequently used and assessed in 
CAP (81-86). In this sense, Muller et al. (60) found a significant increase in PCT levels 
among patients of the group with PSI risk class V. However, the role of CRP seems to 
correlate with the presence of pneumonia, but not with its severity. In fact, some 
authors have stated that only very high CRP values can be used as indicators of the 
presence of CAP (81). 
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Most of the studies of biomarkers conducted to date in patients with CAP have 
assessed their ability to predict short-term mortality. Huang at al. (87) conducted a 
study in 28 different centers with 1,651 patients and demonstrated that PCT 
<0.1ng/mL was associated with a better prognosis, even in high-risk patients 
according to the PSI score. Interestingly, Menéndez et al. (88) observed that the 
addition of PCT levels to the PSI score did not improve predictive ability for 30-day 
mortality, though it improved the prediction by adding the CRP to the PSI and 
CURB65 scores. The German group observed that the PCT levels―but not the CRP 
levels―significantly increased with the severity of CAP measured by the CRB-65 
score (63). In that same study, low PCT levels were associated with low mortality for 
all the risk classes of the CRB-65. There are studies that have indicated discrete 
differences in PCT levels between survivors and non-survivors. It seems that this 
diagnostic marker is useful for both adjustment of antibiotic treatment and as a 
prognostic marker (89). 
 
To date, biomarkers alone had not demonstrated superiority on the scores to predict 
complications. In the last years, studies have been conducted with biomarkers of more 
cardiovascular profiles and found that proADM started gaining greater relevance. Pro-
ADM has demonstrated superiority over CRP and PCT to predict the mortality of these 
patients more accurately (66). This fact could be due to the cardiovascular activity of 
this biomarker in addition to its immunomodulatory and antimicrobial effects. 
 
There are several studies that have highlighted the improvement in prognostic value of 
risk scores with pro-ADM. For example, Huang et al. (90) found that high pro-ADM 
levels exhibited an additional stratified risk to the high risk class measured by the PSI 
score. In another study, Chirst Crain et al. (91) described that the combination of 
proADM and the PSI score improved the prediction of mortality. Albrich et al. (92) 
showed that a new index, such as the CURB65-A based on the combination of the 
CURB65 score and pro-ADM, could accurately predict 30-day mortality, as well as 
adverse effects defined as death from any cause, intensive care unit admission, or 
any disease complication within 30 days. Other authors have assessed the addition of 
proADM in different severity scores with satisfactory results for both severe 
complications and short-term mortality (93). 
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The role of biomarkers in short-term prediction seems to be more clear. However, 
long-term mortality is more difficult to predict. Recently, the red blood cell 
distribution―a determination that measures the heterogeneity of erythrocyte 
volume―has been associated with increased 30-day morbimortality (94). 
Furthermore, Bello et al. (95) observed that from a cut-off point of 14, it had a higher 
predictive power for mortality than other predictive biomarkers and, in addition, the 
prediction improved in the long term. 
 
However, the biomarker that has proven to be better than the rest for predicting long-
term mortality in these patients was proADM. The German group CAPNEZT has 
assessed the role of biomarkers, both in the short and long term (71). They observed 
the validity of proADM as a predictive marker of survival within 28 and 180 days, 
comparable with the CRB-65 score. In addition, the predictive ability of the CRB65 
score improved significantly when proADM was added. Furthermore, some authors 
have described improvement such as longer-term predictive ability for mortality (6 
years) by adding proADM to the PSI and CURB65 scores (43). 
 
Guertler et al. (96) obtained biomarkers at days three, five, and seven, as well as on 
the day of discharge, among patients with CAP included in a multicenter trial with 18-
month follow-up after hospital discharge. The authors found that the male sex, chronic 
obstructive pulmonary disease, neoplastic disease, and the highest quartile of peak 
proADM level were independent risk factors for long-term mortality. Interestingly, initial 
presentation with temperature >38.7 °C, chills, and the highest quartile of CRP were 
independent protective factors. Without a doubt, proADM seems to have gained the 
first place in the prediction of long-term mortality in CAP patients. 
 
As mentioned earlier, it is worth noting the transcendent role of cardiovascular 
diseases as main cause of medium-and long-term mortality in these patients. 
Biomarkers can be of great utility to identify a persistent chronic inflammation state 
initiated after a CAP episode, which can lead to the development of cardiovascular 
diseases (97,98). 
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2.5 Clinical prediction rules 
 
2.5.1 Introduction 
 
Clinical prediction rules  (CPR) were firstly developed to improve physicians’ decision-
making as they are a powerful tool to provide an outcome, hence, to estimate the 
probability that a certain outcome is present or will occur in an individual. These 
prediction rules, also known as risk scores, usually combine patient characteristics, 
physical examination data or laboratory data. They aim to standardize clinical data 
interpretation, trying to avoid medical errors and minimizing the use of costly 
diagnostic testing. An example would be prediction rules for diagnosis of pulmonary 
embolism, which actually avoid many computed tomographic. Clinical judgment is the 
first step when assessing a patient, however, clinical prediction rules provide more 
accurate and less variable estimates. 
 
CPR have been developed for many conditions, for instance, to determine the 
likelihood of death within 4 years in patients with coronary artery disease, to identify 
children with increase probability for urinary tract infections or to identify patients who 
are likely to develop postoperative vomiting after anesthesia. Moreover, they can help 
physicians not only assessing patient prognosis, but also guiding treatment location 
and strategies. Once we focused on CAP, the initial evaluation leads to assess 
severity of disease in order to predict the likely clinical outcomes of the patient. This 
information can be used to help clinical decision-making in terms of site of care, extent 
of laboratory work-up, and therapeutic interventions. Clinical judgment has shown a 
poor predictive value to predict clinical outcomes, thus, CPR were developed to 
support physician in the approach of assessing severity and outcomes. More 
interestingly, they use the diagnostic properties of sensitivity, specificity, and positive 
and negative likelihood ratios leading to a more practical use, readily applied to 
individual patients.  
 
In the last decades, an increasing number of papers have been published concerning 
prediction rules. Indeed, 6,744 papers were published in 1995 compared to 15,662 in 
2005. There is an overwhelming number of prediction rules for the same outcome, 
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especially in some specific topics, such as, over 100 prognostic models for predicting 
outcome after brain trauma (99), over 100 models for prostate cancer (100), or 45 
models for cardiovascular events after being diagnosed with diabetes (101). However, 
most articles are focused on the development of the rule and little is known concerning 
other methodological issues. Many reviews have suggested limitations in reporting 
data quality from the development of prediction rules (102,103). In a recent review of 
predictive models, performance measures, i.e., calibration and discrimination were 
only reported in 12% and 27% of studies, respectively (102). Rigorous methodoly 
should be used when elaborating CPR.  
 
In this sense, in an attempt to improve quality of reported data, The Transparent 
Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis 
(TRIPOD) Initiative developed a set of recommendations for the reporting of studies 
developing, validating, or updating a prediction model, whether for diagnostic or 
prognostic purposes (104). The TRIPOD Statement is a checklist of 22 items, 
developed essentially for transparent reporting of a prediction model study (105).  
 
As explained in the TRIPOD statement, the derivation of a prediction model should 
start by selecting predictors and combining them into a multivariable model. For short-
term prognosis logistic regression is commonly used while Cox regression is used for 
long-term prognostic outcomes. These studies should always include some form of 
internal validation to quantify any optimism in the predictive performance of the 
developed model and adjust the model for overfitting. External validation tipically use 
the same predictor but tested in a different setting by other investigators. It is 
important to specifically report all methodological issues in order to accurately 
replicate the performed model. 
 
There are two important aspects for the performance of a model that should be always 
reported. The first one is discrimination, which refers to the ability of the score to 
differentiate between patients who do and do not experience the outcome event. For 
survival models is measured by the concordance index (C-index), which equals the 
area under the receiver- operating characteristic curve for logistic prediction models. 
The second one is calibration, which reflects the agreement between predictions from 
the model and observed outcomes. In addition other measures of overall performance 
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can be reported, such as, explained variation (R2)  and the Brier score. Finally, all 
developed prediction model should be compared to already published models, ideally 
in a quantitative manner.  
 
2.5.2 CPR for assessment of CAP severity. 
 
In order to establish the severity of CAP, different authors and scientific societies have 
created a series of rules or severity scores that allow predicting short-term evolution in 
patients. The best-known prognostic scores are the PSI, created by Fine et al. (106), 
and the CURB-65 created by Lim at al. (107). These scores are very useful in the 
optimization of antibiotic treatment, as well as in the decision-making for admissions. 
In addition, the implementation of the severity scores has shown a reduction in the 
number of hospital admissions of patients with CAP. 
 
The PSI score was created with a large cohort of patients and validated in another 
cohort. This score is based on 20 variables related to age, comorbidity, clinical and 
radiological signs, and analytical data. Depending on the punctuation obtained, the 
patients are classified into five groups according to the increase in risk of 30-day 
mortality, namely: group 1 will include patients aged under 50 years, without 
comorbidities and with normal physical condition, corresponding to the risk class I, 
without the need for analytical determinations and with a mortality rate between 0.1 
and 2.8%; group 2 would obtain less than 70 points; group 3 from 71 to 90; group 4 
from 91 to 130; and group 5 would obtain more than 130 points. 
 
This way, patients of low risk classes (I-III) could be treated as outpatient patients and 
the rest would require hospital admission. Specifically, the patients of risk class III 
could be treated at home or require a short length of hospital stay. Patients of group 4 
would have a probability of mortality between 8.2 and 9.3%, and group 5 would exhibit 
a high mortality rate (31 to 37%). This is a good severity score, since subsequent 
works have validated its prognostic reliability. 
 
The British Thoracic Society initially created the CURB (108) and, subsequently, Lim 
at al.(107) modified it by incorporating age and using the acronym CURB-65. This 
  LONG‐TERM MORTALITY IN HOSPITALIZED PATIENTS WITH COMMUNITY‐ACQUIRED PNEUMONIA
 
 46
score uses five variables and stratifies the patients according to the score with 
probability of mortality between 0.7% if they obtain 0, and 40% if they obtain 4 points 
or more. 
 
However, the two scores have limitations. The first underestimates severity, especially 
in young patients without comorbidities, and the second does not include blood 
oxygen saturation among its variables. The two scores have a high negative predictive 
value to identify the patients who will develop complications. On the other hand, their 
positive predictive value is unsatisfactorily low to prescribe admission to intensive care 
units. Usually, these patients tend to be younger and exhibit less number of 
comorbidities, due to which it is not surprising that, when age is included as one of the 
important criteria, the results obtained by these scores are worse for predicting 
intensive care unit admissions. 
 
The IDSA/ATS created a new score to predict which patients should be treated in 
intensive care units (76). It contains two major criteria (invasive mechanical ventilation 
and septic shock requiring vasopressor drugs) and eight minor criteria (respiratory rate 
>30 breaths per minute; PaO2/FiO2 <250 mmHg; multilobar infiltrates observed on the 
chest radiograph; confusion/disorientation; uremia >20 mg/dL; leukopenia <4,000 
leukocytes/mm3; thrombocytopenia <100,000 platelets/mm3; hypothermia <36 ºC and 
hypotension requiring aggressive fluid therapy). The presence of one major criterion or 
the sum of at least three minor criteria will indicate the need for admission to intensive 
care units or those with intensive monitoring. However, the obviousness of the major 
criteria limits the operation of this score, even though it has a validated predictive 
ability. 
 
Charles et al. (109) created the SMART-COP (systolic blood pressure, multilobar 
chest radiography involvement, albumin level, respiratory rate, tachycardia, confusion, 
oxygenation, and arterial pH) score with the purpose of establishing the need for 
intensive respiratory or vasopressor support. It consists of eight clinical and analytical 
variables with different cut-off points according to age. The patients were classified 
into four risk groups on the basis of the need for mechanical ventilation. España et al. 
(110) created a new prognostic score (CAP-SCAP), to predict in-hospital mortality 
and/or the need for mechanical ventilation and/or onset of septic shock during hospital 
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admission in patients with CAP. This score consists of eight variables measured at the 
time of diagnosis, namely: pH <7.30 and systolic blood pressure <90, as major criteria, 
and confusion; respiratory rate >30 breaths/min; urea nitrogen >30; multilobar 
radiographic infiltrates, PaO2/FiO2 <250; and age >80, as minor criteria. From a cut-
off point (>9 points would be equivalent to two minor criteria or one major criterion), it 
is recommended that patients are monitored or admitted to intermediate respiratory 
care units/intensive care units, whereas those with a score less than nine are 
classified as low risk and can be treated as outpatients. 
 
The objectives of stratifying patients with CAP in groups are multiple. On the one 
hand, defining what type of patients can be treated as outpatients, and on the other 
hand, identifying those patients that require greater control or being monitored in 
intermediate respiratory care units/intensive care units. All these prognostic models 
predict the probability of mortality in percentage terms and help decide which patients 
require hospitalization and who can be treated as outpatients. However, the 
heterogeneity of CAP limits their predictive ability. This limitation implies the need of 
using "clinical judgment", which is certainly difficult to define in objective terms. 
 
In addition, the scores are not able to measure the mechanisms of the inflammatory 
response of the organ affected against the microorganism, nor can predict the 
individual responses of the patients to the established treatments. They only predict 
short-term mortality and, to date, scores to predict long-term mortality after a CAP 
episode have not been created. 
 
  
 
 
  LONG‐TERM MORTALITY IN HOSPITALIZED PATIENTS WITH COMMUNITY‐ACQUIRED PNEUMONIA
 
 48
	
 
  49
 
 
 
 
 
 
 
3. JUSTIFICATION 
 
 
 
	
 
 
 
  
Justification  
 
  51
CAP continues to be a leading cause of morbidity and mortality worldwide (14). The 
annual incidence of CAP ranges from 5 to 11 cases per 1000 adults and accounts for 
considerable healthcare costs (7,8). The severity of illness has been a matter of 
concern in recent decades since it has been related to short-term prognosis. In this 
sense, different CAP guidelines have suggested different risk scores in order to 
predict 30-day mortality.  
 
Recently, increasing interest has emerged concerning long-term prognosis. Despite 
current evidence about risk factors for one-year mortality after CAP, it seems that 
predicting long-term prognosis after an episode of CAP remains challenging. To date, 
no risk scores have been developed in order to predict one-year mortality in 
hospitalized patients with CAP.  
 
In addition, the utility of biomarkers has been widely evaluated to predict poor 
outcomes in CAP. Most researchers have focused on short-term outcomes. However, 
several authors have suggested that a few biomarkers could also be useful to predict 
long-term prognosis. Little is known about how the addition of biomarkers could 
improve long-term prediction.  
 
In an attempt to clarify this issue, three different cohorts were assessed in this study. 
The first one was evaluated in order to develop a one-year prediction score among 
hospitalized patients with CAP from January 2001 to July 2009 at the Hospital of 
Galdakao-Usansolo.  
 
The second one was tested in hospitalized patients with CAP in which blood samples 
were obtained from June 2008 to July 2009 at the Hospital of Galdakao-Usansolo, to 
assess whether biomarkers are useful for predicting one-year mortality. Finally, a third 
cohort was assessed to investigate long-term prognosis among hospitalized patients 
with CAP from June 2001 to November 2006 in the Veterans Affairs Medical Center of 
Louisville, Kentucky.  
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4.1 Hypotheses 
 
 
Study I. One-year mortality prediction among hospitalized patients with CAP in 
Galdakao-Usansolo Hospital 
1. In patients admitted for CAP, it is possible to identify clinical variables relating to 
one-year mortality after hospital admission. 
2. Depending on the variables previously identified, it is possible to create a prognostic 
index that can help in the stratification of one-year mortality prediction in patients 
admitted for CAP. 
3. A prognostic index specifically created for the prediction of one-year mortality may 
have greater predictive ability than usual risk scores in patients admitted for CAP. 
 
 
Study II. Role of biomarkers for one-year mortality prediction among 
hospitalized patients with CAP in Galdakao-Usansolo Hospital 
1. The severity at the time of clinical diagnosis measured by biomarkers or risk scores 
may be associated with one-year mortality in patients admitted for CAP. 
2. The incorporation of inflammatory response biomarkers to risk scores could 
improve the ability for predicting one-year mortality. 
3. The decrease in levels of inflammation biomarkers from the time of diagnosis until 
three to five days could help in predicting one-year mortality in patients admitted for 
CAP. 
 
 
Study III. One-year mortality prediction among hospitalized patients with CAP in 
the Veterans Affairs Medical Center of Louisville, Kentucky, USA 
1. The variables of patients admitted for CAP to a Veterans Hospital in the United 
States will differ from the sample of study I. 
2. The creation of a prognostic index for long-term mortality in patients of an American 
cohort admitted for CAP to a Veterans Hospital could help professional health teams 
to better identify the patients with high mortality risk in order to perform enhanced 
monitoring. 
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4.2 Objectives 
 
 
Primary 
 
Study I. One-year mortality prediction among hospitalized patients with CAP in 
Galdakao-Usansolo Hospital 
1. To assess the factors associated with one-year mortality in patients admitted after a 
CAP episode. 
2. To create and validate a prognostic index for one-year mortality in patients admitted 
after a CAP episode. 
3. To compare the predictive ability of existing severity scores and the new prognostic 
index for one-year mortality. 
 
Secondary: 
 
Study II. Role of biomarkers for one-year mortality prediction among 
hospitalized patients with CAP in Galdakao-Usansolo Hospital 
1. To assess the relationship between severity scores and levels of biomarkers of 
systemic inflammation (CRP, proADM, and PCT) obtained at the time of diagnosis and 
one-year mortality in patients admitted for CAP. 
2. To determine the predictive ability of biomarkers and prognostic scores and 
associate them in order to improve the predictive value. 
3. To assess the relationship between the evolution of biomarkers levels from 
admission to three to five days and one-year mortality in patients admitted for CAP. 
 
Study III. One-year mortality prediction among hospitalized patients with CAP in 
the Veterans Affairs Medical Center of Louisville, Kentucky, USA 
1. To assess the differences between the variables of a sample from a Veterans 
Hospital in the United States and the variables of study I. 
2. To create a predictive score for long-term mortality in an American cohort of 
patients admitted for CAP to a Veterans Hospital. 
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STUDY I. ONE-YEAR MORTALITY PREDICTION AMONG 
HOSPITALIZED PATIENTS WITH CAP IN GALDAKAO-
USANSOLO HOSPITAL. 
 
5.1. Study design  
This was an observational, prospective study of adults aged ≥18 years admitted to the 
Hospital of Galdakao-Usansolo, from January 2001 to July 2009 with a diagnosis of 
CAP. The entire cohort was divided into two parts in order to develop a one-year 
mortality predictive model in the first cohort (the derivation cohort) that was validated 
using the second cohort (the validation cohort).  
Firstly, a subset of variables considered clinically important to predict one-year 
mortality were selected. Secondly, the relationships between those variables and one-
year mortality was assessed and statistically significant variables were considered in a 
multivariate analysis. Once the predictive variables were identified, a weighted score 
was developed and validated in the validation cohort. At the same time, the score was 
divided into three categories: mild, moderate and high risk groups. Finally, the 
predictive accuracy of the score was compared to other risk scores. 
 
5.2. Setting and study population 
The study was carried out at the Hospital of Galdakao-Usansolo (Galdakao, Spain), a 
400-bed teaching hospital in the Basque Country (northern Spain) that serves a 
population of 300,000 inhabitants. This medical institution belongs to the network of 
public hospitals of the Basque Health Care Service, which provides free unrestricted 
care to nearly 100% of the population.  
The Pneumology Department staff is composed of full-time physicians qualified in 
standardized national residency programs. Since 2000, the team has developed a 
consolidated line of research with a clear influence on science confirmed by loads of 
publications. The Infections Division of the Pneumology Department has developed a 
clinical guideline for CAP management that is still working and that has led to many 
publications. It should be highlighted that this team developed a specific score to 
predict severe CAP, the SCAP score, with a clear impact on the literature. 
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5.3 Patient selection criteria 
5.3.1. Diagnosis definition 
Pneumonia was defined as pulmonary infiltrate on chest X-ray not seen previously 
plus at least one symptom compatible with pneumonia such as cough, fever, dyspnea, 
and/or chest pain (106). 
5.3.2 Inclusion criteria 
Hospitalized patients diagnosed with CAP were recruited from January 2001 to July 
2009. Eligible patients were ≥18 years old, hospitalized with a diagnosis of CAP.  
5.3.3 Exclusion criteria 
. Death within the first 15 days from diagnosis. 
. Had been discharged from an acute care hospital, an onsite subacute care unit, or a 
palliative care unit within the previous 14 days. 
. Infected with the human immunodeficiency virus. 
. Chronically immunosuppressed, defined as: 
 . Solid organ transplantation 
 . Post-splenectomy 
 . Receiving ≥10 mg/day prednisone or equivalent for more than 30 days 
 . Being on other immunosuppressive agents 
 . Having neutropenia, i.e., <1.0 x109/L neutrophils 
 
5.4 Sample size estimation 
Studies of predictive model development indicate that it is necessary to include at 
least 10 events of the dependent variable of interest (in this case: mortality, major 
complications, relapses, or readmissions) for each independent variable included in 
the multivariate logistic regression model [111,112]. Therefore, we estimated that at 
least 100 events of the dependent variable in the sample are required in order to 
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ensure that the regression model would adequately converge. Previous data indicate 
that the number of events of the dependent variable mortality would be >15% of 
patients operated on in the first year, higher that the expected percentages of other 
parameters. We therefore estimated that more than 300 events of any of the 
dependent variables of interest should be included. Thus, we consecutively collected 
all new cases until the sample size was achieved. 
 
5.5 Missing data 
No assumptions were made for missing data, analyzing only the available data. 
 
5.6 Data collection 
At baseline, the demographic and clinical data for each patient were collected from 
medical records, including comorbidities, physical examination, radiological 
presentation, analytics as well as complications during hospitalizations. Antibiotic 
treatment was assessed according to Spanish Pulmonology and Thoracic Surgery 
Society (SEPAR) guidelines (113).  
Disease severity was determined with the PSI, CURB65, and SCAP scores, 
calculated within the first 24 hours after diagnosis (106,107,110). One-year mortality 
was retrospectively assessed by the computer system support of the Basque Health 
Care Service.  
 
5.7 Ethics and confidentiality issues 
All participants provided signed informed consent before their inclusion in the study 
and after being informed and having discussed the goals, risks, and potential benefits 
of the study. Patient rights were protected in line with the Declaration of Helsinki. The 
project was approved by the hospitals’ ethical review boards.  
  LONG‐TERM MORTALITY IN HOSPITALIZED PATIENTS WITH COMMUNITY‐ACQUIRED PNEUMONIA
 
 62
In order to preserve patient data confidentiality, restricted access to the database was 
limited to a single person, with a user name and password. Similarly, patient 
identifying information was managed separately from the rest of the study information.  
 
5.8 Definitions of variables 
● Primary outcome was one-year mortality after admission for CAP.  
Patients who died within the first 15 days after diagnosis were excluded in order to 
avoid the impact of severity of illness on mortality.  
● Secondary outcomes  
- Patient condition at the time of diagnosis 
Demographics, comorbidities, physical examination, radiological presentation and 
analytics.  
. Alcohol consumption: More than 80 g/day of alcohol intake. 
. Nursing home: Being a nursing home resident. 
. Aspiration: Suspicion of aspiration at diagnosis, usually seen in patients with 
difficulties swallowing. 
. Diabetes mellitus: Patients with diabetes under treatment with oral antidiabetic 
agents or insulin therapy. 
. COPD: Chronic pulmonary obstructive disease including chronic bronchitis and 
emphysema. 
. Cancer: History of cancer. 
. CHF: Patients with exertional dyspnea, paroxysmal nocturnal dyspnea and 
responding symptomatically or in a physical examination to treatment with digitalis, 
diuretics or afterload reducers drugs. Patients without symptomatic improvement after 
medication or those without improvement in physical examination were not included. 
. CAD: Patients with a history of acute or chronic coronary artery disease. 
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. CVD: Patients with a clinical or radiological diagnosis of cerebrovascular accident or 
transient ischemic attack. 
. Dementia: Chronic cognitive impairment. 
. Renal failure: Chronic kidney disease or abnormal blood levels of creatinine. 
. Confusion: Altered mental status, previously not reported disorientation of place, time 
or person. 
. Pleural effusion (X-ray): Pleural effusion on the X-ray at diagnosis. 
. Bilateral/multilobar (X-ray): Bilateral or multilobar involvement on the X-ray at 
diagnosis. 
. Mixed radiological pattern: Both alveolar and interstitial pattern on the X-ray. 
● Treatment administration 
. Previous antibiotic treatment. 
. Antibiotic according to SEPAR guidelines. 
. Time until first antibiotic dose. 
. Corticosteroids administration: systemic corticosteroids administration during 
hospitalization. 
● Complications during hospitalization 
. Intensive Care Unit (ICU) admission: ICU admission during hospitalization. 
. Intermediate Respiratory Care Unit (IRCU) admission: IRCU admission during 
hospitalization. 
. Mechanical ventilation: Need for invasive mechanical ventilation. 
. Septic shock: Sepsis-induced hypotension despite adequate fluid resuscitation along 
with the presence of perfusion abnormalities that may include but are not limited to 
lactic acidosis, oliguria, or an acute alteration in mental status. Patients receiving 
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inotropic or vasopressor agents may not be hypotensive at the time that perfusion 
abnormalities are measured (114). 
. Need for vasopressors: Need for vasopressor agents. 
. Respiratory failure: Presence of pO2/FiO2 <300. 
. Renal failure: Abnormal blood levels of creatinine, not previously reported. 
. Pleural effusion: Development of pleural effusion not reported at the time of 
diagnosis. 
. Empyema: Pus in the pleural space. 
. Antibiotic adverse events: appearance of symptoms such as diarrhea attributable to 
antibiotics. 
. Embolism: Pulmonary embolism diagnosis by computerized tomography. 
. Deep vein thrombosis diagnosis by ultrasonography. 
. Decompensated comorbidities: Exacerbation of previously diagnosed diabetes 
mellitus, asthma, COPD, heart disease, neurological disease, or renal failure. 
● Severity of illness at the time of diagnosis 
PSI, CURB65 and SCAP scores were used to assess the severity of illness at 
admission. The PSI and CURB65 were both developed and validated for 30-day 
mortality while the SCAP score was developed and validated for in-hospital mortality 
and/or need for mechanical ventilation and/or septic shock. 
The PSI score was elaborated in the USA by Fine et al. (106) and is based on 20 
weighted variables including, age, sex, comorbidities, vital signs, analytical data, and 
radiological presentation. Patients are stratified into five risk categories depending on 
30-day mortality risk. In the original study, mortality rates were 0.1%, 0.6%, 0.9%, 
9.3%, and 27% for risk classes I, II, III, IV, and V, respectively.  
The CURB65 score was elaborated by the British Thoracic Society and designed by 
Lim et al. (107). It is composed of five variables, with one point for each: confusion, 
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urea 7 mmol/L, respiratory rate >30/min, low systolic (<90 mm Hg) or diastolic (<60 
mm Hg) blood pressure, and age >65 years. Scores ranged from 0 to 5 points based 
on 30-day mortality risk (score 0, 0.7%; score 1, 2.1%; score 2, 9.2%; scores 3-5, 15-
40%).  
The SCAP score was elaborated by España et al. (110), based on two major criteria 
(pH <7.30 and systolic blood pressure <90 mmHg) and six minor criteria (confusion, 
respiratory rate >30 breaths/min, BUN >30 mg/dL, multilobar/bilateral X-ray, 
PaO2/FiO2 <250 mmHg, and age >80 years). Based on eight weighted variables, 
patients are stratified into mild (0-9 points), moderate (10-19 points), and high (>20 
points) risk groups. 
 
5.9 Statistical analysis  
Descriptive statistics included frequency tables and means and standard deviations 
(SD) or medians and interquartile ranges (IQRs). No assumptions were made in 
relation to missing values.  
The entire cohort was split randomly into derivation (50%) and validation (50%) sets. 
To assess the homogeneity of both samples, categorical variables were compared 
with the chi-squared and Fisher’s exact tests, and continuous variables with Student’s 
t-tests or non-parametric Wilcoxon tests. 
A univariate analysis using the chi-squared/Fisher’s exact test (categorical variables) 
or t-test (continuous effects) was performed to identify the variables related to one-
year mortality. Variables with statistically significant results at p <0.20 were entered 
into the multivariate model.  
Firstly, a logistic regression model to select the variables for the prediction rule was 
performed. The model was replicated in the validation cohort. The area under the 
curve (AUC) of the model (AUC ≥0.80 means a good discrimination) and the odds 
ratios (OR) and 95% confidence intervals (CI) of all selected variables were provided. 
For the assessment of the goodness-of-fit of the model, the Hosmer-Lemeshow test 
was performed (a p-value ≥0.05 represents good calibration of the model).  
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Secondly, a survival multivariate model was carried out with the selected variables. 
The hazard ratios (HR) and 95% confidence intervals (CI) of all selected variables 
were provided. The beta coefficients from the survival model were used to weight the 
relative importance of each variable for the calculation of the prediction score. For 
weights, the beta coefficient for each predictor variable in the model was divided by 
the variable with the lowest beta coefficient and rounded to the nearest whole number. 
This produced a “relative weight” of each variable in relation to its ability to predict 
each outcome. The model was replicated in the validation cohort. 
Thirdly, the weights of the variables for each patient were added together to produce 
the prediction scores for each patient and three categories were established (low, 
moderate, and high) based on predicted versus observed one-year mortality. Risk 
categories were replicated in the validation cohort.  
Fourthly, the associations between PSI, CURB65, SCAP, and one-year CAPSI were 
assessed by hazard ratios (HR) and 95% confidence intervals (CI) in the derivation 
and the validation cohorts. Kaplan-Meier survival curves were used to assess 
operating severity scores for one-year mortality. 
Fifthly, the predictive accuracy of the different risk scores was assessed in the 
derivation and the validation cohorts by the C-index. Akaike information criteria (AIC) 
and R-squared (R2) were provided in both cases. To assess the ability of the model to 
match predicted and observed one-year mortality rates in all developed survival 
models, the Greenwood-Nam D’Agostino (GND) method was used.  
All effects were considered significant at p<0.05, unless otherwise stated. All statistical 
analysis was performed using SAS for Windows, version 9.4 (SAS Institute, Cary, 
NC). Figures were prepared using R version 3.3.0.  
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STUDY II. ROLE OF BIOMARKERS FOR ONE-YEAR 
MORTALITY PREDICTION AMONG HOSPITALIZED 
PATIENTS WITH CAP IN GALDAKAO-USANSOLO 
HOSPITAL. 
 
5.1. Study design  
This was an observational, prospective study of adults aged ≥18 years admitted to 
Hospital of Galdakao-Usansolo, from June 2008 to July 2009 with a diagnosis of CAP 
and in whom blood samples could be obtained for biomarker analysis at the time of 
diagnosis as well as after 3-5 days when possible. The predictive accuracy of the risk 
scores and biomarkers at diagnosis was assessed for one-year mortality. In addition, 
the evolution of biomarker levels between time points was evaluated for the one-year 
mortality prediction. 
 
5.2. Setting and study population 
The study was carried out at the Hospital of Galdakao-Usansolo (Galdakao, Spain), a 
400-bed teaching hospital in the Basque Country (northern Spain) that serves a 
population of 300,000 inhabitants. This medical institution belongs to the network of 
public hospitals of the Basque Health Care Service, which provides free unrestricted 
care to nearly 100% of the population.  
 
5.3 Patient selection criteria 
4.3.1. Diagnosis definition 
Pneumonia was defined as pulmonary infiltrate on chest X-ray not seen previously 
plus at least one symptom compatible with pneumonia such as cough, fever, dyspnea, 
and/or chest pain (106). 
5.3.2 Inclusion criteria 
Hospitalized patients diagnosed with CAP were recruited from January 2001 to July 
2009. Eligible patients were ≥18 years old, hospitalized with a diagnosis of CAP.  
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5.3.3 Exclusion criteria 
. Death within the first 15 days from diagnosis. 
. Had been discharged from an acute care hospital, an onsite subacute care unit, or a 
palliative care unit within the previous 14 days. 
. Infected with the human immunodeficiency virus. 
. Chronically immunosuppressed, defined as: 
 . Solid organ transplantation 
 . Post-splenectomy 
 . Receiving ≥10 mg/day prednisone or equivalent for more than 30 days 
 . Being on other immunosuppressive agents 
 . Having neutropenia, i.e., <1.0 x109/L neutrophils 
 
5.4 Sample size estimation 
Studies of predictive model development indicate that is necessary to include at least 
10 events of the dependent variable of interest (in this case: mortality, major 
complications, relapses, or readmissions) for each independent variable included in 
the multivariate logistic regression model (111,112). Therefore, we estimated that at 
least 100 events of the dependent variable in the sample are required in order to 
ensure that the regression model would adequately converge. Previous data indicate 
that the number of events of the dependent variable mortality would be >15% of 
patients operated on in the first year, higher that the expected percentages of other 
parameters. We therefore estimated that more than 300 events of any of the 
dependent variables of interest should be included. Thus, we consecutively collected 
all new cases until the sample size was achieved. 
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5.5 Missing data 
No assumptions were made for missing data, analyzing only the available data. 
 
5.6 Data collection 
At baseline, the demographic and clinical data for each patient were collected from 
medical records, including comorbidities, physical examination, radiological 
presentation, analytics as well as complications during hospitalization. Antibiotic 
treatment was assessed according to Spanish Pulmonology and Thoracic Surgery 
Society (SEPAR) guidelines (113). Disease severity was determined with the PSI, 
CURB65, and SCAP scores, calculated within the first 24 hours after diagnosis 
(106,107,110). Blood samples were obtained at diagnosis as well as 3-5 days later 
when possible in order to analyze CRP, PCT, and proADM levels. All patients were 
evaluated at day 30 in a medical consultation. One-year mortality was retrospectively 
assessed by the computer system support of the Basque Health Care Service. 
CRP was quantified by immunoturbidimetry with an analytical sensitivity of 1 mg/L. 
PCT was analyzed by electrochemiluminescence with an analytical sensitivity of 0.02 
ng/mL. PADM was analyzed by a sandwich immunoassay using TRACE technology 
(time-resolved amplified cryptate emission) with a sensitivity of 0.05 nmol analytical/L. 
 
5.7 Ethics and confidentiality issues 
All participants provided signed informed consent before their inclusion in the study 
and after being informed and having discussed the goals, risks, and potential benefits 
of the study. Patient rights were protected in line with Declaration of Helsinki. The 
project was approved by the hospitals’ ethical review boards.  
In order to preserve patient data confidentiality, restricted access to the database was 
limited to a single person, with a user name and password. Similarly, patient 
identifying information was managed separately from the rest of the study information.  
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5.8 Definitions of variables  
● Primary outcome was one-year mortality after admission for CAP.  
Patients who died within the first 15 days after diagnosis were excluded in order to 
avoid the impact of severity of illness on mortality.  
● Secondary outcomes: See section I for definitions. 
- Patient conditions at the time of diagnosis. 
- Treatment administration. 
- Complications during hospitalization. 
- Severity of illness at the time of diagnosis measured by risk scores. 
- Biomarker levels at the time of diagnosis (CRP, PCT, and proADM). 
- Biomarker levels at 3-5 days (CRP, PCT, and proADM). 
 
5.9 Statistical analysis  
Descriptive statistics included frequency tables and means and standard deviations 
(SD) or medians and interquartile ranges (IQRs). No assumptions were made in 
relation to missing values. Biomarker values were compared between risk score 
levels: PSI (I-III vs. IV-V), CURB65 (0-1 vs. ≥2), SCAP (0-1 vs. ≥2), and one-year 
CAPSI (≤3 vs.>3), by non-parametric Wilcoxon tests. In addition, the predictive 
accuracy of one-year mortality for each biomarker was assessed by a survival model. 
The hazard ratios (HR) and 95% confidence intervals (CI) of all selected variables 
were provided. Similarly, the predictive accuracy of one-year mortality for each risk 
score was assessed and compared to PSI, CURB65, SCAP, and one-year CAPSI. 
Finally, whether the inclusion of biomarkers significantly increased the predictive 
ability of risk scores was assessed by comparing the C-index of the nested survival 
models. Thus, the model including the risk score with the biomarker was compared to 
the model with the risk score itself. 
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In addition, the above mentioned analyses were performed including all deaths within 
one year. 
ProADM changes were calculated by subtracting the biomarker value at 3-5 days from 
the baseline value so that a positive difference meant an improvement. The hazard 
ratios (HR) and 95% confidence intervals (CI) of ProADM changes were provided, 
adjusted by PSI, SCAP, CURB65, and one-year CAPSI as well as proADM baseline 
values. Predictive accuracies were assessed by the C-index. The same analyses were 
performed after the inclusion of all deaths within one year and after the exclusion of 
those patients who died from 15 days to one year.  
All effects were considered significant at p<0.05, unless otherwise stated. All statistical 
analysis was performed using SAS for Windows, version 9.4 (SAS Institute, Cary, 
NC).  
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STUDY III. ONE-YEAR MORTALITY PREDICTION AMONG 
HOSPITALIZED PATIENTS WITH CAP IN THE VETERANS 
AFFAIRS MEDICAL CENTER OF LOUISVILLE, KENTUCKY. 
 
5.1. Study design  
This was a retrospective, observational study of a cohort of adult patients admitted to 
the Veterans Affairs Medical Center of Louisville, Kentucky, from June 2001 to 
November 2006 with a diagnosis of CAP. One-year and five-year mortality was 
obtained in order to develop one-year and five-year prediction scores. 
 
5.2. Setting and study population 
The Division of Infectious Diseases at the University of Louisville School of Medicine is 
a nationally and internationally recognized clinical research program in infectious 
disease under the direction of Dr. Julio Ramirez. It is dedicated to excellence in patient 
care, teaching and research with Dr. Paula Peyrani as director of the Clinical 
Research Unit. 
Numerous manuscripts have been published by members of the team as well as a 
large number of presentations at national and international conferences. There are 
different areas of research, mostly focused on pneumonia, HIV/AIDS, influenza, 
antimicrobial stewardship, multidrug-resistant organisms, disease surveillance, and 
statistical process control. All research activities are supported by a Computational 
Epidemiology Unit, which takes care of all the analysis. 
The division is the headquarters of the Community-Acquired Pneumonia Organization 
(CAPO) with a database including over 7,000 patients from 15 countries. In addition, a 
funded project was carried out on the incidence of influenza and other viruses in 
Kentucky. The group recently carried out a randomized clinical trial, Rapid Empiric 
Treatment with Oseltamivir Study (RETOS), in nine hospitals in the city of Louisville. 
At the moment, there are other two studies that are actively enrolling patients. The first 
study is a population-based study to define the clinical and economic burden of 
pneumococcal pneumonia in hospitalized adult patients in Jefferson County, Kentucky 
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(HAPPI). The second one is a funded study on Streptococcus pneumoniae serotypes 
in adults 18 years and older with radiographically confirmed CAP.  
Jefferson County was founded in 1780 and is one of 120 counties of the state of 
Kentucky in the USA. In 2007, the county had a population of 709,264 inhabitants and 
a population density of 695 inhabitants/km². The county seat is Louisville. There are 
nine hospitals in Jefferson County and, at the moment, the Division of Infectious 
Diseases has more than 50 research associates engaged in screening, enrollment, 
and data collection from patients with CAP in those hospitals. A total of 89,363 
patients were hospitalized in Jefferson County from May 2014 to April 2015. A total of 
4,578 patients were hospitalized with CAP in Jefferson County from May 2014 to April 
2015.  
One of those hospitals is The Veterans Affairs Medical Center. Services are available 
to more than 150,000 veterans living in a 35-county area of the Kentuckiana area. 
Robley Rex Veterans Affairs Medical Center provides a continuum of care through an 
integrated health care delivery system. Today’s Veterans Health Administration (VHA) 
originated during the Civil War as the first federal hospitals and domiciliary ever 
established for the nation’s volunteer forces. The VHA is the largest of three 
administrations that comprise the U.S. Department of Veterans Affairs. The VHA’s 
primary mission is to provide medical care and services to America’s military veterans. 
 
5.3 Patient selection criteria 
5.3.1. Diagnosis definition 
A CAP diagnosis was made if patients met the following criteria:  
The presence of a new pulmonary infiltrate on chest radiograph or CT scan at the time 
of hospitalization, plus at least one of the following three criteria (76):  
- New or increased cough 
- Abnormal temperature (<35.6°C or >37.8°C) 
- Abnormal serum leukocyte count (leukocytosis, left shift, or leukopenia) as defined 
by local laboratory values. 
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5.3.2 Inclusion criteria 
Hospitalized patients diagnosed with a diagnosis of CAP from June 2001 to November 
2006. 
5.3.3. Exclusion criteria 
. Death within the first 15 days from diagnosis. 
. Had been discharged from an acute care hospital, an onsite subacute care unit, or a 
palliative care unit within the previous 14 days. 
. Infected with the human immunodeficiency virus. 
. Chronically immunosuppressed, defined as: 
 . Solid organ transplantation 
 . Post-splenectomy 
 . Receiving ≥10 mg/day prednisone or equivalent for more than 30 days 
 . Being on other immunosuppressive agents 
 . Having neutropenia, i.e., <1.0 x109/L neutrophils 
 
5.4 Missing data 
No assumptions were made for missing data, analyzing only the available data. 
 
5.5 Data collection 
At baseline, the demographic and clinical data for each patient were collected from 
medical records, including comorbidities, physical examination, radiological 
presentation, analytics as well as complications during hospitalizations. 
 
Methods  
 
  75
5.6 Ethics and confidentiality issues  
This study was approved by the Veterans Affairs Medical Center Institutional Review 
Board. For several years, the Human Subjects Protection Program Office has offered 
an in-service education program for all researchers, coordinators and administrators 
associated with the University of Louisville and its affiliated institutions. The Offices of 
the Executive Vice President for Research and the Executive Vice President for 
Health Affairs have mandated that all researchers, including study coordinators and all 
other key study personnel, attend human subject protections training. Beginning July 1 
2000, the Human Subjects Protection Program Office no longer considers initial or 
continuing reviews of protocols without certification of participation in such a course. It 
is obvious to the Institutional Review Board that the efficient approval and continuing 
review of protocols is enhanced if the researchers are better acquainted with the basic 
principles, standards and requirements of human subject protections as they pertain to 
local institutions. 
For the reasons mentioned above, I carried out the Collaborative Institutional Training 
Initiative (CITI) program before reviewing the database. A description of the courses is 
provided below: 
- Human subjects and HIPAA – Research-Biomedical Research. 
- Human subjects and HIPAA – Research-Social, Behavioral or Educational Research. 
- HIPAA Privacy - covers Component Workforce Members with access to PHI. 
- Institutional Compliance – funded researcher 
- Institutional Compliance – U of L general population 
- Same as curriculum group 
- Conflict of interest 
 
5.7 Definitions of variables  
● Primary outcomes were one-year and five-year mortality after admission for CAP.  
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Patients who died within the first 15 days after diagnosis were excluded in order to 
avoid the impact of severity of illness on mortality.  
● Secondary outcomes: See section 1 for definitions. 
- Patient condition at the time of diagnosis. 
Demographics, comorbidities, physical examination, and analytics.  
. Hypertension: patients with elevated blood pressure on drug treatment. 
. Liver disease: cirrhosis or other chronic liver disease such as active chronic hepatitis. 
 
5.8 Statistical analysis  
Categorical variables were compared with those from study I with the chi-squares and 
Fisher’s exact tests, and continuous variables with Student’s t-tests or non-parametric 
Wilcoxon tests. One-year CAPSI was assessed for the study II sample by the C-index. 
Prediction scores for one-year and five-year mortality were created. For each 
outcome, the same methods were utilized. First, a clinically meaningful subset of 
variables was selected based on physician input. Second, multicollinearity was 
assessed using variance inflation factor (VIF) values. Variables with a VIF>10 were 
considered collinear and were either evaluated in combination or dropped. Third, a 
genetic algorithm (R package “glmulti”) was used to select the best-fit model based on 
the Akaike information criterion (AIC) (115). The beta coefficients from the logistic 
regression models were used to weight the relative importance of each variable for the 
calculation of the prediction score.  For weights, the beta coefficient for each predictor 
variable in the model was divided by the variable with the lowest beta coefficient. This 
produced a “relative weight” of each variable in relation to its ability to predict each 
outcome. The weights of the variables for each patient were added together to 
produce the prediction scores for each patient.  
Receiver operating characteristic (ROC) curves were used to calculate the 
discriminatory ability of each score in the prediction of each outcome. One score was 
created for one-year mortality and was assessed via the area under the ROC curve 
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(AUC). The same score was evaluated for predicting five-year mortality. A new score 
was created with a subset of variables selected specifically to predict five-year 
mortality. R version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria) 
was used for all analyses.  
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STUDY I. ONE-YEAR MORTALITY PREDICTION AMONG 
HOSPITALIZED PATIENTS WITH CAP IN GALDAKAO-
USANSOLO HOSPITAL. 
 
6.1 Descriptive statistics. 
 
A total of 2,351 patients, with 1,208 and 1,143 in the derivation and validation cohorts, 
respectively, were included. Baseline characteristics and comorbidities are shown in 
Table 1. The mean age (SD) of the entire cohort was 69 (16.58) years, with 784 
(33.35%) ≥80 years old. Both cohorts were similar except for the COPD rate, which 
was more frequent in the validation cohort. 
Table 1. Baseline characteristics and comorbidities of hospitalized patients with CAP 
in the derivation cohort, the validation cohort, and the entire cohort.  
 Derivation 
(n=1208) 
Validation 
(n=1143) 
Entire cohort 
(n=2351) 
p-value 
Age, mean (SD) 69.68 (16.51) 69.94 (16.66) 69.81 (16.58) 0.58 
Age, n (%)    0.73 
≥80 years  407 (33.69%) 377 (32.98%) 784 (33.35%)  
<80 years  801 (66.31%) 766 (67.02%) 1567 (66.65%)  
Sex, n (%)     
Male 788 (65.23%) 752 (65.79%) 1540 (65.50%) 0.79 
Female 420 (34.77%) 391 (34.21%) 811 (34.50%) 0.79 
AC, n (%) 63 (5.23%) 52 (4.59%) 115 (4.92%) 0.50 
Nursing home, n (%) 86 (7.12%) 68 (5.95%) 154 (6.55%) 0.28 
Aspiration 44 (3.64%) 36 (3.15%) 80 (3.40%) 0.57 
Comorbidities, n (%)     
Diabetes mellitus 191 (15.92%) 171 (15.13%) 362 (15.54%) 0.61 
COPD 278 (23.11%) 335 (29.54%) 613 (26.23%) 0.0004 
Cancer 76 (6.29%) 54 (4.72%) 130 (5.53%) 0.10 
CHF 81 (6.71%) 99 (8.66%) 180 (7.66%) 0.09 
CAD 119 (9.88%) 105 (90.74%) 224 (9.58%) 0.62 
CVD 105 (8.69%) 94 (8.22%) 199 (8.46%) 0.71 
Dementia 123 (10.18%) 107 (9.36%) 230 (9.84%) 0.58 
Renal failure 87 (7.20%) 89 (7.79%) 176 (7.49%) 0.64 
Data are presented as n (%). AC: Alcohol consumption; COPD: Chronic obstructive pulmonary 
disease; CHF; Congestive heart failure; CAD; Coronary artery disease; CVD; Cerebrovascular 
disease. 
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Table 2 shows the physical examination and radiological presentation data. Both the 
derivation and validation cohorts were similar, with a predominantly alveolar pattern 
and about 23% presenting multilobar and or bilateral involvement. 
 
Table 2. Physical examination and radiological presentation of hospitalized patients 
with CAP in the derivation cohort, the validation cohort, and the entire cohort. 
 Derivation 
(n=1208) 
Validation 
(n=1143) 
Entire cohort 
(n=2351) 
p-value 
Confusion, n (%) 131 (10.84%) 116 (10.15%) 247(10.51%) 0.59 
HR ≥125 beats/min, n (%) 116 (9.60%) 117 (10.24%) 233 (9.91%) 0.63 
RR ≥30 breaths/min, n (%) 175 (14.49%) 179 (15.66%) 354 (15.06%) 0.45 
SBP <90 mmHg, n (%) 52 (4.30%) 45 (3.94%) 97 (4.13%) 0.68 
DBP <60 mmHg, n (%) 207 (17.29%) 200 (17.68%) 407 (17.48%) 0.83 
BT ≥40°C, n (%) 4 (0.33%) 7 (0.61%) 11 (0.47%) 0.37 
X-ray, n (%)     
Pleural effusion 123 (10.18%) 112 (9.80%) 235 (10%) 0.78 
Bilateral/multilobar 266 (22.07%) 264 (23.14%) 530 (22.59%) 0.55 
Radiological pattern, n (%)     0.58 
Alveolar 1188 (98.75) 1129 (99.04%) 2317 (98.81%)  
Interstitial 13 (1.08%) 9 (0.79%) 22 (0.94%)  
Mixed 4 (0.33%) 2 (0.18%) 6 (0.26%)  
Data are presented as n (%). HR: Heart rate; RR: Respiratory rate; SBP: Systolic blood pressure; DBP: 
Diastolic blood pressure; BT: Body temperature. 
 
Table 3 shows the analytical data with almost half of the population presenting with 
respiratory insufficiency while one third showed a BUN >30 mg/dL. Nearly 80% of 
patients in both groups received adherent antibiotic treatment according to SEPAR 
guidelines within the first 8 hours. In addition, corticosteroid administration was slightly 
more frequent in the validation cohort (Table 4). 
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Table 3. Analytical data of hospitalized patients with CAP in the derivation cohort, the 
validation cohort, and the entire cohort. 
 Derivation 
(n=1208) 
Validation 
(n=1143) 
Entire cohort 
(n=2351) 
p-value 
Glucose ≥250 mg/dL, n (%) 102 (8.44%) 95 (8.31%) 197 (8.38%) 0.94 
BUN >30 mg/dL, n (%) 333 (27.57%) 328 (28.70%) 661 (28.12%) 0.55 
Sodium <130 mmol/L, n (%) 79 (6.54%) 73 (6.39%) 152 (6.47%) 0.93 
Hematocrit <30%, n (%) 32 (2.65%) 25 (2.19%) 57 (2.42%) 0.50 
PaO2 <60 mmHg, n (%) 534 (44.21%) 490 (42.87%) 1024 (43.56%) 0.53 
pH <7.35, n (%) 56 (4.64%) 48 (4.20%) 104 (4.42%) 0.62 
Data are presented as n (%). BUN: Blood urea nitrogen. 
 
Table 4. Antibiotic and systemic corticosteroid treatment of hospitalized patients with 
CAP in the derivation cohort, the validation cohort, and the entire cohort. 
 Derivation 
(n=1208) 
Validation 
(n=1143) 
Entire cohort 
(n=2351) 
p-value 
Antibiotic, n (%)     
Previous antibiotic 269 (22.31%) 263 (23.09%) 532 (22.69%) 0.66 
Antibiotic according to 
SEPAR guidelines 
964 (79.80%) 929 (81.35%) 1893 (80.55%) 0.35 
Antibiotic within first 4 h 705 (60.62%) 667(60.53%) 1372 (60.57%) 0.96 
Antibiotic within first 8 h 966 (83.06%) 933 (84.66%) 1899 (83.84%) 0.30 
Corticosteroids, n (%) 327 (27.07%) 357 (31.23%) 684 (29.09%) 0.03 
Data are presented as n (%). SEPAR: Spanish Pulmonology and Thoracic Surgery Society. 
 
There were no statistical differences in terms of complications among the derivation 
and validations cohorts. However, COPD exacerbations and decompensated 
neurological diseases were significantly more frequent in the validation cohort(table 5). 
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Table 5. Complications during hospitalization among hospitalized patients with CAP in 
the derivation cohort, the validation cohort, and the entire cohort. 
 Derivation 
(n=1208) 
Validation 
(n=1143) 
Entire cohort 
(n=2351) 
p-value 
ICU admission, n (%) 54 (4.47%) 52 (4.55%) 106 (4.51%) >.99	
IRCU admission, n (%) 55 (4.55%) 51 (4.46%) 106 (4.51%) 0.92 
Need for IMV, n (%) 18 (1.49%) 14 (1.22%) 32 (1.36%) 0.60 
Shock, n (%) 49 (4.06%) 42 (3.67%) 91 (3.87%) 0.67 
Need for vasopressors, n (%) 36 (3.64%) 31 (3.40%) 67 (3.52%) 0.80 
Respiratory failure, n (%) 560 (46.36) 523 (45.76%) 1083 (46.07%) 0.77 
Renal failure, n (%) 100 (8.28%) 98 (8.57%) 198 (8.42%) 0.82 
Pleural effusion, n (%) 54 (4.47%) 60 (5.25%) 114 (4.85%) 0.39 
Empyema, n (%) 8 (0.66%) 5 (0.44%) 13 (0.55%) 0.58 
Antibiotic AE, n (%) 99 (8.20%) 77 (6.74%) 176 (7.49%) 0.18 
Embolism, n (%) 6 (0.50%) 5 (0.44%) 11 (0.47%) >.99 
DVT, n (%) 4 (0.33%) 3 (0.26%) 7 (0.30%) >.99 
Decompensated 
comorbidities, n (%) 
    
Diabetes mellitus 62 (5.13%) 41 (3.59%) 103 (4.38%) 0.07 
Asthma 19 (1.57%) 22 (1.92%) 41 (1.74%) 0.53 
COPD 43 (3.56%) 64 (5.60%) 107 (4.55%) 0.02 
Heart disease 44 (3.64%) 38 (3.32%) 82 (3.49%) 0.74 
Neurological disease 9 (0.75%) 19 (1.66%) 28 (1.19%) 0.05 
Renal failure 28 (2.32%) 22 (1.92%) 50 (2.13%) 0.57 
Data are presented as n (%). ICU: Intensive care unit; IRCU: Intermediate respiratory care unit; IMV: 
Invasive mechanical ventilation; AE: Adverse events; DVT: Deep vein thrombosis; COPD: Chronic 
obstructive pulmonary disease. 
 
 
Table 6 shows baseline severity measured by risk scores. The mean PSI (SD) score 
was 91.39 (32.73) and 91.58 (31.65) in the derivation and the validation cohorts, 
respectively (p = 0.88). The mean CURB65 (SD) score was 1.63 (1.06) and 1.67 
(1.05) in the derivation and the validation cohorts, respectively (p = 0.88). The mean 
SCAP (SD) score was 7.67 (7.58) and 7.71 (7.26) in the derivation and the validation 
cohorts, respectively (p = 0.90). About 50% of the cohort was defined as severe by the 
PSI score, 20% by the CURB65 score, and 40% by SCAP score. 
 
 
Results  
 
  85
Table 6. Baseline severity of hospitalized patients with CAP in the derivation cohort, 
the validation cohort, and the entire cohort, measured by risk scores. 
 Derivation 
(n=1208) 
Validation 
(n=1143) 
Entire cohort 
(n=2351) 
p-value 
PSI mean (SD) 91.39 (32.73) 91.58 (31.65) 91.48 (32.20) 0.88 
PSI, n (%)    0.40 
I 158 (13.08%) 148 (12.95%) 306 (13.02%)  
II 157 (13%) 128 (11.20%) 285 (12.12%)  
III 298 (24.67%) 268 (23.45%) 566 (24.07%)  
IV 464 (38.41%) 481 (42.08%) 945 (40.20%)  
V 131 (10.84%) 118 (10.32%) 249 (10.59%)  
PSI, n (%)    0.13 
I-III 613 (50.75%) 544 (47.59%) 1157 (49.21%)  
IV-V 595 (49.25%) 599 (52.41%) 1194 (50.79%)  
CURB65 mean (SD) 1.63 (1.06) 1.67 (1.04) 1.65 (1.05) 0.88 
CURB65, n (%)    0.66 
0 213 (17.63%) 186 (16.27%) 399 (16.97%)  
1 302 (25%) 287 (25.11%) 589 (25.05%)  
2 450 (37.25%) 422 (36.92%) 872 (37.09%)  
3 207 (17.14%) 215 (18.81%) 422 (17.95%)  
4 32 (2.65%) 32 (2.80%) 64 (2.72%)  
5 4 (0.33%) 1 (0.09%) 5 (0.21%)  
CURB65, n (%)    0.36 
0-2 965 (79.88%) 895 (78.30%) 1860 (79.12%)  
3-5 243 (20.12%) 248 (21.70%) 491 (20.88%)  
SCAP mean (SD) 7.67 (7.58) 7.71 (7.26) 7.69 (7.43) 0.90 
SCAP, n (%)    0.19 
0 369 (30.55%) 313 (27.38%) 682 (29.01%)  
1 349(28.89%) 371 (32.46%) 720 (30.63%)  
2 387 (32.04%) 367 (32.11%) 754 (32.07%)  
3 87 (7.20%) 83 (7.26%) 170 (7.23%)  
4 16 (1.32%) 9 (0.79%) 25 (1.06%)  
SCAP, n (%)    0.87 
0-1 718 (59.44%) 684 (59.84%) 1402 (59.63%)  
2-4 490 (40.56%) 459 (40.16%) 949 (40.37%)  
Data are presented as n (%) or mean (SD). PSI: Pneumonia severity index; CURB65: 
Confusion, urea, respiratory rate, blood pressure, age >65. SCAP: Severe community acquired 
pneumonia. 
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In total, 208 (7.99%) patients died during hospitalization, while 251 patients died 
before 15 days from diagnosis. After deaths before 15 days were excluded, one-year 
mortality was 10.63%, respectively. No differences were observed between the 
derivation and the validation cohorts in terms of mortality (Table 7). 
 
Table 7. Mortality rates of hospitalized patients with CAP in the derivation cohort, the 
validation cohort, and the entire cohort, after the exclusion of deaths before 15 days 
from diagnosis. 
 Derivation 
(n=1208) 
Validation 
(n=1143) 
Entire cohort 
(n=2351) 
p-value 
30-day mortality, n (%) 23 (1.90%) 16 (1.40%) 39 (1.66%) 0.42 
45-day mortality, n (%) 30 (2.48%) 27 (2.36%) 57 (2.42%) 0.89 
90-day mortality, n (%) 60 (4.97%) 51 (4.46%) 111 (4.72%) 0.63 
180-day mortality, n (%)  88 (7.28%) 77 (6.74%) 165 (7.02%) 0.63 
One-year mortality, n (%) 131 (10.84%) 119 (10.41%) 250 (10.63%) 0.74 
  Data are presented as n (%). 
 
 
 
 
 
 
 
 
 
Results  
 
  87
6.2 Univariate analysis 
 
In order to identify possible predictors of one-year mortality we first performed 
univariate analysis, taking into account the variables more likely associated with that 
outcome.  
Table 8 shows the baseline characteristics and comorbidities among survivors and 
non-survivors. The mean (SD) age in survivors was 68.46 years (16.71) and 79.71 
years (10.23) in non-survivors (p <0.0001). Compared with survivors at one year, non-
survivors were older and were more frequently nursing home residents. Once 
comorbidities were analyzed, there were no statistical differences in diabetes mellitus, 
COPD, or CAD. However, cancer, congestive heart failure, cerebrovascular disease, 
and dementia were more common in people who died within one year of CAP 
diagnosis.  
 
Table 8. Baseline characteristics and comorbidities of survivors and non-survivors at 
one year in the derivation cohort. 
 Alive 
(n=1077) 
Dead 
 (n=131) 
p-value 
Age, mean (SD) 68.46 (16.71) 79.71 (10.23) <0.0001 
Age ≥80 years, n (%) 323 (79.36%) 84 (20.64%) <0.0001 
Sex, n (%)   0.44 
Male 698 (64.81%) 90 (68.70%)  
Female 379 (35.19%) 41 (31.30%)  
AC, n (%) 58 (5.40%) 5 (3.88%) 0.67 
Nursing home, n (%)  56 (5.20%) 30 (22.90%) <0.0001 
Aspiration 27 (61.36%) 17 (38.64%) <0.0001 
Comorbidities, n (%)    
Diabetes mellitus 166 (15.50%) 25 (19.38%) 0.25 
COPD 249 (23.18%) 29 (22.48%) 0.91 
Cancer 59 (5.48%) 17 (12.98%) 0.0033 
CHF 65 (6.04%) 16 (12.21%) 0.01 
CAD 101 (9.40%) 18 (13.95%) 0.12 
CVD 80 (7.43%) 25 (19.08%) <0.0001 
Dementia 81 (7.53%) 42 (32.56%) <0.0001 
Renal failure 72 (6.69%) 15 (11.45%) 0.07 
Data are presented as n (%) or mean (SD). AC: Alcohol consumption; COPD: Chronic 
obstructive pulmonary disease; CHF; Congestive heart failure; CAD; Coronary artery 
disease; CVD; Cerebrovascular disease. 
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Table 9 shows the physical examination, radiological presentation and analytics data 
among survivors and non-survivors. Non-survivors presented more frequently 
confusion and a respiratory rate ≥30 breaths/min compared to survivors. In terms of 
analytics, people who died presented more commonly BUN >30 mmol/L, hematocrit 
<30%, and respiratory insufficiency. 
 
Table 9. Physical examination, radiological presentation, analytics and treatment of 
survivors and non-survivors at one year in the derivation cohort.  
 Alive 
(n=1077) 
Dead 
 (n=131) 
p-value 
Physical examination, n (%)    
Confusion 96(8.91%) 35 (26.72%) <0.0001 
HR ≥125 beats/min 108 (10.03%) 8 (6.11%) 0.21 
RR ≥30 breaths/min 144 (13.37%) 31 (23.66%) 0.0035 
SBP <90 mmHg 46 (4.27%) 6 (4.58%) 0.82 
DBP <60 mmHg 181 (16.93%) 26 (20.31%) 0.32 
BT ≥40°C 4 (0.37%) 0 (0%) >.99 
X-ray, n (%)    
Pleural effusion 114 (10.58%) 9 (6.87%) 0.22 
Multilobar/bilateral 233 (21.67%) 33 (25.38%) 0.37 
Radiological pattern, n (%)   0.68 
Alveolar  1060 (98.60%) 128 (98.46%)  
Interstitial  11 (1.02%) 2 (1.54%)  
Mixed  4 (0.37%) 0 (0%)  
Analytics, n (%)    
Glucose ≥250 mg/dL 91 (8.45%) 11 (8.40%) >.99 
BUN >30 mg/dL 270 (25.07%) 63 (48.09%) <0.0001 
Sodium <130 mmol/L 69 (6.41%) 10 (7.63%) 0.57 
Hematocrit <30% 24 (2.23%) 8 (6.11%) 0.02 
PaO2 <60 mmHg 458 (42.53%) 76 (58.02%) 0.0010 
pH <7.35 47 (4.36%) 9 (6.87%) 0.19 
Treatment, n (%)    
Previous antibiotic 242 (22.51%) 27 (20.61%) 0.66 
Antibiotic according to SEPAR 
guidelines 
862 (80.04%) 102 (77.86%) 0.56 
Antibiotic within first 4 h 618 (59.71%) 87 (67.97%) 0.08 
Antibiotic within first 8 h 861 (83.19%) 105 (82.03%) 0.71 
Corticosteroids 282 (26.18%) 45 (34.35%) 0.06 
Data are presented as n (%). HR: Heart rate; RR: Respiratory rate; SBP: Systolic blood 
pressure; DBP: Diastolic blood pressure; BT: Body temperature; BUN: Blood urea 
nitrogen; SEPAR: Spanish Pulmonology and Thoracic Surgery Society. 
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Severe sepsis was observed more commonly in non-survivors, as were respiratory 
insufficiency and renal failure. Compared with survivors at one year, non-survivors 
more frequently developed decompensations from previous cardiac and neurologic 
diseases (Table 10).  
 
Table 10. Complications during hospitalization of survivors and non-survivors at one 
year in the derivation cohort. 
 Alive 
(n=1077) 
Dead 
 (n=131) 
p-value 
ICU admission, n (%) 53 (4.92%) 1 (0.76%) 0.02 
IRCU admission, n (%) 52 (4.83%) 3 (2.29%) 0.26 
Need for IMV, n (%) 18 (1.67%) 0 (0%) 0.25 
Shock, n (%) 44 (4.09%) 5 (3.82%) >.99 
Need for vasopressors, n (%) 36 (4.06%) 0 (0%) 0.03 
Respiratory failure, n (%) 480 (44.57%) 80 (61.07%) 0.0003 
Renal failure, n (%) 85 (7.89%) 15 (11.45%) 0.18 
Pleural effusion, n (%) 47 (4.36%) 7 (5.34%) 0.65 
Antibiotic AE, n (%) 90 (8.36%) 9 (6.87%) 0.73 
Embolism, n (%) 4 (0.37%) 2 (1.53%) 0.13 
DVT, n (%) 3 (0.28%) 1 (0.76%) 0.37 
Decompensated comorbidities, n 
(%) 
   
Diabetes mellitus 55 (5.11%) 7 (5.34%) 0.83 
Asthma 19 (1.76%) 0 (0%) 0.25 
COPD 35 (3.25%) 8 (6.11%) 0.13 
Heart disease 35 (3.25%) 9 (6.87%) 0.0467 
Neurological disease 5 (0.46%) 4 (3.05%) 0.01 
Renal failure 22 (2.04%) 6 (4.58%) 0.11 
Data are presented as n (%). ICU: Intensive care unit; IRCU: Intermediate respiratory care 
unit; IMV: Invasive mechanical ventilation; AE: Adverse events; DVT: Deep vein 
thrombosis; COPD: Chronic obstructive pulmonary disease. 
 
Table 11 shows severity of illness among survivors and non-survivors. Patients who 
died within one year were more severely ill at the time of diagnosis or at the index 
admission, as evidenced by higher risk scores.  
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Table 11. Severity of illness measured by risk scores of survivors and non-survivors at 
one year in the derivation cohort. 
 Alive 
(n=1077) 
Dead 
 (n=131) 
p-value 
PSI mean (SD) 88.23 (31.60) 117.35 (30.36) <0.0001 
PSI, n (%)   <0.0001 
I 157 (14.58%) 1 (0.76%)  
II 150 (13.93%) 7 (5.34%)  
III 282 (26.18%) 16 (12.21%)  
IV 400 (37.14%) 64 (48.85%)  
V 88 (8.17%) 43 (32.82%)  
PSI, n (%)   <0.0001 
I-III 589 (54.69%) 24 (18.32%)  
IV-V 488 (45.31%) 107 (81.68%)  
CURB65 mean (SD) 1.55 (1.03) 2.31 (1.03) <0.0001 
CURB65, n (%)   <0.0001 
0 206 (19.13%) 7 (5.34%)  
1 285 (26.46%) 17 (12.98%)  
2 399 (37.05%) 51 (38.93%)  
3 166 (15.41%) 41(31.30%)  
4 18 (1.67%) 14 (10.69%)  
5 3 (0.28%) 1 (0.76%)  
CURB65, n (%)   <0.0001 
0-2 890 (82.64%) 75 (57.25%)  
3-5 187 (17.36%) 56 (42.75%)  
SCAP mean (SD) 7.05 (7.30) 12.77 (7.93) <0.0001 
SCAP, n (%)   <0.0001 
0 357 (33.15%) 12 (9.16%)  
1 324 (30.08%) 25 (19.08%)  
2 320 (29.71%) 67 (51.15%)  
3 63 (5.85%) 24 (18.32%)  
4 13 (1.21%) 3 (2.29%)  
SCAP, n (%)   <0.0001 
0-1 681 (63.23%) 37 (28.24%)  
2-4 396 (36.77%) 94 (71.76%)  
Data are presented as n (%) or mean (SD). PSI: Pneumonia severity index; CURB65: 
Confusion, urea, respiratory rate, blood pressure, age>65. SCAP: Severe community 
acquired pneumonia. 
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6.3 Multivariate analysis 
 
From the identification of variables related to one-year mortality, we proceeded to try 
to combine them in a single multivariate model. We first performed multivariable 
logistic regression model which identified age ≥80 years, CHF, dementia, respiratory 
rate ≥30 breaths/min and BUN ≥30 mg/dL as predictors of one-year mortality (Table 
12).  
Regarding the discriminatory ability of the model in the derivation cohort, the receiver 
operating characteristic (ROC) curve was 0.78 (0.73-0.82) and 0.79 (0.75-0.83) in the 
validation cohort. The Hosmer-Lemeshow calibration test was 0.05 in the derivation 
cohort and 0.01 in the validation cohort. 
 
Table 12. Multivariate logistic regression model for one-year mortality in the derivation cohort and the 
validation cohort. 
 Derivation cohort Validation cohort  
Variables Beta (s.e.) OR (95% CI) p-value Beta (s.e.) OR (95% CI) p-value 
Age (years)       
≥80 vs. <80 0.98 (0.21) 2.66 (1.77, 4.00) <0.001 0.82 (0.22) 2.28 (1.48, 3.50) <0.001 
CHF       
Yes vs. No 0.74 (0.32) 2.10 (1.13, 3.90) 0.02 0.75 (0.29) 2.12 (1.19, 3.75) 0.01 
Dementia       
Yes vs. No 1.45 (0.24) 4.27 (2.68, 6.78) <0.001 1.64 (0.25) 5.16 (3.17, 8.41) <0.001 
RR (breaths/min)       
 ≥30 vs. <30 0.64 (0.24) 1.89 (1.18, 3.04) 0.009 0.64 (0.25) 1.89 (1.17, 3.07) 0.01 
BUN (mg/dL)       
 >30 vs. ≤30 0.71 (0.20) 2.02 (1.36, 3.01) <0.001 0.54 (0.21) 1.71 (1.13, 2.60) 0.01 
AUC 0.78 (0.73-0.82) 0.79 (0.75-0.83) 
H-L 0.05 0.01 
Beta (s.e): Beta regression coefficient with standard error; OR: Odds ratio; CI: Confidence interval; AUC: Area under 
the curve. CHF: Congestive heart failure; RR: Respiratory rate; BUN: Blood urea nitrogen. H-L: Hosmer Lemeshow. 
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6.4 Score development 
 
The logistic regression model was satisfactorily replicated in the multivariable survival 
analysis with similar p-values (Table 13). In order to develop a one-year mortality CAP 
severity index, now called the one-year CAPSI (community acquired pneumonia 
severity index), a prediction score was developed using the beta coefficients to weight 
the relative importance of the categories of each variable. Dementia being weighted 
with 6 points, followed by age ≥80 scored with 4 points, BUN >30 mg/dL scored with 3 
points, and CHF and respiratory rate ≥30 breaths/min, both scored with 2 points. The 
prediction score distribution for each patient in the derivation and the validation cohort 
is shown in Figure 1.  
 
Table 13. Multivariate survival analysis for one-year mortality in the derivation cohort and the validation 
cohort, i.e. one-year CAPSI. 
 Derivation cohort Validation cohort 
Variables Beta (s.e.)  HR (95% CI) p-value Weight Beta (s.e.) HR (95% CI) p-value 
Age (years)    4    
≥80 vs. <80 0.87 (0.20) 2.39 (1.63,3.50) <0.001  0.74 (0.21) 2.10 (1.40,3.15) 0.0003 
CHF    2    
Yes vs. No 0.57 (0.27) 1.78 (1.05,3) 0.0331  0.52 (0.24) 1.68 (1.04,2.72) 0.03 
Dementia    6    
Yes vs. No 1.20 (0.20) 3.33 (2.25,4.91) <0.001  1.38 (0.21) 3.98 (2.64,5.99) <0.001 
RR (breaths/min)    2    
 ≥30 vs. <30 0.49 (0.21) 1.63 (1.09,2.45) 0.018  0.49 (0.21) 1.63 (1.08,2.47) 0.02 
BUN (mg/dL)    3    
 >30 vs. ≤30 0.66 (0.18) 1.93 (1.35,2.75) <0.0003  0.44 (0.19) 1.55 (1.07,2.24) 0.02 
GND test 0.03 0.23 
Beta (s.e): Beta regression coefficient with standard error; HR: Hazard ratio; CI: Confidence interval. CHF: Congestive 
heart failure; RR: Respiratory rate; BUN: Blood urea nitrogen. GND test: Greenwood-Nam-D'agostino calibration test for 
the one-year CAPSI as a continuous variable. 
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Figure 1. One-year CAPSI distribution in the derivation cohort and validation cohort. 
 
 
 
For each unit increase in the score, the one-year mortality risk increased by 24% (1.24 
(1.19, 1.28), HR (95%CI)). The one-year CAPSI was then categorized into three risk 
groups: low, moderate, and high risk, according to the one-year CAPSI risk score 
(Table 14). One-year mortality risk ranged from 3.35% in the lowest group to 28.38% 
in the highest group in the derivation cohort.  
Similarly, one-year mortality risk ranged from 4.21% in the lowest group to 25% in the 
highest group in the validation cohort. Therefore, an 82-year-old patient with dementia 
would have 9.91 (6.30, 15.59) (HR (95%CI)) times higher probability of dying one year 
after an admission for CAP. At the same time, a 50-year-old patient with congestive 
heart failure and a respiratory rate of 32 breaths/min would have a 3.19 (1.75, 5.83) 
(HR (95%CI)) times higher probability of dying one year after an admission for CAP.  
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Table 14. Multivariate survival analysis for one-year mortality in the derivation cohort and the validation 
cohort by risk stratification groups. 
 
 
HR: Hazard ratio; CI: Confidence interval. GND test: Greenwood-Nam-D'agostino calibration test for the one-year 
CAPSI as categorical variable. *Hazard risk of each increase in one unit in the one-year CAPSI. 
 
 
 
 
 
 
 
 
 
 
 Derivation cohort Validation cohort 
Variables Dead/exposed HR (95% CI) p-value Dead/exposed HR (95% CI) p-value 
One-year 
CAPSI* 
- 1.24 (1.19, 1.28) <0.001  1.21 (1.17, 1.26) <0.001 
One-year 
CAPSI 
      
0-3 24/717 (3.35%) Reference  29/689 (4.21%) Reference  
4-5 19/184 (10.33%) 3.19 (1.75, 5.83) 0.0002 21/168 (12.5%) 3.03 (1.73, 5.32) <0.001 
>5 86/303 (28.38%) 9.91 (6.30, 15.59) <0.001 69/276 (25%) 5.95 (3.86, 9.19) <0.001 
GND test 0.98 0.93 
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6.5 Validation, discrimination, calibration and classification 
measures  
 
The C-index of the one-year CAPSI as a continuous variable in the derivation cohort 
was 0.76 (0.024), the AIC was 1707.43, and R2 was 8.8%. In the validation cohort, the 
C-index of the one-year CAPSI as a continuous variable was 0.77 (0.025), the AIC 
was 1589.23, and R2 was 8.5%. When the one-year CAPSI was measured as a 
categorical variable, i.e. the one-year CAPSI risk score, the C-index of the derivation 
cohort was 0.72 (0.021), the AIC was 1715.30 and R2 was 8.2%. In the validation 
cohort, the C-index of the one-year CAPSI as a categorical variable was 0.70 (0.023), 
the AIC was 1589.23 and R2 was 6.3%.  
Table 15 shows the statistical measures of performance with different cut-offs of the 
one-year CAPSI. For a cut-off point of four for the one-year CAPSI, the results of the 
statistical measures of performance were sensitivity 81.40%, specificity 64.47%, 
positive predictive value (PPV) 21.56%, and negative predictive value (NPV) 96.65% 
with an accuracy of 66.28% for the derivation cohort. In the validation cohort, 
sensitivity was 75.63%, specificity 65.09%, PPV 20.27%, and NPV 95.79% with an 
accuracy of 66.20%.  
For a cut-off of six for the one-year CAPSI, sensitivity was 66.67%, specificity 79.81%, 
PPV 28.38%, and NPV 95.23% with an accuracy of 78.41% in the derivation cohort. In 
the validation cohort, sensitivity was 57.98%, specificity 79.59%, PPV 25%, and NPV 
94.17% with an accuracy of 77.32%.  
For a cut-off of eight for the one-year CAPSI, sensitivity was 39.53%, specificity 
90.70%, PPV 33.77%, and NPV 95.59% with an accuracy of 85.22% in the derivation 
cohort. In the validation cohort, sensitivity was 40.34%, specificity 90.83%, PPV 
34.04%, and NPV 92.84% with an accuracy of 85.53%. 
The Greenwood-Nam-D'agostino (GND) calibration test for survival models for the 
multivariate model was 0.002 and 0.49 in the derivation and the validation cohorts, 
respectively. The GND calibration test for the survival model for the one-year CAPSI 
as a continuous variable was 0.03 and 0.23 in the derivation and the validation 
cohorts, respectively.  
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Finally, the GND calibration test for the survival model for one-year CAPSI as a 
categorical variable, i.e. the one-year CAPSI risk score, was 0.98 and 0.93 in the 
derivation and the validation cohorts, respectively. 
 
Table 15. Statistical measures of performance with different cut-offs for one-year 
CAPSI. 
 
 Sensitivity (%) 
(95%CI) 
Specificity (%) 
(95% CI) 
PPV (%) 
(95%CI) 
NPV (%) 
(95%CI) 
Accuracy (%) 
(95%CI) 
Derivation      
≥4 81.40 (73.59-87.70) 64.47 (61.52-67.33) 21.56 (17.99-25.48) 96.65 (95.06-97.84) 66.28 (63.53-68.95) 
≥6 95.23 (93.63-96.52) 78.41 (75.97-80.70) 66.67 (57.83-74.72) 79.81 (77.29-82.18) 28.38 (23.37-33.82) 
≥8 39.53 (31.04-48.52) 90.70 (88.80-92.37) 33.77 (26.29-41.91) 92.59 (90.84-94.10) 85.22 (83.08-87.17) 
Validation      
≥4 75.63 (66.91-83.03) 65.09 (62.06-68.02) 20.27 (16.63-24-32) 95.79 (94.01-97.16) 66.20 (63.36-68.95) 
≥6 57.98 (48.59-66.97) 79.59 (76.97-82.03) 25 (20-30.54) 94.17 (92.38-95.64) 77.32 (74.77-79.73) 
≥8 40.34 (31.45-49.72) 90.83 (88.88-92.53) 34.04 (26.28-42.49) 92.84 (91.06-94.37) 85.53 (83.3487.52) 
PPV: Positive predictive value; NPV: Negative predictive value; CI: Confidence interval. 
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6.6 Comparison with other scores 
 
The association between the severity of illness, measured by different risk scores, and 
one-year mortality in the derivation is shown in Table 16. Higher scores on PSI, 
CURB65, SCAP, and one-year CAPSI were associated with a higher risk of one-year 
mortality (Figures 2-5). 
 
Table 16. Hazard ratios for the association between the severity of illness measured 
by risk scores and one-year mortality in the derivation cohort.  
One-year mortality Beta (s.e.) HR (95% CI) p-value 
PSI  0.91 (0.11) 2.49 (2.02,3.06) <0.0001 
PSI  
I-III Reference 
IV-V 1.61 (0.23) 4.99 (3.21,7.77) <0.0001 
CURB65  0.67 (0.08) 1.95 (1.66,2.30) <0.0001 
CURB65  
≤2 Reference 
>2 1.20 (0.18) 3.31 (2.34,4.68) <0.0001 
SCAP  0.67 (0.08) 1.95 (1.66,2.30) <0.0001 
SCAP    
<2 Reference 
≥2 1.41 (0.19) 4.09 (2.79, 5.98) <0.0001 
One-year CAPSI 0.21 (0.02) 1.24 (1.19,1.28) <0.0001 
One-year-CAPSI    
≤3 Reference 
>3 1.97 (0.23) 7.17 (4.62,11.74) <0.0001 
Beta (s.e): Beta regression coefficient with standard error; HR: Hazard ratio; CI: 
Confidence interval. PSI: Pneumonia severity index; CURB65: Confusion, urea, 
respiratory rate, blood pressure, age>65; SCAP: Severe community-acquired 
pneumonia; one-year CAPSI: one-year community-acquired severity index. 
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Figure 2. Kaplan-Meier survival curve for the derivation cohort, stratified by PSI risk 
groups. 
 
 
 
Figure 3. Kaplan-Meier survival curve for the derivation cohort, stratified by CURB65 
risk groups. 
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Figure 4. Kaplan-Meier survival curve for the derivation cohort, stratified by SCAP risk 
groups. 
 
 
 
 
 
 
 
 
Figure 5. Kaplan-Meier survival curve for the derivation cohort, stratified by one-year 
CAPSI risk groups. 
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Table 17 shows the association between the severity of illness, measured by risk 
scores, and one-year mortality in the validation cohort. Higher scores on PSI, 
CURB65, SCAP, and one-year CAPSI were associated with a higher risk of one-year 
mortality (Figures 6-9). 
 
Table 17. Hazard ratios for the association between the severity of illness measured by 
risk scores and one-year mortality in the validation cohort.  
One year 
mortality 
Beta (s.e.) HR (95% CI) p-value 
PSI  1.10 (0.12) 3.00 (2.35,3.83) <0.0001 
PSI  
I-III  
IV-V 2.38 (0.33) 10.82 (5.66, 20.68) <0.0001 
CURB65  0.72 (0.09) 2.08 (1.74, 2.49) <0.0001 
CURB65  
≤2 Reference 
>2 1.17 (0.18) 3.22 (2.24,4.61) <0.0001 
SCAP  0.69 (0.09) 2.00 (1.66,2.41) <0.0001 
SCAP    
<2 Reference 
≥2 1.39 (0.20) 4.03 (2.71, 6.00) <0.0002 
One-year CAPSI 0.20 (0.02) 1.23 (1.18,1.28) <0.0001 
One-year CAPSI    
≤3 Reference 
>3 1.67 (0.21) 5.29 (3.48,8.05) <0.0001 
Beta (s.e): Beta regression coefficient with standard error HR: Hazard ratio; CI: 
Confidence interval. PSI: Pneumonia severity index; CURB65: Confusion, urea, 
respiratory rate, blood pressure, age>65. SCAP: Severe community acquired 
pneumonia; one-year CAPSI: one-year community-acquired severity index. 
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Figure 6. Kaplan-Meier survival curve for the validation cohort, stratified by PSI risk 
groups. 
 
 
Figure 7. Kaplan-Meier survival curve for the validation cohort, stratified by CURB65 
risk groups. 
 
 
 
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Time
Su
rv
iv
al
 P
ro
ba
bi
lit
y
PSI
IV-V
I-II-III
One-year mortality for PSI risk scale groups in the validation sample
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Time
Su
rv
iv
al
 P
ro
ba
bi
lit
y
CURB65
III-IV-V
0-I-II
One-year mortality for CURB65 risk scale groups in the validation sample
  LONG‐TERM MORTALITY IN HOSPITALIZED PATIENTS WITH COMMUNITY‐ACQUIRED PNEUMONIA
 
 102
Figure 8. Kaplan-Meier survival curve for the validation cohort, stratified by SCAP risk 
groups. 
 
 
Figure 9. Kaplan-Meier survival curve for the validation cohort, stratified by one-year 
CAPSI risk groups. 
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Table 18 shows the predictive accuracy of different risk scores as continuous 
variables for one-year mortality in the derivation and the validation cohorts. One-year 
CAPSI showed the best predictive accuracy in the derivation cohort with a C-index of 
0.76, followed by PSI with a C-index of 0.73 (p=0.18), CURB65 0.69 (p=0.009) and 
SCAP 0.70 (p=0.025). Likewise, one-year CAPSI showed the best predictive accuracy 
in the validation cohort with a C-index of 0.77, followed by PSI with a C-index of 0.75 
(p=0.39), CURB65 0.71 (p=0.03), and SCAP 0.70 (p=0.01). The p values refer to 
statistical differences between one-year CAPSI C-index with other prediction scores. 
 
Table 18. Predictive accuracy and goodness of fit for one-year mortality of continuous 
risk scores. 
 Derivation Validation 
 C-index AIC R2 C-index AIC R2 
PSI 0.73 (0.024) 1750.74 7.6% 0.75 (0.025) 1556.01 9.1% 
CURB65 0.69 (0.024) 1782.87 5.2% 0.71 (0.025) 1598.38 5.7% 
SCAP 0.70 (0.024) 1784.05 5.1% 0.70 (0.025) 1608.79 4.8% 
One-year CAPSI 0.76 (0.024) 1707.43 8.8% 0.77 (0.025) 1562.67 8.5% 
AIC: Akaike information criterion; R2: R-square. PSI: Pneumonia severity index; CURB65: 
Confusion, urea, respiratory rate, blood pressure, age>65. SCAP: Severe community acquired 
pneumonia; one-year CAPSI: one-year community-acquired severity index. 
 
Table 19 shows the predictive accuracy of different risk scores as categorical 
variables for one-year mortality in the derivation and the validation cohorts. One-year 
CAPSI showed the best predictive accuracy in the derivation cohort with a C-index of 
0.72, followed by PSI with a C-index of 0.67 (p=0.065), CURB65 0.62 (p<0.001) and 
SCAP 0.67 (p=0.065). Likewise, one-year CAPSI showed the best predictive accuracy 
in the validation cohort with a C-index 0.70, followed by PSI with a C-index of 0.71 
(p=0.519), CURB65 0.62 (p=0.02), and SCAP 0.67 (p=0.36). The p values refer to 
statistical differences between one-year CAPSI C-index with other prediction rules. 
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Table 19. Predictive accuracy and goodness of fit for one-year mortality of categorical 
risk scores. 
 Derivation Validation 
 C-index AIC R2 C-index AIC R2 
PSI 0.67 (0.022) 1780.09 5.4% 0.71 (0.023) 1569.64 8% 
CURB65 0.62 (0.017) 1805.63 3.3% 0.62 (0.019) 1628.26 3.2% 
SCAP 0.67 (0.021) 1787.01 4.8%  0.67 (0.012) 1611.58 4.6% 
one-year CAPSI 0.72 (0.021) 1715.30 8.2% 0.70 (0.023) 1589.23 6.3% 
AIC: Akaike information criterion; R2: R-square. PSI: Pneumonia severity index; CURB65: 
Confusion, urea, respiratory rate, blood pressure, age>65. SCAP: Severe community acquired 
pneumonia. 
 
Figures 10 and 11 show the ROC analysis for continuous risk scores in the derivation 
and validation cohorts. Figures 12 and 13 show ROC analysis for categorical risk 
scores in the derivation and validation cohorts. 
 
Figure 10. ROC curve analysis for continuous risk scores in the derivation cohort. 
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Figure 11. ROC curve analysis for continuous risk scores in the validation cohort. 
 
 
Figure 12. ROC curve analysis for categorical risk scores in the derivation cohort. 
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Figure 13. ROC curve analysis for categorical risk scores in the validation cohort. 
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STUDY II. ROLE OF BIOMARKERS FOR ONE-YEAR 
MORTALITY PREDICTION AMONG HOSPITALIZED 
PATIENTS WITH CAP IN GALDAKAO-USANSOLO 
HOSPITAL. 
 
6.1 Descriptive statistics 
 
For this second study, 231 patients in whom blood samples could be obtained were 
included after the exclusion of deaths within 15 days of diagnosis. Of these patients, 
38.10% were ≥80 years old, male sex was more frequent and 21.21% had been on 
previous antibiotic treatment. COPD was the most frequent comorbidity, with diabetes 
mellitus and CVD being the second and third, respectively (Table 20).  
Table 20. Baseline characteristics and comorbidities of hospitalized patients with CAP 
in which blood samples were obtained. 
  
n=231 
Age  
   <80 years 143 (61.9%) 
   ≥80 years 88 (38.10%) 
Sex  
   Male 154 (66.67%) 
   Female 77 (33.33%) 
Previous antibiotic 49 (21.21%) 
Comorbidities  
   Diabetes mellitus 40 (17.32%) 
  COPD 56 (24.24%) 
   Cancer  12 (5.19%) 
   Liver disease 7 (3.03%) 
   CHF 19 (8.23%) 
   CVD 28 (12.12%) 
   Dementia 28 (12.12%) 
   Renal failure 22 (9.52%) 
Data are presented as n (%). COPD: Chronic obstructive 
pulmonary disease; CHF; Congestive heart failure; CVD; 
Cerebrovascular disease. 
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Table 21 shows the physical examination and radiological presentation data. Around 
20% of the patients presented with confusion, diastolic blood pressure less than 60 
mmHg and bilateral and or multilobar involvement at diagnosis. 
 
Table 21. Physical examination and radiological presentation of hospitalized patients 
with CAP in which blood samples were obtained. 
 n=231 
Physical examination, n (%)  
   Confusion 46 (19.91%) 
   HR ≥125 beats/min 31 (13.42%) 
   RR ≥30 breaths/min 17 (7.36%) 
   SBP <90 mmHg 4 (1.73%9 
   DBP <60 mmHg 44 (19.05%) 
   BT ≥40°C 1 (0.43%) 
X-ray, n (%)  
  Pleural effusion 24 (10.39%) 
  Bilateral/multilobar 43 (18.61%) 
Radiological pattern, n (%)   
  Alveolar 227 (98.27%) 
  Interstitial 3 (1.30%) 
  Mixed 1 (0.43%) 
Data are presented as n (%). HR: Heart rate; RR: Respiratory 
rate; SBP: Systolic blood pressure; DBP: Diastolic blood 
pressure; BT: Body temperature. 
 
Table 22 shows the analytical data with 43.72% suffering from respiratory 
insufficiency, almost 30% presenting with a BUN higher than 30 mg/dL and 6.9% 
presenting with glucose >250 mg/dL. More than 80% of patients received adherent 
antibiotic treatment according to SEPAR guidelines and within the first 8 hours. In 
addition, nearly 40% received corticosteroids during hospitalization (Table 23). 
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Table 22. Analytical data of hospitalized patients with CAP in which blood samples 
were obtained. 
 n=231 
Analytics, n (%)  
   Glucose >250 mg/dL 16 (6.93%) 
   BUN >30 mg/dL 67 (29%) 
   Sodium <130 mmol/L 13 (5.63%) 
   Hematocrit <30  11 (4.76%) 
   PaO2 <60 mmHg  101 (43.72%) 
   pH arterial <7.35      13 (5.63%) 
Data are presented as n (%). BUN: Blood urea nitrogen. 
Table 23. Antibiotic and systemic corticosteroid treatment of hospitalized patients with 
CAP in which blood samples were obtained. 
 n=231 
Antibiotic, n (%)  
Previous antibiotic 49 (21.21%) 
Antibiotic according to 
SEPAR guidelines 
193 (83.91%) 
Antibiotic within first 4 h 164 (73.54%) 
Antibiotic within first 8 h 202 (90.58%) 
Corticosteroids, n (%) 91 (39.39%) 
Data are presented as n (%). SEPAR: Spanish 
Pulmonology and Thoracic Surgery Society. 
 
Table 24 shows complications during hospitalization, the most frequent one being 
respiratory failure. Of these patients, 15.58% required admission to the IRCU and 
5.19% admission to the ICU. However, only eight patients required vasopressors and 
only one patient needed invasive ventilation. 
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Table 24. Complications during hospitalization among hospitalized patients with CAP 
in which blood samples were obtained. 
 n=231 
ICU admission, n (%) 12 (5.19%) 
IRCU admission, n (%) 36 (15.58%) 
Need for IMV, n (%) 1 (0.43%) 
Severe sepsis, n (%) 103(44.59%) 
Need for vasopressors, n (%) 8 (3.46%) 
Respiratory failure, n (%) 98 (42.42%) 
Renal failure, n (%) 31 (13.42%) 
Pleural effusion, n (%) 21 (9.09%) 
Antibiotic AE, n (%) 10 (4.33%) 
Embolism, n (%) 1 (0.43%) 
DVT, n (%) 2 (0.87%) 
Decompensated 
comorbidities, n (%) 
 
Diabetes mellitus 14 (6.06%) 
Asthma 9 (3.90%) 
COPD 10 (4.33%) 
Heart disease 10 (4.33%) 
Neurological disease 10 (4.33%) 
Renal failure 8 (3.46%) 
Data are presented as n (%). ICU: Intensive care unit; IRCU: 
Intermediate respiratory care unit; IMV: Invasive mechanical 
ventilation; AE: Adverse events; DVT: Deep vein thrombosis; COPD: 
Chronic obstructive pulmonary disease. 
 
Table 25 shows the severity of illness at diagnosis. The mean PSI (SD) score was 
93.30 (36.14), the mean CURB65 (SD) score was 1.71 (1.09), and the mean SCAP 
score was 7.79 (7.57). About 50% of the cohort was defined as severe by the PSI 
score, 23% by the CURB65 score and 42% by the SCAP score. 
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Table 25. Baseline severity of hospitalized patients with CAP in which blood samples 
were obtained. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are presented as n (%) or mean (SD). PSI: Pneumonia severity 
index; CURB65: Confusion, urea, respiratory rate, blood pressure, 
age >65. SCAP: Severe community acquired pneumonia. 
  
n=231 
PSI mean (SD) 93.30 (36.14) 
PSI, n (%)  
I 32 (13.85%) 
II 26 (11.26%) 
III 54 (23.38%) 
IV 86 (37.23%) 
V 33 (14.29%) 
PSI, n (%)  
I-III 112 (48.48) 
IV-V 119 (51.52%) 
CURB65 mean (SD) 1.71 (1.09) 
CURB65, n (%)  
0 39 (16.88%) 
1 52 (22.51%) 
2 86 (37.23%) 
3 44 (19.05%) 
4 10 (4.33%) 
5 - 
CURB65, n (%)  
0-2 177 (76.62%) 
3-5 54 (23.38%) 
SCAP mean (SD) 7.79 (7.57) 
SCAP, n (%)  
O 68 (29.44%) 
1 65 (28.14%) 
2 75 (32.47%) 
3 21 (9.09%) 
4 2 (0.87%) 
SCAP, n (%)  
0-1 133 (57.58%) 
2-4 98 (42.42%) 
One-year CAPSI mean (SD) 3.43 (3.69) 
One-year CAPSI, n (%)  
≤3 129 (55.84%) 
>3 102 (44.16%) 
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Table 26 shows the mortality rate excluding deaths within the first 15 days as well as 
including all deaths up to one year. Within one year, 51 (19.78%) patients died 
including all deaths, 20 patients during hospitalization, 7 after discharge up to 15 days 
after diagnosis, and 24 patients 15 days after diagnosis up to one year. After the 
exclusion of 27 patients who died within 15 days of diagnosis, 24 (10.39%) died within 
one year.  
 
Table 26. Mortality rates of hospitalized patients with CAP in whom blood samples 
could be obtained (n=231). 
Including all deaths within one year N= 258 
In-hospital mortality, n (%) 20 (7.75%) 
15-day mortality1, n (%) 27 (10.47%) 
One-year mortality2, n (%) 51 (19.78%) 
Excluding deaths within 15 days N= 231 
One-year mortality, n (%) 24 (10.39%) 
1Including in-hospital mortality, 2Including all deaths within one year. 
Data are presented as n (%). 
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6.2 Biomarkers and risk scores predictive accuracy for one-year 
mortality, after the exclusion of deaths within 15 days 
 
Table 27 shows the relationship between biomarker levels obtained at the time of 
diagnosis and severity of illness, measured by risk scores after the exclusion of deaths 
within the first 15 days. More severe patients measured by PSI, CURB65, SCAP, and 
one-year CAPSI had significantly higher levels of proADM. In addition, more severe 
patients measured by the one-year CAPSI had significantly lower levels of CRP. 
Table 27. Relation between biomarkers and severity of illness, measured by risk 
scores1. 
 CRP PCT ProADM 
PSI    
I-III (n=112) 218.7 (97-323) 0.49 (0.10-2.41) 1.00 (0.77-1.37) 
IV-V (n=119) 177.4 (62.10-285.6) 0.36 (0.15-2.56) 1.64 (1.14-2.41) 
p-value 0.14 0.99 <0.0001 
CURB65    
≤2 (n=177) 182.2 (81-305.3) 0.37 (0.10-2.09) 1.16 (0.83-1.62) 
>2 (n=54) 198.25 (73-341.9) 0.87 (0.20-3.68) 1.97 (1.31-2.67) 
p-value 0.36 0.08 <0.0001 
SCAP    
<2 (n=133) 210.55 (89.6-289.6) 0.52 (0.12-2.41) 1.01 (0.80-1.40) 
≥2 (n= 98) 176.1 (64.0-341.9) 0.35 (0.14-2.13) 1.68 (1.23-2.41) 
p-value 0.24 0.73 <0.0001 
One-year CAPSI    
≤3 (n=129) 243.7 (91-353.3) 0.64 (0.12-2.75) 1.05 (0.78-1.56) 
>3 (n=102) 147.85 (62.1-256.9) 0.3 (0.13-1.44) 1.58 (1.14-2.05) 
p-value 0.0025 0.08 <0.0001 
1After exclusion of deaths within 15 days. Data are presented as median (IQR) of each biomarker. CRP: 
C reactive protein; PCT: Procalcitonin; ProADM: Proadrenomedullin; PSI: Pneumonia severity index. 
CURB65: Confusion, Urea, Respiratory rate, Blood pressure, age>65. SCAP: Severe community-
acquired. Pneumonia; one-year CAPSI: one-year community-acquired pneumonia severity index. 
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Table 28 shows the Cox regression model with the predictive ability of biomarkers for 
one-year mortality as continuous variables showing a poor predictive accuracy with a 
C-index of 0.57 for CRP (p=0.11), 0.51 for PCT (p value=0.55), and 0.64 for proADM 
(p=0.39). 
Table 28. Survival models of the predictive accuracy of biomarkers for one-year 
mortality, as continuous variables1. 
One-year mortality HR (95% CI) C-index AIC R2 p-value
CRP 0.99 (0.99,1.00) 0.57 (0.05) 257.91 1.2% 0.11 
PCT 0.98 (0.91,1.05) 0.51 (0.06) 225.04 0.2% 0.55 
proADM* 1.01 (0.99,1.04) 0.64 (0.06) 259.04 0.3% 0.39 
1After exclusion of deaths within 15 days. *for 0.1- nmol/L increment. HR: Hazard ratio; CI: Confidence interval; 
AIC: Akaike information criterion; R2: R-square. CRP: C reactive protein; PCT: Procalcitonin; ProADM: 
Proadrenomedullin.  
 
Table 29 shows the Cox regression model with the predictive ability of risk scores for 
one-year mortality. All the scores demonstrated a high predictive capacity, with a C-
index of 0.78 (0.05) for one-year CAPSI (p=<0.001). 
Table 29. Predictive accuracy of risk scores for one-year mortality, as continuous 
variables1. 
One-year mortality HR (95% CI) C-index AIC R2 p-value
PSI 4.20 (2.28, 7.72) 0.80 (0.06) 226.00 13.8% <0.001 
CURB65 1.96 (1.32, 2.90) 0.70 (0.06) 247.43 5.8% <0.001 
SCAP 2.64 (1.76, 3.96) 0.77 (0.06) 236.95 9.6% <0.001 
one-year CAPSI 1.21 (1.11,1.32) 0.75 (0.06) 243.18 7% <0.001 
1After exclusion of deaths within 15 days. HR: Hazard ratio; CI: Confidence interval; AIC: Akaike information 
criterion; R2: R-square. PSI: Pneumonia Severe Index. CURB65: Confusion, Urea, Respiratory rate, Blood 
pressure, age>65. SCAP: Severe Community Acquired Pneumonia; one-year CAPSI: one-year community-
acquired pneumonia severity index. 
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Table 30 shows risk scores prediction ability for one-year mortality once proADM was added. 
In all cases, proADM failed to improve the predictive accuracy. The C-index values were PSI 
+ proADM 0.82 (0.06), CURB65 + proADM 0.70 (0.06), SCAP + proADM 0.77 (0.06), and 
one-year CAPSI + proADM 0.75 (0.06) (p values= 0.05, 0.42, 0.38, 0.83, respectively). 
 
Table 30. Nested model comparison to assess risk scores ability with the proADM 
value added1. 
One-year mortality C-index AIC p-value 
PSI 0.80 (0.06) 226.00 Ref. 
PSI + ProADM 0.82 (0.06) 224.04 0.05 
CURB65 0.70 (0.06) 247.43 Ref. 
CURB65 + ProADM 0.70 (0.06) 248.77 0.42 
SCAP 0.77 (0.06) 236.95 Ref. 
SCAP + ProADM 0.77 (0.06) 238.17 0.38 
One-year CAPSI 0.75 (0.06) 243.18 Ref. 
One-year CAPSI + ProADM 0.75 (0.06) 245.14 0.83 
1After exclusion of deaths within 15 days. AIC: Akaike information criterion; R2: R-square. P-value 
indicate the statistical significance comparing with the same model without the biomarker. ProADM: 
Proadrenomedullin; PSI: Pneumonia Severe Index. CURB65: Confusion, Urea, Respiratory rate, Blood 
pressure, age>65. SCAP: Severe Community Acquired Pneumonia; one-year CAPSI: one-year 
community-acquired pneumonia severity index. 
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6.3 Biomarkers and risk scores predictive accuracy for one-year 
mortality, with the inclusion of all deaths within one year 
 
In order to assess the impact of short-term mortality, a similar analysis was carried out 
including all deaths. Table 31 shows the relationships between biomarker levels 
obtained at the time of diagnosis and the severity of illness, measured by risk scores 
including all deaths up to one year. Similarly, more severe patients measured by PSI, 
CURB65, SCAP, and one-year CAPSI had significantly higher levels of proADM. In 
addition, more severe patients, measured by one-year CAPSI, had significantly lower 
levels of CPR at diagnosis. 
 
Table 31. Relation between biomarkers and severity of illness, measured by risk 
scores1. 
 CRP PCT ProADM 
PSI    
I-III (n=113) 219.3 (103-328) 0.48 (0.09-2.41) 1.00 (0.77-1.38) 
IV-V (n=145) 177.4 (72.6-279.1) 0.43 (0.15-2.99) 1.68 (1.17-2.51) 
p-value 0.11 0.75 <0.0001 
CURB65    
≤2 (n=187) 181.1 (81-297.6) 0.36 (0.09-2.09) 1.17 (0.83-1.67) 
>2 (n=71) 200.3 (90.3-355.5) 0.93 (0.2-3.87) 2.06 (1.49-2.93) 
p-value 0.65 0.01 <0.0001 
SCAP    
<2 (n=135) 211 (89.6-289.6) 0.52 (0.12,2.41) 1.01 (0.80-1.43) 
≥2 (n=123) 174 (73-341.9) 0.43 (0.15-2.98) 1.74 (1.27-2.54) 
p-value  0.34 0.96 <0.0001 
One-year CAPSI    
≤3 (n=130) 244.35 (91-353.3) 0.66 (0.13-1.81) 1.06 (0.78-1.56) 
>3 (n=128) 149.7 (65.5,257.85) 0.31 (0.14-1.81) 1.67 (1.18-2.28) 
p-value 0.0038 0.13 <0.0001 
1Including all deaths within one year. Data are presented as median (IQR).CRP: C reactive protein; 
PCT: Procalcitonin; ProADM: Proadrenomedullin. PSI: Pneumonia Severe Index; CURB65: 
Confusion, Urea, Respiratory rate, Blood pressure, age>65; SCAP: Severe Community Acquired 
Pneumonia; one-year CAPSI: one-year community-acquired pneumonia severity index. 
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Table 32 shows the Cox regression models with the predictive ability of biomarkers for 
one-year mortality including all deaths within one year. ProADM showed a high 
predictive accuracy for one-year mortality with a C-index of 0.71 (0.04), (p<0.001). 
However, both CRP and PCT showed a low predictive accuracy for one-year mortality 
(C-index 0.54 (0.04), p=0.24; C-index 0.53 (0.04), p=0.47). All risk scores showed a 
high predictive accuracy for one-year mortality when all deaths were included (Table 
33). 
 
Table 32. Predictive accuracy of biomarkers for one-year mortality. 
One-year mortality HR (95% CI) C-index AIC R2 p-value
PCR 1.00 (0.99,1.00) 0.54 (0.04) 556.52 0.6% 0.24 
PCT 1.01 (0.98,1.04) 0.53 (0.04) 485.71 0.2% 0.47 
PROADM* 1.03 (1.02, 1.04) 0.71 (0.04) 518.52 5.8% <0.001 
1Including all deaths within one year. HR: Hazard ratio; CI: Confidence interval; AIC: Akaike information 
criterion; R2: R-square. CRP: C reactive protein; PCT: Procalcitonin; ProADM: Proadrenomedullin. *for 0.1-
unit increment 
 
 
Table 34 shows the risk scores when the proADM value was added when all deaths 
within one year were included in the analysis. ProADM failed to improve the predictive 
accuracy of the PSI score for one-year mortality 0.79 (0.04), p=0.15. The predictive 
ability of CURB65 significantly improved when proADM was added, i.e. 0.74 (0.04), 
p=0.0498. ProADM failed to improve the predictive accuracy of the SCAP score for 
one-year mortality, i.e. 0.80 (0.04), p= 0.21. Finally, the predictive accuracy of the one-
year CAPSI improved up to 0.83 (0.04) when proADM was added, p=0.010. 
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Table 33. Predictive accuracy of risk scores for one-year mortality1. 
One-year mortality HR (95% CI) C-index AIC R2 p-value
PSI 3.27 (2.20,4.85) 0.77 (0.04) 481.37 18.8% <0.001 
CURB65 2.15 (1.64,2.83) 0.71 (0.04) 500.70 12.3% <0.001 
SCAP 2.95 (2.23,3.92) 0.79 (0.04) 473.09 21.4% <0.001 
one-year CAPSI 1.27 (1.20,1.35) 0.81 (0.04) 474.91 20.9% <0.001 
  1Including all deaths within one year. HR: Hazard ratio; CI: Confidence interval; AIC: Akaike information 
criterion; R2: R-square. PSI: Pneumonia Severe Index. CURB65: Confusion, Urea, Respiratory rate, Blood 
pressure, age>65. SCAP: Severe Community Acquired Pneumonia; one-year CAPSI: one-year community-
acquired pneumonia severity index. 
 
 
Table 34. Nested model comparison to assess the predictive accuracy of risk scores 
when the proADM value was added1. 
One-year mortality C-index AIC p-value 
PSI 0.77 (0.04) 481.37 Ref. 
PSI + ProADM 0.79 (0.04) 481.34 0.15 
CURB65 0.71 (0.04) 500.70 Ref. 
CURB65 + ProADM 0.74 (0.04) 498.75 0.0498 
SCAP 0.79 (0.04) 473.09 Ref. 
SCAP + ProADM 0.80 (0.04) 473.54 0.21 
One-year CAPSI 0.81 (0.04) 474.91 Ref. 
One-year CAPSI + 
ProADM 
0.83 (0.04) 470.61 0.010 
1Including all deaths within one year. AIC: Akaike information criterion; R2: R-squared. ProADM: 
Proadrenomedullin; PSI: Pneumonia Severe Index. CURB65: Confusion, Urea, Respiratory rate, Blood 
pressure, age>65. SCAP: Severe Community Acquired Pneumonia; one-year CAPSI: one-year 
community-acquired pneumonia severity index. 
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6.4 Role of serial biomarkers levels in one-year mortality prediction 
 
Descriptive values of biomarker levels at diagnosis, at 3-5 days and changes from the 
first 24 hours to 3-5 days are shown in Table 35. Biomarker changes was calculated 
by subtracting the biomarker value at 3-5 days from the baseline value. In an attempt 
to assess the predictive accuracy of biomarkers over time, blood samples were 
obtained from 117 patients at 3-5 days. 
 
Table 35. Biomarker levels at diagnosis and at 3-5 days. 
Biomarker  24 hours 3-5 days Change* 
CRP 200.3 (81,353.3) 78 (44,148) 94 (-2.5, 212.2) 
PCT 0.52 (0.15,2.36) 0.32 (0.13,0.88) 0.19 (0.001,1.7) 
ProADM 1.28 (0.92,1.82) 0.86 (0.651.14) 0.32 (0.10,0.78) 
*Change was calculated by subtracting the biomarker value at 3-5 days from the baseline value. 
Data are presented as median (IR) 
 
Taking into account that proADM showed better predictive accuracy for one-year 
mortality than the other biomarkers, a subanalysis was carried out with this specific 
biomarker. ProADM change was obtained by subtracting the proADM value at 3-5 
days from the proADM value at the time of diagnosis.  
Table 36 shows the predictive accuracy of proADM changes for one-year mortality 
among three different samples adjusted by proADM value at baseline: after the 
exclusion of deaths within 15 days from diagnosis, including all deaths within one 
year, and excluding patients who died from 15 days to one year. In all cases, proADM 
changes showed a statistically significant predictive accuracy for one-year mortality. 
Hence, for each 0.1-nmol/L decrease in proADM from admission to 3-5 days, mortality 
rate decreases 8% for one-year mortality, excluding deaths within 15 days from 
diagnosis. 
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Table 36. Predictive accuracy of proADM change for one-year mortality    
One-year mortality HR (95% CI) C-index AIC R2 p-value
ProADMchange1 0.92 (0.84,1.00) 0.72 (0.08) 143.23 3.4% 0.04 
ProADMchange2 0.88 (0.83,0.93) 0.78 (0.06) 193.80 15.2% <0.001 
ProADMchange3 0.87 (0.78,0.92) 0.92 (0.11) 50.48 15.5% <0.001 
  Adjusted by proADM value at baseline.1Excluding deaths within 15 days of diagnosis, 2Including all deaths 
within one year, 3Excluding patients who died from 15 days after diagnosis to one year. The p values refer to 
the proADMchanges. HR: Hazard ratio; CI: Confidence interval; AIC: Akaike information criterion; R2: R-
square.ProADM difference: obtained by subtracting the proADM value at 3-5 days from proADM value at the 
time of diagnosis; 
 
Table 37 shows the predictive accuracy of the proADM change for one-year mortality 
after the exclusion of deaths within 15 days, adjusted by risk scores and the proADM 
value at baseline. In this case, ProADM changes failed to predict one-year mortality. 
The same analysis was carried out including all deaths within one year, as shown in 
table 38. For each 0.1-nmol/L decrease in proADM from admission to 3-5 days, the 
mortality rate decreased by 9% when adjusted by the one-year CAPSI and proADM 
baseline value. 
 
Table 37. Predictive accuracy of proADM change for one-year mortality among different 
risk scores, after the exclusion of deaths ≤ 15 days .  
One-year mortality HR (95% CI) C-index AIC R2 p-value
ProADMchange* (PSI) 1.02 (0.91, 1.13) 0.70 (0.08) 129.35 5.6% 0.76 
ProADMchange* (SCAP) 0.94 (0.84, 1.04) 0.76 (0.08) 137.79 8.9% 0.24 
ProADMchange* (CURB65) 0.93 (0.84,1.02) 0.70 (0.08) 142.40 5.6% 0.13 
ProADMchange*(one-year CAPSI) 0.95 (0.86, 1.05) 0.75 (0.08) 141.76 6% 0.32 
 Adjusted by severity and proADM value at baseline, *for each 0.1-nmol/L increment. The p values refer to the 
proADMchanges. HR: Hazard ratio; CI: Confidence interval; AIC: Akaike information criterion; R2: R-square. 
ProADM difference: obtained by subtracting PRADM value at 3-5 days from proADM value at the time of 
diagnosis; PSI: Pneumonia Severe Index. CURB65: Confusion, Urea, Respiratory rate, Blood pressure, 
age>65. SCAP: Severe Community Acquired Pneumonia; one-year CAPSI: one-year community-acquired 
pneumonia severity index. 
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Table 38. Predictive accuracy of proADM difference for one-year mortality among 
different risk scores, including all deaths within one year1. 
One-year mortality HR (95% CI) C-index AIC R2 p-value
ProADMchange* (PSI) 0.92 (0.86,0.98) 0.83 (0.06) 187.09 20.5% 0.007 
ProADMchange* (SCAP) 0.88 (0.83,0.94) 0.79 (0.06) 187.81 20.1% <0.001 
ProADMchange* (CURB65) 0.87 (0.82,0.93) 0.78 (0.06) 189.74 18.9% <0.001 
ProADMchange*(one-year CAPSI) 0.91 (0.85,0.96) 0.80 (0.06) 188.20 19.9% 0.0015 
1Adjusted by severity and proADM value at baseline,*for each 0.1-nmol/L increment. HR: Hazard ratio; CI: 
Confidence interval; AIC: Akaike information criterion; R2: R-square. ProADM difference: obtained by 
subtracting PRADM value at 3-5 days from ProADM value at the time of diagnosis; PSI: Pneumonia Severe 
Index. CURB65: Confusion, Urea, Respiratory rate, Blood pressure, age>65. SCAP: Severe Community 
Acquired Pneumonia; one-year CAPSI: one-year community-acquired pneumonia severity index. 
 
In addition, the same analysis was carried out after excluding patients who died between 15 
days from diagnosis and one year (Table 39). ProADM changes adjusted by severity showed 
a high predictive accuracy with a C-index of 0.94 (0.11) for one-year CAPSI. For each 0.1- 
nmol/L decrease in proADM from admission to 3-5 days, the mortality rate decreased by 
11% when adjusted by the one-year CAPSI and proADM value at baseline. 
Table 39. Predictive accuracy of the proADM difference for one-year mortality among 
different risk scores, excluding patients who died between 15 days after diagnosis and 
one year1. 
One-year mortality HR (95% CI) C-index AIC R2 p-value
ProADMchange* (PSI) 0.86 (0.79,0.93) 0.92 (0.11) 51.23 16.04% 0.0003 
ProADMchange* (SCAP) 0.84 (0.77,0.92) 0.90 (0.11) 49.02 17.9% <0.0001 
ProADMchange* (CURB65) 0.79 (0.71,0.90) 0.94 (0.11) 43.92 21.4% 0.0001 
ProADMchange*(one-year CAPSI) 0.89 (0.82,0.96) 0.94 (0.11) 44.99 20.70% 0.004 
1Adjusted by severity and proADM value at baseline, *for each 0.1-nmol/L increment. HR: Hazard ratio; CI: 
Confidence interval; AIC: Akaike information criterion; R2: R-square. ProADM difference: obtained by 
subtracting PRADM value at 3-5 days from ProADM value at the time of diagnosis; PSI: Pneumonia Severe 
Index. CURB65: Confusion, Urea, Respiratory rate, Blood pressure, age>65. SCAP: Severe Community 
Acquired Pneumonia; one-year CAPSI: one-year community-acquired pneumonia severity index. 
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STUDY III. ONE-YEAR MORTALITY PREDICTION AMONG 
HOSPITALIZED PATIENTS WITH CAP IN THE VETERANS 
AFFAIRS MEDICAL CENTER OF LOUISVILLE, KENTUCKY. 
 
6.1 Descriptive statistics 
 
A total of 455 patients were included in the analysis. Of these, 121 (27%) patients died 
within one year while 265 (58%) of patients died within five years. All patients were 
male, 39.56% were older than 75, and almost half of the cohort were current smokers. 
Hypertension, COPD, and CAD were the most frequent comorbidities. In addition, 
almost half of the cohort had an albumin <3.5 and a BUN >20 mg/dL (Tables 40 and 
41). 
Table 40. Baseline characteristics and comorbidities of hospitalized patients with CAP.  
 n=455 
Age ≥75 years 180 (39.56%) 
Sex (male) 455 (100%) 
Current smoker 191 (42.26%) 
BMI <21 40 (8.93%) 
Nursing home resident 17 (3.74%) 
Suspicion of aspiration 18 (4.25%) 
Hypertension 320 (70.33%) 
Diabetes 157 (34.51%) 
COPD 227 (49.89%) 
Cancer 58 (12.75%) 
CHF 117 (25.71%) 
CAD 198 (43.52%) 
CVD 57 (12.53%) 
Dementia 39 (9.21%) 
Renal disease 67 (14.73%) 
Liver disease 15 (3.3%) 
Data are presented as n (%). BMI: Body mass index; COPD: Chronic obstructive pulmonary 
disease; CHF: Congestive heart failure; CAD: Coronary artery disease; CVA: Cerebrovascular 
disease.  
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Table 41. Physical examination and analytics of hospitalized patients with CAP. 
 n=455 
Respiratory rate >30 breaths/min 44 (9.67%) 
BUN >20 mg/dL 237 (52.43%) 
Albumin <3.5 mg/dL 216 (47.47%) 
Hematocrit <30% 26 (5.71%) 
Platelets <100x109/L or >400x109/L, n (%) 78 (17.18%) 
Data are presented as n (%). BUN: blood urea nitrogen. 
 
Patient sociodemographic characteristic and comorbidities were compared between 
study I and study III (Table 42). Patients in study III were all men, were significantly 
younger, and more frequently presented diabetes mellitus, COPD, cancer, CHF, CAD, 
CVD, and renal failure. In addition, patients in study III were more severe at 
admission, measured by PSI, and more frequently had a respiratory rate ≥30 
breaths/min, BUN >30 mg/dL, and hematocrit <30% compared with patients in study I. 
 
From the initial 2351 patients at Galdakao-Usansolo Hospital, 250 (10.63%) patients 
died within one year after the exclusion of deaths within the first 15 days, while 120 
(27.71%) patients died in the sample of patients hospitalized at the Veterans Affairs 
Medical Center in Louisville, Kentucky. 
 
One-year CAPSI was applied to this sample and it failed to properly validate the 
previous results with a C-index of 0.62 (0.03), AIC of 1405.44, and R2 5.1%. 
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Table 42. Comparison of patient sociodemographic characteristics and comorbidities 
between study I and study III. 
 STUDY I STUDY III p-value 
Age, n (%)   0.0001 
≥80 years  784 (33.35%) 115 (24.42%)  
<80 years  1567 (66.65%) 356 (75.58%)  
Sex, n (%)   <0.0001 
Male 1540 (65.50%) 471 (100%)  
Female 811 (34.50%) 0 (0%)  
Nursing home, n (%) 154 (6.55%) 20 (4.25%) 0.05 
Aspiration 80 (3.40%) 20 (4.28%) 0.33 
Comorbidities, n (%)    
Diabetes mellitus 362 (15.54%) 160 (33.97%) <0.0001 
COPD 613 (26.23%) 235 (49.89%) <0.0001 
Cancer 130 (5.53%) 69 (14.65%) <0.0001 
CHF 180 (7.66%) 120 (25.48%) <0.0001 
CAD 224 (9.58%) 198 (42.04%) <0.0001 
CVD 199 (8.46%) 55 (11.68%) 0.03 
Dementia 230 (9.84%) 48 (10.28%) 0.79 
Renal failure 176 (7.49%) 70 (14.86%) <0.0001 
Respiratory rate ≥30 
breaths/min 
354 (15.06%) 48 (10.19%) 0.005 
BUN >30 mg/dL 661 (28.12%) 116 (24.63%) 0.12 
Hematocrit <30% 57 (2.42%) 31 (6.58%) <0.0001 
PSI mean (SD) 91.48 (32.20) 97.23 (37.24) 0.0019 
PSI, n (%)   0.0063 
I-III 1157 (49.21%) 199 (42.25%)  
IV-V 1194 (50.79%) 272 (57.75%)  
Data are presented as n (%) or mean (SD); COPD: Chronic obstructive 
pulmonary disease; CHF: Congestive heart failure; CAD: Coronary artery 
disease; CVA: Cerebrovascular disease; BUN: Blood urea nitrogen. 
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6.2 Univariate analysis 
 
Table 43 shows the patient characteristics among survivors and non-survivors at one 
year. Compared to those who survived at one year, non-survivors were older, were 
more frequently nursing home residents, and more frequently had cancer, COPD, 
CVD, and dementia. In addition, non-survivors presented with lower levels of albumin 
and hematocrit and more frequently had BUN >20 mg/dL and platelet counts 
<100,000 or >400,000/L.  
 
Table 43. Characteristics among survivors and non-survivors at one year. 
Variable 
 
Alive Dead p-value 
Age, median (IQR) 70 (22) 75 (12) <0.001 
Age ≥75 years, n (%) 118 (35) 62 (51) 0.002 
Current smoker, n (%) 146 (44) 45 (37) 0.198 
BMI <21, n (%) 26 (8) 14 (12) 0.259 
Nursing home resident, n (%) 5 (1) 12 (10) <0.001 
Suspicion of aspiration, n (%) 10 (3) 8 (7) 0.179 
Hypertension, n (%) 231 (69) 89 (74) 0.417 
Diabetes, n (%) 113 (34) 44 (36) 0.656 
COPD, n (%) 167 (50) 60 (50) >0.999 
Cancer, n (%) 15 (4) 43 (36) <0.001 
CHF, n (%) 83 (25) 34 (28) 0.544 
CAD, n (%) 140 (42) 58 (48) 0.285 
CVD, n (%) 32 (10) 24 (20) 0.006 
Dementia, n (%) 19 (6) 20 (17) 0.002 
Renal disease, n (%) 48 (14) 19 (16) 0.765 
Liver disease, n (%) 9 (3) 6 (5) 0.241 
Respiratory rate >30 breaths/min, n (%) 30 (9) 14 (12) 0.472 
BUN >20 mg/dL, n (%) 164 (49) 73 (61) 0.033 
Albumin <3.5 mg/dL, n (%) 148 (44) 68 (56) 0.026 
Hematocrit <30%, n (%) 9 (3) 17 (14) <0.001 
Platelets <100x109/L or >400x109/L, n (%) 44 (13) 34 (28) <0.001 
pO2/FiO2 <250 mmHg, n (%) 85 (46) 31 (43) 0.78 
Data are presented as n (%) and median (IQR). BMI: Body mass index; COPD: Chronic obstructive 
pulmonary disease; CHF: Congestive heart failure; CAD: Coronary artery disease; CVA: Cerebrovascular 
accident; BUN: blood urea nitrogen. 
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Those patients who died within five years were also older, were more frequently 
nursing home residents, and more frequently had cancer, COPD, CVD, and dementia. 
Similarly, non-survivors at five years presented with lower levels of albumin and 
hematocrit and more frequently had BUN >20 mg/dL and platelet counts <100,000 or 
>400,000/L (Table 44). 
 
Table 44. Characteristics among survivors and non-survivors at five years. 
Variable 
 
Alive Dead p-value 
Age, median (IQR) 66 (20.8) 74 (17) <0.001 
Age ≥75 years, n (%) 55 (29) 125 (47) <0.001 
Current smoker, n (%) 84 (45) 107 (40) 0.384 
BMI <21, n (%) 12 (6) 28 (11) 0.133 
Nursing home resident, n (%) 2 (1) 15 (6) 0.011 
Suspicion of aspiration, n (%) 4 (3) 14 (5) 0.218 
Hypertension, n (%) 130 (68) 190 (72) 0.468 
Diabetes, n (%) 67 (35) 90 (34) 0.842 
COPD, n (%) 82 (43) 145 (55) 0.017 
Cancer, n (%) 8 (4) 50 (19) <0.001 
CHF, n (%) 40 (21) 77 (29) 0.064 
CAD, n (%) 71 (37) 127 (48) 0.028 
CVD, n (%) 18 (9) 38 (14) 0.148 
Dementia, n (%) 7 (4) 32 (12) 0.009 
Renal disease, n (%) 25 (13) 42 (16) 0.503 
Liver disease, n (%) 4 (2) 11 (4) 0.292 
Respiratory rate >30 breaths/min, n (%) 15 (8) 29 (11) 0.335 
BUN >20 mg/dL, n (%) 88 (47) 149 (57) 0.036 
Albumin <3.5 mg/dL, n (%) 78 (41) 138 (52) 0.022 
Hematocrit >30%, n (%) 3 (2) 23 (9) 0.001 
Platelets <100x109/L or >400x109/L, n (%) 21 (11) 57 (22) 0.004 
pO2/FiO2 <250 mmHg, n (%) 47 (47) 69 (44) 0.798 
Data are presented as n (%) and median (IQR). BMI: Body mass index; COPD: Chronic obstructive 
pulmonary disease; CHF: Congestive heart failure; CAD: Coronary artery disease; CVA: 
Cerebrovascular accident; BUN: blood urea nitrogen. 
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6.3 Multivariate analyses and score development 
 
Table 45 shows the one-year prediction score. A score based on age ≥75 years, 
cancer, CHF, dementia, albumin <3.5mg/dL and platelets <100.000 or >400.000/L 
could predict one-year mortality with an AUC of 0.77. When the same score was used 
to predict five-year mortality, the AUC was 0.70. Representation of the score for one-
year and five-year mortality is shown in Figure 14. 
 
Table 45. One-year mortality prediction score.  
Variable Beta (se) Statistic p-value Weight
Intercept -2.28 (0.26) -8.78 <0.001  
Age ≥75 years 0.65 (0.26) 2.51 0.01 2 
Cancer 2.52 (0.34) 7.29 <0.001 7 
CHF 0.40 (0.28) 1.44 0.15 1 
Dementia 1.25 (0.37) 3.38 <0.0001 4 
Albumin <3.5 mg/dL 0.55 (0.25) 2.18 0.03 2 
Platelets<100x109/Lor>400x109/L 0.72 (0.31) 2.32 0.02 2 
ONE YEAR AUC                                                                0.77 
FIVE YEARS AUC                                                             0.70 
Beta (s.e): Beta regression coefficient with standard error; AUC: Area under the curve; BMI: Body mass 
index; CHF: Congestive heart failure; 
 
 
Table 46 shows the five-year prediction score. Age ≥75 years old, aspiration, being 
nursing home resident, cancer, CHF, underweight, and platelets <100,000 or 
>400,000/L could predict five-year mortality with an AUC of 0.69. Representation of 
this second score for five-year mortality is shown in Figure 15. 
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Table 46. Five-year mortality prediction score. 
Variable Beta (s.e) Statistic p-value Weight 
Intercept -0.42 (0.17) -2.50 0.01  
Age ≥75 0.95 (0.23) 4.05 <0.001 2 
BMI <21 0.92 (0.44) 2.08 0.04 2 
Nursing home 1.94 (1.06) 1.82 0.07 3 
Aspiration 0.85 (0.60) 1.40 0.16 2 
Cancer 1.4 (0.41) 3.41 0.0006 2 
CHF 0.80 (0.27) 2.94 0.003 2 
Platelets <100x109/L or >400x109/L 0.75 (0.31) 2.41 0.02 1 
AUC                                                                           0.69 
Beta (s.e): Beta regression coefficient with standard error; AUC: Area under the curve; BMI: Body mass 
index; CHF: Congestive heart failure 
 
Figure 14. Representation of the initial score to predict one-year and five-year 
mortality. 
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Figure 15. Representation of the second score to predict five-year mortality. 
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7.1 Overall interpretation of results 
 
There are three major issues in this study: 
 
1. This study indicates that long-term mortality in hospitalized patients with CAP is 
high. An easy-to-use score with five variables can help physicians identify those 
patients with CAP at high risk of death within one year of an index admission. A 
weighted score, called the one-year CAPSI, constructed by age ≥80, CHF, dementia, 
BUN >30 mg/dL and a respiratory rate of ≥30 breaths/min can predict one-year 
mortality with a high predictive accuracy. Indeed, one-year CAPSI showed significantly 
better predictive accuracy than CURB65 and SCAP. 
 
2. In recent decades, increasing interest has emerged concerning biomarkers. In this 
sense, this study demonstrates that proADM is associated with the severity of disease 
measured by severity scores. Hence, patients with more severe disease at diagnosis 
present higher levels of proADM. After the exclusion of deaths within 15 days, only 24 
patients died within one year. Biomarkers showed poor predictive accuracy for one-
year mortality and were not able to improve the prediction ability of risk scores for one-
year mortality when added to the scores. In a subanalysis carried out including all 
deaths up to one year, proADM showed the best predictive ability for one-year 
mortality and, when added to the one-year CAPSI, the prediction ability of the score 
was significantly improved.  
On the other hand, a decrease in proADM from the first 24 hours to 3-5 days, adjusted 
by proADM value at baseline, was associated with a significantly reduced risk of death 
at one year. However, once it was adjusted by severity of disease and proADM 
baseline value, only when all deaths within one year were analyzed was associated 
with a significantly reduced risk of death at one year, meaning that, based on our 
sample, its predictive ability is mainly for short-term mortality.  
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3. Long-term mortality was assessed in an external cohort at the Veterans Affairs 
Medical Center of Louisville, Kentucky. Patients from this study differed from the 
patients in study I in terms of sociodemographics and comorbidities. Hence, the one-
year CAPSI failed to properly validate previous results when applied to this sample. 
Thus, a specific cohort with different variables from one-year CAPSI was developed 
for one-year mortality with a high predictive accuracy and based on age ≥75 years, 
cancer, CHF, dementia, albumin <3.5mg/dL and platelets <100,000 109/L or >400,000 
109/L. However, it seems that predicting mortality on a longer time prediction model is 
more difficult. In fact, the same score was tested for five-year mortality with a 
decrease in predictive ability. Another specific score was developed for five-year 
mortality but the predictive accuracy was not as high as expected.  
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7.2. Comparison with the literature 
 
7.2.1. STUDY I: This study indicates that long-term mortality in hospitalized 
patients with CAP is high. An easy-to-use score with five variables can help 
physicians identify those patients with CAP at high risk of death within one year 
of an index admission. A weighted score, called the one-year CAPSI, 
constructed by age ≥80, CHF, dementia, BUN >30 mg/dL and a respiratory rate 
of ≥30 breaths/min can predict one-year mortality with a high predictive 
accuracy. Indeed, one-year CAPSI showed significantly better predictive 
accuracy than CURB65 and SCAP. 
Despite advances in supportive care, CAP continues to be a leading cause of 
morbidity and mortality worldwide (14). Along with influenza, is currently the eighth 
leading overall cause of death in the United States (116). However, this mortality is 
only related to short-term mortality. Most researchers have focused their interest on 
the first months after an episode of pneumonia. It has been postulated that deaths 
within 15 days of a pneumonia diagnosis are related to the acute episode. 
Consequently, those patients were excluded from the present study in order to avoid 
the immediate impact of pneumonia on mortality. Increasing interest is emerging 
concerning the long-term prognosis after pneumonia, with mortality rates between 10-
20% in the literature (6,14). However, predicting long-term mortality remains 
challenging. 
In the present study and coinciding with literature, the one-year mortality rate in the 
entire cohort after the exclusion of deaths within 15 days of diagnosis was as high as 
10%. This increased risk has been found to be independent of previous comorbid 
diseases (27). However, the impact on prognosis of the interaction between an acute 
episode and comorbidities should be cautiously assessed. It has been suggested that 
patients hospitalized with CAP have higher long-term mortality rates. Furthermore, it 
seems that the mortality rate is even higher than those patients hospitalized for other 
reasons. In this sense, Bordon et al. (50) identified a 40% higher risk of death within 7 
years after a hospitalization for CAP when compared to patients hospitalized for other 
reasons. Recently, a German study compared mortality rates after an episode of CAP 
with a control group and observed 17%, 43%, and 53% mortality rates at 2, 5 and, 7 
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years, respectively, among patients with CAP versus 4%, 19%, and 24% in the control 
group (71).  
In this sense, specific prognostic indices for one-year mortality after hospitalization for 
any reason have been developed (23,24,117). Walter et al. (23) identified that male 
sex, functional status, CHF, cancer, creatinine, and low albumin are risk factors for 
one-year mortality in older adults after a hospitalization. However, the authors limited 
their analysis to patients over 70 years of age and to all patients discharged from a 
general medical service at a tertiary care hospital. The prognostic index developed in 
the present study focused on patients with CAP. Moreover, all age groups were 
considered, which actually makes it more useful due to the similarity to real life, as in 
daily clinical practice. 
The one-year CAPSI is a one year prognostic index that weights dementia with 6 
points, age ≥80 with 4 points, BUN >30 mg/dL with 3 points, and 2 points for both RR 
≥30 breaths/min and CHF. Therefore, an 82-year-old patient with congestive heart 
failure would have a 9.91 (6.30,15.59), HR (95%CI) times higher probability of dying 
one year after an admission for CAP. At the same time, a 50-year-old patient with a 
respiratory rate of 32 breaths/min and 50 mg/dL of BUN would have a 3.19 (1.75, 
5.83), HR (95%CI)) times higher probability of dying one year after an admission for 
CAP.  
Dementia was the best predictor of one-year mortality in hospitalized patients with 
CAP. Dementia is defined as chronic cognitive impairment; its origin is usually due to 
cerebrovascular disease, which is closely related to inflammation (28,36). Patients 
with CAP suffer an inflammatory storm during the acute episode, which could lead to a 
worsening of previously existing inflammation. Chronic persistent inflammation after 
an acute episode with CAP could lead to the high long-term mortality of these patients. 
There are other variables usually related to dementia in clinical practice, such as being 
a nursing home resident, having poor functional status, and aspiration. Being a 
nursing home resident is included in the HCAP concept. The definition of HCAP was 
developed and published in the 2005 ATS/IDSA guidelines, in order to identify an 
increased risk of drug resistant pathogens in patients coming from the community  
(76). The HCAP concept included any patient who was hospitalized in an acute care 
hospital for two or more days within 90 days of the infection, who resided in a nursing 
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home or long-term care facility, received recent intravenous antibiotic therapy, 
chemotherapy or wound care within the past 30 days of the current infection, attended 
a hospital or hemodialysis clinic, or who had a family member infected with a drug-
resistant pathogen. Patients with HCAP are known to have a worse prognosis, mostly 
due to poor functional status and treatment restrictions (39). Moreover, Cecere et al. 
(42) described high long-term mortality among patients with HCAP, i.e. even higher 
than those patients with CAP. However, HCAP was not assessed as a different entity 
in this study and only 6% of the population lived in a nursing home. In addition, 
functional status measured by the Katz index was postulated to be a 90-day mortality 
predictor after an episode of CAP by Capelastegui et al. (46). However, previous 
functional status could not be assessed in the present study. 
Patients suffering from dementia usually have problems related to swallowing, which 
leads to aspiration. As reported by Lanspa et al. (118), a clinical diagnosis of 
aspiration pneumonia is associated with confusion, nursing home residence, and 
cerebrovascular disease. However, these authors observed a 2.3 odds ratio for 
mortality, after adjusting for age, disease severity, and comorbidities. Nevertheless, 
clinician-diagnosed aspiration was assessed in this study and only dementia was 
significantly associated with one-year mortality in the multivariate analysis, probably 
underlying the poor functional status of these patients. In addition, there is a problem 
with definitions in studies assessing aspiration, and it usually becomes difficult to 
differentiate aspiration pneumonitis from aspiration pneumonia (119). 
The second most powerful predictor of one-year mortality was age ≥80. Sir William 
Osler stated that “Pneumonia may well be called the friend of the aged”. However, 
doubts have arisen in the last decades about pneumonia being limited to an acute 
episode. Several studies have identified increasing age as a risk factor for long-term 
mortality after an episode of pneumonia, which is more frequent at the extremes of 
life. The impact of an aging population has become a major issue of concern. The 
proportion of US elderly patients is expected to increase from 12% in 2000 to almost 
20% in 2030. Immunosenescence is a term to describe a series of physiological 
changes associated with aging which cause progressive deterioration of the immune 
system (120).  
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Due to the growing elderly population, the number of patients being admitted to 
hospitals has notably increased. In addition, these patients usually have more 
comorbidities and a poor functional status. It has been suggested that one out of ten 
hospitalized patients with CAP between 60-79 years of age have an increased risk of 
mortality. In a recent paper, which CAP patients were compared with a control group, 
the lowest absolute rate difference for mortality was observed among patients <25 
years old while patients >80 years old had the highest absolute rate difference (29). 
However, the starting risk age is controversial, ranging from 50 years proposed by 
Hedlund et al. (34) to 70 years proposed by Sligl et al. (36) or 80 proposed in the one-
year CAPSI. 
The severity of illness has demonstrated an impact on long-term prognosis. Scores 
such as, PSI, CURB65, or SCAP, initially developed for short-term prognosis, have 
been also used to assess long-term mortality. All these scores include data from a 
physical examination and analytics, with two variables that were also included in the 
one-year CAPSI: BUN >30 mg/dL was weighted with 3 points and RR ≥30 breaths/min 
with 2 points. 
BUN is an important biochemical parameter determined by the complex balance 
between urea production, urea metabolism, and urea excretion. In addition, BUN can 
be influenced by several renal and non-renal dependent factors such as glomerular 
filtration, tubular reabsorbtion of urea, dietary protein intake, parenteral 
hyperalimentation therapy, catabolism of endogenous proteins, exogenous 
glucocorticoid dependent catabolism, volume status, and upper gastrointestinal 
bleeding. BUN levels are well-known to increase with the severity of renal disease. 
However, increased levels can be also observed in other illnesses, such as 
pneumonia, myocardial infarction, bone marrow transplant, and esophagectomy 
(106,121,122,123). Long-term regulation of the urea cycle occurs during adaptation to 
chronic increases in enteral or parenteral protein intake or to other protein catabolic 
states, such as starvation or critical illness (124). Whether elevated levels of BUN with 
normal values of creatinine impact on prognosis have been a matter of concern. 
Recently, Beier et al. (44) conducted a multicenter observational study among critically 
ill patients with one year follow-up and concluded that elevated levels of BUN are 
associated with increased long-term mortality, independent of serum creatinine.  
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Few authors have tried to explain the relationship between mortality and high BUN 
levels. The neurohumoral response to arterial underfilling may be responsible for this 
association. This response involves AVP, the renin-angiotensin-aldosterone system 
and the sympathetic nervous system (125). High plasma AVP concentrations can 
result in increased urea reabsorption in the collecting duct, resulting in increased BUN 
(126). Angiotensin and adrenergic stimulation increase proximal tubular sodium and 
water reabsorption, decreasing distal fluid delivery, which increases flow-dependent 
urea reabsorption (127). Such arterial underfilling states are common in cardiac failure 
and sepsis (128). High BUN levels indicate renal hypoperfusion, and patients with 
pneumonia are usually dehydrated resulting from increased levels of BUN excretion 
from the kidneys. Elevations in BUN independent of creatinine may impact on 
mortality due to the extent of catabolism. Protein catabolism and net negative nitrogen 
balance are common features of critical illness, and persistent hypercatabolism in 
critical illness results in decreased immune function (129), which could explain higher 
long-term mortality. Recently, a new index, named UBMo, was created for in-hospital 
and one-year mortality among very elderly patients with CAP, by multiplying the 
uremia by the NT-proBNP plasmatic rate, divided by the monocyte count (130). 
It may be more difficult to explain how an acute parameter like RR ≥30 breaths/min 
was also associated with one-year mortality after a hospitalization for CAP. A high 
respiratory rate reflects the severity of disease and has been frequently associated 
with a worse short-term prognosis in patients suffering from CAP. Mortensen et al. 
(22) assessed long-term mortality among patients enrolled in the PORT cohort after 
excluding deaths up to 90 days from CAP presentation. The authors identified that the 
PSI risk class was significantly associated with decreased long-term survival in this 
cohort with 5.9 years of follow-up. Similarly, Capelastegui et al. (46) showed that the 
severity of illness measured by CURB was also associated with 90-day mortality after 
an episode of CAP. Both CURB65 and PSI have been recently assessed for long-term 
mortality in a six-year follow-up study in patients with CAP (43). Both PSI, which 
includes comorbidities, and CURB65 showed excellent predictive accuracy. Actually, 
both scores include RR >30 breaths/min; thus, the impact of a high RR may reflect the 
impact of severity of illness on long-term prognosis.  
Of note, contradictory data have been published concerning the utility of current risk 
scores for long-term mortality prediction in CAP. Both PSI and CURB65 have been 
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assessed for long-term mortality, PSI showing the best predictive accuracy (36,37,43). 
This may be due to the fact that PSI includes comorbidities into the score. However, in 
the present study, many comorbidities were assessed, and only CHF and dementia 
showed a great influence on mortality. Recently, other scores such as CURB65 and 
CRB65 have been compared with the Charlson comorbidity index for one-year 
mortality prediction after an episode of CAP (50). All the ROC analysis showed a weak 
and comparable performance leading to the idea that these two easy-to-use indices 
showed a similar predictive accuracy to a complex comorbidity index. Thus, it seems 
that CURB65 could be useful in predicting one-year mortality, despite demonstrating a 
lower predictive accuracy.  
In the last decade, substantial evidence has accumulated concerning the association 
between cardiovascular diseases and pneumonia. Firstly, patients suffering from CAP 
present higher rates of cardiac complications during hospitalization for CAP, such as 
acute myocardial infarction, heart failure, or arrhythmia (31,131). This idea was 
strengthened by Dong et al. (132) in a meta-analysis showing that acute respiratory 
infections were associated with a higher rate of acute coronary syndromes. Secondly, 
it has been postulated that suffering from pneumonia increases the risk of developing 
new-onset heart failure and other cardiovascular diseases in late follow-up (53). 
Thirdly, patients with CAP that suffer intra-hospital cardiac complications have greater 
long-term mortality (54). 
CHF is included in the one-year CAPSI, and actually has a considerable impact on 
long-term mortality. Pneumonia leads to an inflammatory storm and factors such as 
systemic inflammation, coronary artery inflammation, platelet activation and 
thrombosis, endothelial dysfunction, and the effects of CAP on the heart have been 
suggested as possible mechanisms for increased cardiovascular events following 
respiratory infections (133). Thus, pneumonia may reflect an acute state of 
inflammation while CHF leads to chronic inflammation. Hence, pneumonia may lead to 
chronic state of inflammation, triggering the onset of new cardiovascular events or an 
impairment of a previously present inflammatory state. 
Cardiovascular diseases have been suggested as causes of long-term mortality after 
an episode of CAP (30). In fact, cardiovascular events have been postulated to 
contribute to more than 30% of deaths in long-term follow-up in patients with CAP 
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(31). More recently, Adamuz et al. (32) determined the causes of death of 1,284 
patients discharged after an episode of CAP and observed that infectious diseases 
were the main reason for one-year mortality, followed by acute cardiovascular events. 
Moreover, mortality from infectious diseases was higher during the first six months 
and decreased progressively after that point while cardiovascular causes were stable 
throughout the follow-up period, which reinforces the idea of chronic persistent 
inflammation after an episode of CAP. Unfortunately, causes of death could not be 
obtained in the present study. 
Identifying the best prognostic index in any disease is difficult. A good prognostic 
score should be easily performed in clinical practice. In this sense, it should be taken 
into account that one-year CAPSI is an easy-to-use index specifically developed to 
predict one-year mortality among patients admitted for CAP and is based on five easy 
to remember variables, while PSI is a laborious index, which requires a complex 
computer program in order to be implemented. 
Specific issues should be discussed from the univariate analysis. Not only previously 
mentioned variables, but also cancer, CVD, confusion, a low hematocrit, a low pO2, 
and the use of corticosteroids were significantly associated with one-year mortality in 
the univariate analysis. Cancer is a clear variable that could impact on mortality. In 
fact, it has been recently demonstrated that ≤10% of patients hospitalized with CAP 
are diagnosed with either a primary lung cancer or pulmonary metastasis within 
several years of admission (134). It should be emphasized that immunosuppressed 
patients were excluded from the present study and only those with a history of cancer 
were taken into account. In addition, around 5% of the population had a history of 
cancer, while more than 10% had a history of cancer in Louisville cohort, as will be 
discussed later on. Several parameters from the physical examination and analytics 
have been postulated as risk factors for mortality. It should be mentioned that 
confusion and dementia are different parameters, the first being of new onset and the 
latter a chronic cognitive impairment. Low hematocrit has already been described as a 
risk factor for long-term mortality by Brancati et al. (35) and more recently by Waterer 
et al. (49). A low hematocrit or albumin usually reflects a poor nutritional status, which 
could actually mask other diseases.  
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Another interesting point is the effect of corticosteroids on CAP. The impact of 
corticosteroids on pneumonia prognosis is controversial. Since it was first suggested 
in the TORCH study, a higher incidence of pneumonia among patients on inhaled 
corticosteroids has been published many papers, mostly focusing on short-term 
prognosis. Recently, in a meta-analysis published in 2015 among hospitalized adults 
with CAP, systemic corticosteroid therapy turned out to may reduce mortality by 
approximately 3% and the need for mechanical ventilation by approximately 5% (135). 
In the present study, non-survivors received corticosteroids more frequently during 
hospitalization (p=0.06). However, this association did not achieve statistical 
significance. 
Finally, it should be highlighted that TRIPOD statements were used for transparent 
reporting of the prediction model (105). The score has shown good statistical 
properties in terms of discrimination, calibration and internal validation Discrimination 
was measured by the C-index, resulting in 0.75 and 0.72 in the derivation and 
validation cohorts, respectively, for the one-year CAPSI risk score. Calibration was 
measured by the GND calibration test for the survival model, and was 0.98 for the 
derivation cohort and 0.93 for the validation cohort for the one-year CAPSI risk score. 
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7.2.2. STUDY II: In recent decades, increasing interest has emerged concerning 
biomarkers. In this sense, this study demonstrates that proADM is associated 
with the severity of disease measured by severity scores. Hence, patients with 
more severe disease at diagnosis present higher levels of proADM. After the 
exclusion of deaths within 15 days, only 24 patients died within one year. 
Biomarkers showed poor predictive accuracy for one-year mortality and were 
not able to improve the prediction ability of risk scores for one-year mortality 
when added to the scores. In a subanalysis carried out including all deaths up 
to one year, proADM showed the best predictive ability for one-year mortality 
and, when added to the one-year CAPSI, the prediction ability of the score was 
significantly improved.  
On the other hand, a decrease in proADM from the first 24 hours to 3-5 days, 
adjusted by proADM value at baseline, was associated with a significantly 
reduced risk of death at one year. However, once it was adjusted by severity of 
disease and proADM baseline value, only when all deaths within one year were 
analyzed was associated with a significantly reduced risk of death at one year, 
meaning that, based on our sample, its predictive ability is mainly for short-term 
mortality.  
 
Current risk scores have demonstrated utility for the management of CAP; however, 
they have several limitations. Firstly, they are vulnerable to bias as they are 
dependent on differences in terms of the definition of variables. Secondly, they have 
shown poor predictive accuracy in predicting patients at high risk of dying; hence, they 
have a high negative predictive value and a low positive predictive value. Thirdly, 
different scores have used different endpoints like 30-day mortality or ICU admission. 
Fourthly, scores do not work as well in elderly people. For example, PSI clearly 
overestimates age, with older people obtaining higher scores while young people are 
underestimated. Due to the limitations of risk scores, a more accurate approach has 
been encouraged in order to identify worse outcomes in CAP. In this sense, multiple 
biomarkers have been studied with good results in the short- and long-term. 
Considerable efforts have been undertaken in order to assess biomarkers alone or 
included in current scores. All the scores measure the effect of infection in the host at 
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the time of diagnosis, but not the inflammatory response mechanisms to the injury, 
which is undoubtedly crucial to the outcome. The routine use of these biomarkers still 
remains challenging, probably due to the high cost. 
Biomarkers have been assessed for different utilities, such as the severity of disease, 
etiology, or duration of antibiotic treatment. CRP is a biomarker that has shown benefit 
in the diagnosis of acute inflammatory responses, including viral and bacterial 
infections, while PCT is a sensitive and specific marker for the diagnosis of systemic 
bacterial infection (136). Both biomarkers have demonstrated established evidence in 
terms of identifying low risk patients, which allow clinicians to send patients home 
safely. Moreover, increasing interest has emerged concerning the duration of antibiotic 
treatment (137). A clinical trial carried out by a Swiss group showed that the duration 
of antibiotic treatment could be safely reduced from 12 days to 5 days using a PCT-
guided protocol (74). However, a more recent clinical trial has suggested that 
treatment reduction could be safely implemented based only on clinical stability criteria 
(138). Menendez et al. (139) suggested that clinical stability is usually achieved by day 
three, hence, taking into account IDSA/ATS guidelines, antibiotic treatment could be 
limited to five days in most patients. 
Recently, new cardiovascular biomarkers have been developed with promising results. 
ProADM is the most stable fragment of adrenomedullin degradation. The importance 
of this biomarker is mostly focused on its activity as a potent vasodilator and the 
immunomodulatory regulation of inflammatory processes. It has been promoted as a 
prognostic biomarker in sepsis as well as a useful marker for risk stratification in 
patients with CAP (140). However, in terms of discriminating etiology, it has been 
described as a weak biomarker (73). 
In a prospective observational study conducted among 228 patients with CAP, the 
authors found significantly higher levels of proADM, PCT and CRP as well as higher 
PSI and CURB65 scores in patients with complications during hospitalization (73). The 
CAPNETZ group assessed new biomarkers, not only for short-term mortality, but also 
for 180-day mortality; the authors concluded that proADM was the best predictor of 
both short- and long-term mortality (71). Bello et al. (73) assessed different biomarkers 
and showed that proADM was the only one able to distinguish between survivors and 
non-survivors at one year after an episode of CAP. Of note, the authors did not 
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exclude in-hospital mortality from analysis, which actually could have had a significant 
influence on the results. 
In our study, three different biomarkers were assessed for one-year mortality, and only 
proADM showed significantly higher levels among more severe patients, as measured 
by different risk scores. Surprisingly, patients with higher scores on the one-year 
CAPSI showed lower levels of CRP, which would support the previously published 
idea of CRP high levels being protective against complications in patients with CAP 
(96).  
All biomarkers failed to predict one-year mortality. However, it should be taken into 
account that deaths up to 15 days from diagnosis were excluded; thus, only 24 
patients died within one year. Due to the small sample size after the exclusion of 
deaths within 15 days, a subanalysis was carried out including all deaths up to one 
year; proADM showed a high predictive ability for one-year mortality. Deaths around 
the acute episode of CAP could have a great influence when assessing long-term 
mortality and, ideally, should be excluded from the analysis. However, in this study, 
proADM was a good predictor of one-year mortality only once all deaths were 
included. In this sense, future research should focus on obtaining a larger sample size 
for the study of biomarkers and long-term mortality prediction after a CAP episode, 
excluding short-term mortality.  
Another matter of concern is how much a biomarker could improve the mortality 
prediction ability of a risk score. España et al. (141) measured proADM levels on 
admission in a prospective cohort of 491 patients with CAP and observed a significant 
correlation with severity scores and an improvement in the predictive ability for 
adverse events when the biomarker was added to the severity score, thus providing 
an additional margin of safety. In another study carried out among an already well-
characterized cohort of patients with CAP from the ProHOSP study, which was first 
developed to assess antibiotic stewardship, patients were prospectively followed for 
six years (74). The authors observed a high mortality rate of almost 50% after 
hospitalization. More interestingly, they described a high predictive accuracy of risk 
scores, which was actually improved when biomarkers were added.  
In our study, the addition of biomarkers failed to improve the predictive accuracy of the 
scores for mortality. As previously explained, in the subanalysis carried out including 
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all deaths up to one year, proADM significantly improved the predictive accuracy of 
one-year CAPSI and CURB65. It would be of great interest to assess this in a bigger 
cohort, i.e. whether proADM improves the prediction ability of risk scores. 
Serial biomarker levels have been assessed by different authors with different aims. A 
PCT-guided protocol with serial PCT measures carried out in a clinical trial could 
safely reduce the duration of antibiotic treatment from 12 days to 5 days (84). In our 
study, the main outcome was one-year mortality, and we strongly believe that 
inflammation and cardiovascular diseases are related to the increased long-term 
mortality that patients suffer after an episode of CAP. Hence, we decided to assess 
serial proADM levels in relation to one-year mortality due to its activity as a potent 
vasodilator and immunomodulatory regulator of inflammatory processes. Measuring 
serial proADM levels at follow-up after an episode of CAP could support the 
hypotheses of chronic persistent inflammation.  
In the present study, we could not obtain blood samples at late follow-up, but we were 
able to obtain biomarkers at 3-5 days after diagnosis. In order to assess the impact of 
serial biomarker levels on one-year mortality, the proADM changes was estimated by 
subtracting the proADM value at 3-5 days from the proADM value at the time of 
diagnosis. ProADM changes failed to significantly predict mortality when deaths within 
first 15 days were excluded but not when all deaths up to one year were included. 
Moreover, when patients who died between 15 days and up to one year were 
excluded, decreases in proADM values were associated with significantly decreased 
one-year mortality, leading to the idea that, at least in this sample, proADM is related 
to short-term mortality.  
Later on, proADM changes were estimated after adjustment by severity scores and, 
similarly, proADM changes failed to be protective of one-year mortality. However, 
when the same analysis was conducted including all deaths up to one year, for each 
0.1 nmol/L decrease in proADM, a decrease of 9% in one-year mortality was 
observed, adjusted by one-year CAPSI. Hence, the greater the reduction in biomarker 
levels over time, the greater the reduction in one-year mortality. Further analysis 
excluding those patients who died after 15 days and up to one year showed that 
decreases in proADM failed to be protective, again leading to the idea that, at least in 
this sample, proADM is related to short-term mortality. It is of special interest to 
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measure biomarker levels at admission as well as at follow-up in order to know 
whether the absence of a decrease is related not only with to increased mortality rate 
but also to an increased rate of cardiovascular events. 
Despite the limitations of the current study results, it seems clear that proADM showed 
a correlation with the severity of disease. ProADM has been widely studied for long-
term mortality, probably due to its cardiovascular effect. As previously mentioned, 
patients suffering from CAP have a greater probability of suffering from cardiovascular 
events in the follow-up; moreover, these cardiovascular events seem to be related to 
the increased mortality rates that these patients suffer at late follow-up. Chronic 
persistent inflammation could be the underlying issue.  
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7.2.3. STUDY III: Long-term mortality was assessed in an external cohort at the 
Veterans Affairs Medical Center of Louisville, Kentucky. Patients from this study 
differed from the patients in study I in terms of sociodemographics and 
comorbidities. Hence, the one-year CAPSI failed to properly validate previous 
results when applied to this sample. Thus, a specific cohort with different 
variables from one-year CAPSI was developed for one-year mortality with a high 
predictive accuracy and based on age ≥75 years, cancer, CHF, dementia, 
albumin <3.5mg/dL and platelets <100,000 109/L or >400,000 109/L. However, it 
seems that predicting mortality on a longer time prediction model is more 
difficult. In fact, the same score was tested for five-year mortality with a 
decrease in predictive ability. Another specific score was developed for five-
year mortality but the predictive accuracy was not as high as expected. 
 
In an attempt to assess mortality in an external cohort, 455 patients from the Veterans 
Affairs Medical Center of Louisville, Kentucky were analyzed. This is a particular 
cohort including American military veterans. Thus, all patients were male, 70% of 
patients were hypertensive, and almost half of the cohort were current smokers and 
suffered from COPD. Despite excluding mortality within 15 days from diagnosis, the 
one-year mortality rate was as twice high as the one observed in our cohort. One-year 
CAPSI was applied to this sample and it failed to properly validate the previous 
results, due to the differences in the sociodemographic and clinical characteristics 
between both cohorts. Hence, a specific prediction score was developed for one-year 
mortality. 
Under these circumstances, a weighted prediction score was developed based on age 
≥75 years, cancer, CHF, dementia, albumin <3.5 and platelets <100,000 or >400,000. 
Similarly to our cohort, age, CHF, and dementia were included in the score. Moreover, 
dementia was the second most important variable with 4 points. The most powerful 
variable was cancer, weighted with 7 points. Although immunosuppressed patients 
were excluded, still, 12.75% of the cohort had suffered from cancer, while only 5.53% 
of patients from the Galdakao-Usansolo Hospital had cancer. In addition, low albumin 
and platelet levels have been related to a poor nutritional status, which actually had a 
considerable impact on mortality, as previously explained. However, in the Galdakao-
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Usansolo Hospital cohort, with a long inclusion period, neither albumin nor platelets 
could be obtained during the study; thus, these parameters could not be analyzed. 
The one-year prediction score showed acceptable prediction accuracy. Nevertheless, 
when the same score was used to assess five-year mortality, accuracy declined. 
Five-year mortality was 58% (265 deaths) and a specific prediction score was 
developed including age, BMI <21, nursing home residence, aspiration, cancer, CHF, 
and platelets <100x109/L or >400x109/L; however, a worse predictive accuracy was 
shown (AUC 0.69). As explained before, patients with BMI <21, nursing home 
residence, and aspiration are usually included in HCAP, which had already been 
suggested as a poor prognosis. 
Therefore, it seems that predicting one-year mortality is more feasible than predicting 
five-year mortality. In this sense, biomarkers could actually become crucial. The 
addition of cardiovascular biomarkers such as proADM to risk scores has been 
postulated to improve the predictive accuracy for short- and long-term mortality. On 
the other hand, it should be taken into account that whenever a score is validated in 
an external sample, patient similarities in terms of sociodemographics and 
comorbidities should be tested first. In this study, the sample characteristics differ 
greatly from those of the first study sample; hence, a specific score was developed for 
this specific sample. 
On the other hand, several issues concerning methodology used for the study carried 
out in the Veterans Affairs Medical Center of Louisville, Kentucky should be 
highlighted. Instead of choosing variables significantly related to one-year mortality, an 
“automatic selection” regression model was used. In order to assess the best fit of the 
regression model compared to models with different variables, a genetic algorithm 
was used to identify a best-fit model somewhat automatically using the AIC. This 
algorithm creates thousands of different regression models, logistic regression in this 
case, and assesses the model fit based on AIC. This is called an optimization 
algorithm because it optimizes the model fit given thousands and thousands of 
different potential variable combinations. When the fit no longer improves by changing 
the variables around, the algorithm stops and the best model is shown. The genetic 
algorithm lets us automate much of this process by looking at thousands of models 
with different variables included and evaluating the AIC of each and comparing them 
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until it finds an optimum set of variables that minimizes the AIC. This model is then 
used to weight the variables and create the score. 
A key point of this methodology is the fact that the variables included in the score were 
not necessarily independently associated with the outcome at the p-value cutoff of 
0.05. The important thing to consider here is that the objective was not to identify 
independent predictors of long-term mortality in hospitalized patients with CAP. 
Indeed, we tried to identify a model that fit the data the best in order to create a 
composite score that could be able to discriminate between patients who died and 
those who did not die at one and five years. The fact that some variables were not 
independently associated with the outcome is not relevant in this situation, as they are 
to be combined at the end into one variable that then independently predicts the 
outcome.  
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7.3 Strengths and limitations 
 
This study has several strengths. The first one is the large sample size of the 
Galdakao-Usansolo Hospital prospective cohort. More than 2,000 patients with CAP 
were assessed during hospitalization. In addition, vital status could be obtained from 
all of them. Deaths within 15 days from diagnosis were excluded in order to avoid the 
impact an acute episode could have on mortality. 
Another strength is that the one-year CAPSI is an easy-to-use score that can 
accurately predict one-year mortality. Compared to the PSI score, which is complex 
and difficult to implement in daily clinical practice, the one-year CAPSI includes five 
easy to determine variables that can easily identify patients at a high risk of death. 
Furthermore, biomarkers could be assessed, showing a clear correlation with the 
severity of disease. Biomarker levels could be also assessed at follow-up, which 
provides a new perspective on the utility of biomarkers. Moreover, a key point of this 
study is that long-term mortality could be assessed in an external cohort of 
hospitalized patients with CAP, which strengthens the quality of the scientific research. 
This study has also several limitations. Firstly, causes of death could not be obtained 
in any case, which could have added important information. Secondly, several 
variables such as tobacco use, albumin, or platelets could not be assessed at the 
Galdakao-Usansolo Hospital cohort due to missing data. Thirdly, the sample size was 
notably reduced once deaths within 15 days of diagnosis were excluded, which had a 
considerable impact, especially in the cohort of section II when biomarkers were 
analyzed. Hence, due to the small sample size, these data should be cautiously 
interpreted. Fourthly, when assessing an external cohort, the peculiarities of patients 
from the Veterans Affairs Medical Center of Louisville, Kentucky limited the results. 
Fifthly, the study design was retrospective in study III, which could add a limitation. 
Finally, immunosuppressed patients, those infected by the human immunodeficiency 
virus, as well as those who had been discharged from an acute care hospital, an 
onsite subacute care unit, or a palliative care unit within the previous 14 days were 
excluded from this study. Thus, the data cannot be extrapolated to these patients.  
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7.4 Potential clinical use and future research 
 
The impact of an aging population has become a major issue of concern. Future 
research in the area of inflammation is needed. Indeed, inflammation among elderly 
people should be assessed independently as it probably has a distinctive role. In 
addition, it seems that persistent chronic inflammation after an episode of CAP could 
lead to higher long-term mortality rates. Future research should include an 
assessment of cardiovascular events after hospitalization for CAP, not only at short-
term follow-up, but also at long-term. In this sense, it would be of special interest to 
evaluate in a larger cohort cardiovascular biomarkers levels in the follow-up after 
hospitalization with CAP in order to demonstrate if patients with less significant 
decreases over time have higher mortality rates. This would support the idea that 
persistently elevated levels of biomarkers are associated with an increased risk of 
cardiovascular events. Moreover, this inflammation could lead to endothelial 
dysfunction or to a prothrombotic state and, consequently, to a higher rate of 
cardiovascular events. Indeed, cardiovascular diseases have been postulated as 
possibly causative of increased mortality in these patients.  
This inflammatory storm could lead to the development of new cardiovascular 
diseases as well as to already established but undiagnosed cardiovascular diseases. 
Therefore, close monitoring should be encouraged among these patients at high risk 
of death in order to make an early diagnosis and for the treatment optimization of 
comorbidities. Additionally, future research should address whether treatment with 
specific drugs to overcome inflammation favorably impacts long-term mortality. 
In conclusion, CAP is an important problem with high morbidity and mortality. In 
addition, an easy-to use score based on age ≥80, CHF, dementia, BUN >30 mg/dL, 
and a respiratory rate ≥30 breaths/min can predict one-year mortality with a high 
predictive accuracy, better than widely known severity scores. Future research should 
be conducted to clarify the impact of inflammation on CAP prognosis. 
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STUDY I. One-year mortality prediction among hospitalized 
patients with CAP in Galdakao-Usansolo Hospital. 
 
1. In this study, 2,351 patients were evaluated to identify one-year mortality predictors, 
with 250 (10.63%) patients dying within one year. Several variables were identified as 
predictors of one-year mortality, but five of them could be combined in a single model 
consisting of age ≥80, CHF, dementia, BUN >30 mg/dL, and a respiratory rate ≥30 
breaths/min. Dementia and age ≥80 were the most powerful variables weighted with 6 
and 4 points, respectively. BUN >30 mg/dL was weighted with 3 points while CHF and 
a respiratory rate ≥30 breaths/min were both weighted with 2 points. Recognizing 
these five variables may be useful for identifying patients with a high probability of 
dying after an episode of CAP. 
2. With these five weighted variables, a new score called the one-year CAPSI was 
developed to predict one-year mortality among hospitalized patients with CAP. The 
score showed good statistical properties in terms of discrimination, calibration, and 
internal validation. Considering one-year CAPSI as a continuous variable, the C-index 
was 0.76 in the derivation cohort and 0.77 in the validation cohort. In addition, the 
GND calibration test for the one-year CAPSI was 0.03 for the derivation cohort and 
0.23 for the validation cohort.  
The previous continuous score was categorized into three risk groups, i.e. minor, 
moderate, and severe, and was called the one-year CAPSI risk score. This risk score 
had a C-index of 0.72 and 0.70 in the derivation and validation cohorts, respectively. 
The GND calibration test for the one-year CAPSI was 0.98 for the derivation cohort 
and 0.93 for the validation cohort.  
For a cut-off point of four on the one-year CAPSI, the results of the statistical 
measures of performance were: sensitivity 81.40%, specificity 64.47%, PPV 21.56%, 
and NPV 96.65%, with an accuracy of 66.28% for the derivation cohort. In the 
validation cohort, sensitivity was 75.63%, specificity 65.09%, PPV 20.27%, and NPV 
95.79%, with an accuracy of 66.20%. 
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3. The one-year CAPSI showed a higher predictive ability than CURB65 and SCAP. In 
the derivation cohort, the C-index for the one-year CAPSI was 0.76 while for PSI it 
was 0.73, for CURB65 0.69, and for SCAP 0.70. In the validation cohort, the C-index 
for the one-year CAPSI was 0.77, while the C-index for PSI was 0.75, for CURB65 
0.71, and for SCAP 0.70. Hence, the one-year CAPSI appears to be more useful than 
current risk scores for the prediction of one-year mortality after a hospitalization for 
CAP. 
 
STUDY II. Role of biomarkers in one-year mortality 
prediction among hospitalized patients with CAP in 
Galdakao-Usansolo Hospital. 
 
1. In this second study, risk scores as well as three biomarkers were assessed for 
one-year mortality, including CRP, PCT, and proADM. ProADM was the only 
biomarker with significantly higher levels at admission among more severe patients, 
while lower levels of CRP were observed among more severe patients measured by 
the one-year CAPSI. In addition, risk scores showed a high predictive accuracy for 
one-year mortality. However, biomarkers failed to predict one-year mortality when 
excluding deaths within 15 days from admission, with a C-index for proADM of 0.64. 
Once all deaths within one year were included in the analysis, proADM showed a high 
predictive accuracy for one-year mortality with a C-index of 0.71; based on our 
sample, its predictive ability is mainly for short-term mortality.  
2. Risk scores were able to predict one-year mortality, but not biomarkers. However, 
as proADM was the only biomarker correlated with the severity of disease, it was 
added to the current risk scores. ProADM failed to improve the prediction ability of 
these scores when excluding deaths within 15 days. Once all deaths within one year 
were included in the analysis, the addition of proADM significantly improved the 
prediction ability for one-year mortality of CURB65 and one-year CAPSI.  
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3. When we assessed the role of changes in proADM values from admission to 3-5 
days, adjusted by proADM basal values and the risk scores, proADM changes predict 
one-year mortality; though mainly explain by short-term mortality (<=15 days). 
Additionally, when proADM changes were adjusted by the one-year CAPSI, a 
decrease of 0.1 nmol/L in proADM from admission to 3-5 days was associated with a 
9% decrease in one-year mortality. Limited sample size and the distribution of the 
outcome may have influenced the results. 
 
STUDY III. One-year mortality prediction among hospitalized 
patients with CAP in the Veterans Affairs Medical Center of 
Louisville, Kentucky. 
 
1. Patients hospitalized for CAP at the Veterans Affairs Medical Center of Louisville, 
Kentucky differed from patients hospitalized for CAP at the Galdakao-Usansolo 
Hospital, in terms of sociodemographics and comorbidities. In addition, when the one-
year CAPSI was applied to this sample, it failed to properly validate the previous 
results, due to the differences in the sociodemographic and clinical characteristics of 
the two cohorts. 
2. Taking into account the specific peculiarities of the sample from the Veterans Affairs 
Medical Center of Louisville, Kentucky, a specific score was developed by a genetic 
algorithm for one-year mortality. The final multivariate score included age ≥75 years 
weighted with 2 points, cancer with 7 points, CHF with 1 point, dementia with 4 points, 
albumin <3.5mg/dL with 2 points, and platelets <100,000 109/L or >400,000 109/L with 
2 points, with an AUC of 0.77. The same score was tested for five-year mortality with a 
poorer predictive accuracy (AUC 0.70). Thus, predicting long-term mortality after an 
episode of CAP remains challenging. 
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10.1 PSI score. 
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10.2 CURB65 score. 
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10.3 SCAP score. 
 
 
 
 
 
 
 
  
 
 
	
 
 
 
